• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a compound having an integrin? V ? 3 antagonistic action, a cell adhesion inhibitory action, a GPIIb / IIIa antagonistic action, and / or a human platelet adhesion inhibiting action and a cardiovascular disease, an angiogenesis- And a platelet aggregation inhibitor. Derivatives according to the invention are the compounds of formula (I) or their pharmaceutically acceptable salts or solvates. Wherein A represents a 5- to 7-membered heterocyclic group containing 2 N, etc., D represents> NH 2 ,> CH 2, etc., X and Z represent CH or N, R 7 and R 8 represents an alkyl, halogen, etc., Q is> C = O,> CH represents a 2, etc., R 9 represents H, alkyl, aralkyl, etc., R 10 represents H, alkyl, etc., R 11 is H , Substituted amino, etc. R 12 represents H or alkyl, m represents 0 to 5, n represents 0 to 4, p and q represent 1 to 3, and r represents 0 or 1. )
    公开号:KR20010042587A
    申请号:KR1020007011257
    申请日:1999-04-09
    公开日:2001-05-25
    发明作者:이시카와미노루；무라카미쇼이치；야마모토미키오；구보타데이；하치슈미츠구；가타노기요아키；아지토게이치
    申请人:기따자또 이찌로；메이지 세이카 가부시키가이샤；
    IPC主号:
    专利说明:

    [0002] AMINOPIPERIDINE DERIVATIVES AS INTEGRIN [alpha] v [beta] 3 ANTAGONISTS as an integrin alpha V beta 3 antagonist,
    Signal transduction systems are of great importance, in terms of physiological significance and regulatory mechanisms for gene expression, in order to maintain life in living organisms and take this to the next generation. Integrin, which is a glycoprotein receptor involved in cell adhesion and penetrating cell membranes, has not only been involved in wound healing, hemostasis, phagocytosis, bio-defense, and the construction of a taxane skeleton, but has become a signaling molecule of its own in recent years. Therefore, organic chemistry related to integrins has been suddenly spotlighted in recent years not only from a chemical point of view, but also from molecular biology to cell biology.
    Integrin has been elucidated to transmit signals in both intracellular and extracellular pathways by binding to various ligands while dynamically and intricately changing its stereostructure (Takashi TAKAGI, et al., The 50th Japanese Society of Cellular Biology, S5- 1, 1997). Recently, T. A. of Harvard Medical School. TASPringer predicted that some kind of activated integrin had a β-propeller structure and that its binding with the ligand was done on the β-propeller top surface (Proc. Natl. Acad scj. USA, 94, 65 , 1999). The diversity of this hypothesis is also supported by researchers in Japan (Ikue et al., The 50th Japanese Society of Cellular Biology, S5-2, 1997), and the activation of integrins and their binding to ligands A three-dimensional interpretation of the molecular level has been launched in earnest.
    Among them, the integrin [alpha] v [ beta] 3 can be used for a wide variety of extracellular matrices such as vitronectin, fibrinogen, fibronectin, osteopontin, trombospondin, Von Willebrand factors, It is very interesting as a potential drug target, because it forms a complex by binding to ligands that are deeply involved in function or disease outbreaks. In fact, V 3 is highly expressed in B cells, macrophages, monocytes, smooth muscle, and activated endothelial cells. It is also known that V 3 is not strongly expressed in the dormant endothelial cells but is highly activated in the course of proliferation and invasion, that is, in angiogenesis, wound healing and inflammation sites. It has also been observed that the frequency of expression of < RTI ID = 0.0 > a v < / RTI > 3 is correlated with an increase in cancer invasion in various types of cancer cells. A group of the Scripps Research Institute in the United States, using a model of baboon, demonstrated that a new expression of α v β 3 in microvasculature when experimentally ischemia-reperfusion of the brachial artery was confirmed by the latest computer video imaging technology (Y. Okada et al., Am. J. Pathol., 149, 37, 1996).
    As it described above, in relation to the cell tumor, which is the integrin α v β 3 in vivo expression and, α v β when the third activation and biological defense mechanism or the like, the molecules having integrin α v β 3 antagonistic activity , Clinical applications of various fields are expected. Indeed, the use of substances having integrin [alpha] v [ beta] 3 antagonistic activity has been aimed at in clinical use and the results of animal experiments of [alpha] v [ beta] 3 antagonists in various disease areas have been reported (SSSrivatsa et al., 69 (US), American Heart Association, 0231, 1996 (DuPont-Metck), JF Gourvest et al., 18th Annual Meeting of American Society for Bone and Brain Biology, Roussel- Hoechst, SB Rodan et al., M430, 1996, 37, 1997 (SmithKline Beecham), AL Racanelli et al., 3734, 1997, (DuPont-Merck), WSWestlin, USA IBC meeting, February 23, 1998, (Searle & Co.).
    An overview of the integrin [alpha] v [ beta] 3 antagonist from a chemical structure is divided into antibodies, peptides of low molecular weight and their analogues, and low molecular weight organic compounds. Any antagonist has a deep structural relationship with the sequence of the tripeptide RGD (arginine-glycine-aspartic acid), which is thought to be essential for its recognition when the ligand binds. Include peptidic antagonists of the low molecular weight, it includes cyclic peptide or the like in addition to such display integrin a venom derived from the snake. One of these is GpenGRGDSPCA is actually rabbit by inhibiting the migration (遊走) of smooth muscle, and the blocking of integrin α v β 3 (ET Choi et al., J. Vasc.Surg., 19, 125, 1994). On the other hand, cyclic peptides containing BTD designed to imitate β-turn have been shown to bind strongly to the α v β 3 receptor (M. Goodman et al., Bioorg. Med. Chem. Lett. , 7, 997, 1997).
    However, several methods for designing a low molecular weight organic compound using the introduced amino acid sequence, here RGD, as a cue have been known. For example, a peptide mimetic that builds a new molecule based on the backbone of a peptide is known. However, a new de novo design that focuses on the chemical structure and spatial arrangement of amino acid side chains (R.Hirchman et al., J. Am., Chem. Soc. 115, 12550, 1993), this approach was applied to the design of an α v β 3 antagonist (KCNicolaou et al., Tetradron, 52, 8751, 1997).
    The low molecular weight organic compounds having an v 3 antagonistic action are now described in WO9532710, WO9637492, WO970701540, WO9708145, WO9723451, WO9723480, WO9724119 WO9726250, WO9733887, WO9736858, WO9736859, WO9736860, WO9736861, WO9736862, EP0796855. The low molecular weight organic compounds having an v 3 antagonistic action are also disclosed in U.S. Patent No. 5843906, U.S. Patent Nos. 5852210, WO9737655, WO9808840, WO9818460, WO981359, WO9835949 (1998) 1185-8, 1998, EP-A-820991, EP 853084, Bioorganic & Medicinal Chemistry, 6, (1998) 1208.
    The present invention relates to aminopiperidine derivatives and medicaments containing them having integrin α V β 3 antagonists.
    We have found that certain groups of derivatives have strong integrin [alpha] v [ beta] 3 antagonism. The present inventors have also found that certain groups of derivatives have strong cell adhesion inhibiting action. The present inventors have also found that certain groups of derivatives have strong GPlb / IIIa antagonism and human platelet aggregation inhibition.
    The object of the present invention is to provide a compound having an integrin V 3 antagonistic action, a cell adhesion inhibitory action, a GP IIb / lla antagonistic action, and / or a human platelet aggregation inhibitory action.
    The present invention also relates to a pharmaceutical composition for the treatment of diseases mediated by integrin [alpha] v [ beta] 3 , therapeutically effective disease inhibition of cell adhesion and GPIIb / IIIa antagonism and / or platelet aggregation inhibitory action selected from the group consisting of therapeutically effective diseases It is an object of the present invention to provide a therapeutic agent and a platelet aggregation inhibitor.
    The compound according to the present invention is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt or solvate thereof.

    (Wherein,
    A is a saturated or unsaturated 5- to 7-membered heterocyclic group containing two nitrogen atoms (which heterocyclic group may be condensed with another saturated or unsaturated 5- to 7-membered monocyclic or heterocyclic ring to form a bicyclic group, heterocyclic ring group and 2 is C 1-6 alkyl group, amino group, C 1-6 alkoxy, C 1-6 alcohol when a carbonyl group, or an aralkyl group (the C 1-6 alkyl group, amino group, C 1-6 alkoxy Group, a C 1-6 alkoxycarbonyl group and an aralkyl group may be substituted by a C 1-6 alkyl group or a C 1-6 alkoxy group), or the following groups

    (Wherein R 1 , R 2 and R 3 may be the same or different and each represents a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, an aralkyl group or a nitrile group Or R 1 and R 2 together may form a group - (CH 2 ) i- (i represents 4 or 5) or a group - (CH 2 ) 2 -O- (CH 2 ) 2 - , A C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, and an aralkyl group may be substituted by a halogen atom, a C 2-6 alkoxy group, an amino group, or a hydroxyl group)
    D is> NR 4 (R 4 is a hydrogen atom or a C 1-6 alkyl group (the alkyl group is optionally Good choehwan by a phenyl group optionally substituted by a C 1-6 alkoxy)
    ,> CR 5 R 6 (wherein R 5 and R 6 each represent a hydrogen atom or a C 2-6 alkyl group, which alkyl group may be substituted by a phenyl group which may be substituted by a C 2-6 alkoxy group) ), -O-, or -S-,
    X and Z may be the same or different and represent either CH or N,
    R 7 is, C 1-6 alkyl, C 1-6 alkoxy group, a halogen atom, an amino group, denotes a nitro group, a hydroxyl group, or an oxygen atom, a C 1-6 alkyl group and a C 1-6 alkoxy group a halogen atom, C 1 -6 alkoxy group, an amino group, or a hydroxyl group,
    R 8 is, C 1-6 alkyl, C 1-6 alkoxy group, a halogen atom, an amino group, a nitro group, or represents a hydroxyl group, C 1-6 alkyl group and a C 1-6 alkoxy group a halogen atom, a C 1-6 alkoxy An amino group, or a hydroxyl group,
    Q represents > C = O, > CHR 13 or > CHOR 13 (R 13 represents a hydrogen atom or a C 1-6 alkyl group)
    R 9 is a hydrogen atom, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, or represents an aralkyl group, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl And the aralkyl group may be substituted by a halogen atom, a C 1-6 alkoxy group, an amino group, or a hydroxyl group,
    R 10 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, an aralkyl group, or an amino group, these C 1-6 alkyl, C 2-6 alkenyl group, C 2 -6 alkynyl group and aralkyl group may be substituted with a halogen atom, a C 1-6 alkoxy group, an amino group, or a hydroxyl group, and the amino group may be substituted with a C 1-6 alkyl group, a C 1-6 alkoxycarbonyl group, a benzenesulfonyl group The phenyl moiety may be substituted by a C 1-6 alkyl group), or a benzyloxycarbonyl group (the phenyl moiety may be substituted by a C 1-6 alkyl group)
    R 11 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, a represents an aralkyl group, or an amino, C 1-6 alkyl, C 2-6 alkenyl, C 2- The alkynyl group and the aralkyl group may be substituted by a halogen atom, a C 1-6 alkoxy group, an amino group, or a hydroxyl group, and the amino group may be substituted with a carboxyl group, a sulfonyl group, a C 1-6 alkyl group, a C 1-6 alkylcarbonyl group , C 1-6 alkoxycarbonyl groups, C 1-6 alkali sulfonyl group, - (C = O) -O- (CH 2) uR 14 (u is an integer of 0 ~ 4, R 14 is a saturated or unsaturated 5 To R < 7 > each independently represent a hydrogen atom or a heterocyclic group, and the carbocyclic group and the heterocyclic group may be the same or different and each represents a C 1-6 alkyl group, a C 1-6 alcohol group, a phenyl group (the phenyl group may be condensed with the carbocyclic group or heterocyclic group (= O) 2 - (CH 2 ) v -R 14 (optionally substituted with a halogen atom), a carboxyl group, a hydroxyl group, a nitro group, an amino group, a C 1-6 alkylamino group or a halogen atom) v is an integer from 0 to 4 Out other, R 14 is good and optionally substituted by indicating the same content as described above),
    R 12 represents a hydrogen atom or a C 1-6 alkyl group,
    m represents an integer of 0 to 5,
    n represents an integer of 0 to 4,
    p represents an integer of 1 to 3,
    g represents an integer of 1 to 3,
    R represents 0 or 1.)
    The compounds according to the present invention are useful for the treatment of disease mediated by integrin V 3 , diseases for which cell adhesion inhibition is therapeutically effective, and GP IIb / IIIa antagonistic action and / or platelet aggregation inhibitory action. The compound according to the present invention is also useful as a platelet aggregation inhibitor.
    compound
    As used herein, the term "C 1-6 alkyl" and "C 1-6 alkoxy" as a group or part of a group means a straight, Lt; / RTI > alkyl or alkoxy.
    In the present specification, a group or part of a group cattle term "C 2-6 alkenyl" and "C 2-6 alkynyl" groups are straight chain, is decided branched, or cyclic, having 2 to 6 carbon atoms, preferably of 2 ≪ / RTI > alkenyl or alkynyl.
    Examples of C 1-6 alkyl include methyl, ethyl, n-propyl, isopropylcyclopropyl, cyclopropylmethyl, n-butyl, i-butyl, s- Hexyl, and cyclohexyl.
    Examples of C 1-6 alkoxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy and t-butoxy.
    An example of C 2-6 alkenyl is an allyl group.
    Examples of C 2-6 alkynyl include a 2-propynyl group and an ethynyl group.
    Examples of the " saturated or unsaturated 5- to 7-membered carbocyclic group " include a phenyl group.
    In the present specification, the term " saturated or unsaturated 5- to 7-membered heterocycle " means a 5- to 7-membered heterocycle containing at least one heteroatom selected from an oxygen atom, a nitrogen atom and a sulfur atom, A 5- to 7-membered heterocyclic ring containing one nitrogen atom, more preferably a 5-or 6-membered heterocyclic ring containing one nitrogen atom. Here, the term " heterogeneous material " means an oxygen atom, a nitrogen atom, and a sulfur atom. Examples of the saturated or unsaturated 5- to 7-membered heterocyclic group include a pyrimidyl group, a 1,4,5,6-tetrahydropyrimidyl group, an imidazolyl group, a tetrahydro- [1,3] diazepinyl group, And a decyl group.
    The saturated or unsaturated heterocyclic group may be condensed with another saturated or unsaturated heterocyclic ring to form two rings. Examples of such a condensed ring group include a benzimidazolyl group, a naphthyl group, an azabenzimidazolyl group (for example, Imidazo [4,5-b] pyridyl group).
    As used herein, the term "aralkyl" as a group or part of a group refers to a C 1-6 alkyl substituted by a saturated or unsaturated 5 to 7 membered carbocyclic or heterocyclic group, preferably a C 1-4 alkyl . Examples of the aralkyl group include a benzyl group and a phenethyl group.
    The halogen atom means a fluorine atom, a chlorine atom, a cancel atom, or an oxo atom.
    A preferable combination of X and Z includes the case where X represents CH, Z represents N, and X and Z together denote N. [
    When D represents > NR < 4 & gt ;, X preferably represents CH.
    When D represents > CR < 5 > R < 6 & gt ;, X preferably represents CH.
    When D represents -O-, X preferably represents CH.
    When D represents -S-, X preferably represents CH.
    D preferably represents > NH or > CH 2 .
    The bicyclic heterocyclic group represented by A is preferably a 9- or 10-membered heterocyclic group, more preferably a 9- or 10-membered heterocyclic group containing 2 or 3 nitrogen atoms.
    A preferably represents the following groups.
    (In the above group,
    Het represents a saturated or unsaturated 5- to 7-membered heterocyclic group containing two nitrogen atoms, and this heterocyclic group may be condensed with another saturated or unsaturated 5- to 7-membered monocyclic or heterocyclic ring to form a bicyclic group , a heterocyclic ring group and 2 is C 1-6 alkyl group, amino group, C 1-6 alkoxy, C 1-6 alkoxycarbonyl group, or an aralkyl group (the C 1-6 alkyl group, amino group, C 1-6 An alkoxy group, a C 1-6 alkoxycarbonyl group and an aralkyl group may be substituted by a C 1-6 alkyl group or a C 1-6 alkoxy group)
    A more preferably represents the following groups.
    (The above air,
    R21, R22, And R23May be the same or different and are a hydrogen atom, C1-6Alkyl group, C1-6An alkoxy group, C1-6Alkoxycarbonyl group, C2-6An alkenyl group, or an aralkyl group, and C1-6Alkyl group, C1-6An alkoxy group, C1-6Alkoxycarbonyl group, C2-6Alkenyl group, or aralkyl group is a halogen atom, C1-6An alkoxy group, an amino group, or a hydroxyl group, or ROneAnd R23(CH2)4-, - (CH2)3-, -CHR24CH2CH2- (R24C1-6An alkyl group or an amino group, and the amino group is C1-6Alkyl group, C1-6An alkoxycarbonyl group, an aralkyl group, or an aralkyloxycarbonyl group), a group -CH2CHR24CH2- (R24Have the same meanings as described above), group -CH2CH2- group -CHR24CH2- (R24Have the same meanings as described above), a group -CR25= CR26- (R25And R26The same Or a hydrogen atom, or a C1-6Alkyl group, or R25And R26Together are -CH = CH-CH = CH-, CR24= CH-CH = CH- (R24Have the same meanings as described above), -CH = CR4-CH = CH- (R24May have the same meanings as defined above, -N = CH-CH = CH-, or -CH = N-CH = CH-)
    R 21 and R 23 together form ═CH-CH═CH-, ═CH-CH═N-, or ═CH-N═CH-, and R 22 is a bond between R 21 and the nitrogen atom to which it is bonded May be represented by a single bond.
    Of the compounds of formula (I), at least one hydrogen atom in the following moiety may be substituted by R 7 .
    When m = 0, R 7 does not exist. When m = 1, one hydrogen atom of the moiety is substituted by R 7 . When m is 2 or more, two or more hydrogen atoms of the moiety are substituted by R 7 , but the substituents may be the same or different. When R 7 is an oxygen atom, the condensation between R 7 and the moiety represents a double bond. m is preferably an integer of 0 to 2.
    Of the compounds of the general formula (I), at least one hydrogen atom of the phenylene moiety may be substituted by R 8 .
    When n = 0, R 8 does not exist. When n = 1, one hydrogen atom of the phenylene moiety is substituted by R 8 . When n is 2 or more, two or more hydrogen atoms of the phenylene moiety are substituted by R 8 , but the substituents may be the same or different. n is preferably an integer of 0 to 2.
    Q preferably represents> C = 0 or> CH 2 .
    R 9 preferably represents a hydrogen atom, a C 1-6 alkyl group (preferably methyl, propyl, cyclopropylmethyl), or an aralkyl group (preferably benzyl or phenethyl).
    R 10 is preferably a hydrogen atom, a C 1-6 alkynyl group or an optionally substituted amino group, more preferably a hydrogen atom or a C 1-6 alkynyl group.
    When r is 0, - (CHR 10 ) r- represents a single bond. r is preferably 1.
    R 11 is preferably a hydrogen atom, a C 1-6 alkynyl group or an optionally substituted amino group, more preferably a hydrogen atom or an optionally substituted amino group.
    The hydrogen atom of the amino group represented by R 11 may be substituted by the same or different two substituents.
    R 11 is a substituent of an amino group represents -C (= 0) -0- (CH 2) preferred examples of uR 14, u is an integer (0 or 1 to more preferably) of from 0 to 3, and R 14 is 5 (More specifically, phenyl) group.
    R 11 represents an -S (= O) substituent of the amino group 2 - (CH 2) v Preferred examples of -R 14, v is an (are 0 or 1, more preferably to) an integer of 0-3, and R 14 is 5 to 7 membered carbocyclic group (more specifically, phenyl).
    The at least one hydrogen atom of the carbocyclic group and the heterocyclic group represented by R 14 is preferably a C 1-6 alkyl group (more preferably methyl), a C 1-6 alkoxy group (more preferably methoxy) A carboxyl group, a hydroxyl group, a nitro group, an amino group, or a halogen atom.
    The substituent of the amino group represented by R 11 is preferably a C 1-6 alkyl group, a C 1-6 alkylcarbonyl group, a C 1-6 alkoxycarbonyl group, a C 1-6 alkylsulfonyl group, a benzyloxycarbonyl group (a phenyl moiety is C 1-6 alkyl, C 1-6 alkoxy group, a carboxyl group, a hydroxyl group, Good optionally substituted by a nitro group, an amino group, or a halogen atom), or a benzene sulfonyl group (the phenyl portion is C 1-6 alkyl, C A hydroxyl group, a nitro group, an amino group, or a halogen atom) having 1 to 6 carbon atoms.
    A preferred group of compounds of the compounds of formula (I)
    A < / RTI >
    (Wherein R 21 , R 22 and R 23 have the same meanings as defined above)
    D represents > NH,
    X represents CH,
    Z represents > N,
    Q represents > C = O or > CH 2 ,
    R 9 represents a hydrogen atom, a C 1-6 alkyl group or an aralkyl group, the C 1-6 alkyl group and the aralkyl group may be substituted by a halogen atom, a C 1-6 alkoxy group, an amino group or a hydroxyl group,
    R 10 represents a hydrogen atom or a C 1-6 alkynyl group,
    R 11 represents a hydrogen atom or an amino group, and the amino group represents a C 1-6 alkyl group, an acetyl group, a C 1-6 alkoxycarbonyl group, a C 1-6 alkylsulfonyl group, a benzyloxycarbonyl group (the phenyl moiety may be substituted) , Or a benzenesulfonyl group (the phenyl moiety may be substituted)
    m and n each represent an integer of 0 to 2,
    p represents 2,
    q represents 1 or 2,
    a compound in which r represents 1, and
    A < / RTI >
    (In the above groups, R 21 , R 22 , and R 23 have the same meanings as defined above)
    D represents > CH 2 ,
    X and Z taken together represent N,
    Q represents > C = O or > CH 2 ,
    R 9 represents a hydrogen atom, a C 1-6 alkyl group or an aralkyl group, the C 1-6 alkyl group and the aralkyl group may be substituted by a halogen atom, a C 1-6 alkoxy group, an amino group, or a hydroxyl group,
    R 10 represents a hydrogen atom or a C 1-6 alkynyl group,
    R 11 represents a hydrogen atom or an amino group, and the amino group may be substituted with a C 1-6 alkyl group, an acetyl group, a C 1-6 alkoxycarbonyl group, a C 1-6 alkylsulfonyl group, a benzyloxycarbonyl group (the phenyl moiety may be substituted) , Or a benzenesulfonyl group (the phenyl moiety may be substituted)
    m and n each represent an integer of 0 to 2,
    p represents 2,
    q represents 1 or 2,
    r represents 1
    Compounds.
    Particularly preferred compounds among the compounds of the general formula (I) are as follows.
    1. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid t-butyl ester.
    2. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid.
    3. Preparation of (2S) -benzenesulfonylamino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] Propionic acid.
    4. (2S) -Benzenesulfonylamino-3- [4 - {(3S) - (pyrimidin-2- ylamino) pyrrolidin-1-yl} benzoylamino] propionic acid t-butyl ester.
    5. (2S) -Benzenesulfonylamino-3- [4 - {(3S) - (pyrimidin-2- ylamino) pyrrolidin-1-yl} benzoylamino] propionic acid.
    6. (2S) -Benzenesulfonylamino-3- [4 - {(3S) - (1,4,5,6-tetrahydropyrimidin- 2- ylamino) pyrrolidin- Benzoylamino] propionic acid.
    7. (2S) -Benzenesulfonylamino-3- [4 - {(3R) - (pyrimidin-2- ylamino) pyrrolidin-1-yl} benzoylamino] propionic acid t-butyl ester.
    8. (2S) -Benzenesulfonylamino-3- [4 - {(3R) - (pyrimidin-2- ylamino) pyrrolidin-1-yl} benzoylamino] propionic acid.
    9. (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid t-butyl ester.
    10. (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    11. (3S) - [4- (4- (Pyrimidin-2-ylamino) piperidin-1-yl} benzoylamino] pent- 4 -phosphoric acid ethyl ester.
    12. (3S) - [4- (4- (Pyrimidin-2-ylamino) piperidin-1-yl} benzoylamino] pent- 4-phosphate.
    13. t-Butyl ester of (2S) - (benzyloxycarbonyl) amino-3- [4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    14. (2S) - (Benzyloxycarbonyl) amino-3- [4- [4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    15. (2S) -amino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    16. Preparation of (2S) - (benzyloxycarbonyl) amino-3- [4- [4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- Benzoylamino] propionic acid.
    17. (2S) -butane-1-sulfonylamino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- Benzoylamino] propionic acid.
    18. Preparation of (2S) -benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- [4- (pyrimidin- 2- ylamino) piperidin- 1- yl} ] Amino] propionic acid t-butyl ester.
    19. Preparation of (2S) -benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} ] Amino] propionic acid.
    20. Preparation of (2S) -benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- {4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) Piperidin-1-yl} benzyl] amino] propionic acid.
    21. (2S) -Benzenesulfonylamino-3- {4- (4-guanidinopiperidin-1-yl) benzoylamino} propionic acid t-butyl ester.
    22. (2S) -Benzenesulfonylamino-3- {4- (4-guanidinopiperidin-1-yl) benzoylamino} propionic acid.
    Benzylamino} - (2S) - {(benzyloxycarbonyl) amino} propionic acid t < RTI ID = 0.0 > -Butyl ester.
    24. 3- [4 - (4 - (lH-Benzimidazol-2-ylamino) piperidin-1 -yl} benzoylamino] - (2S) - {(benzyloxycarbonyl) amino} propionic acid.
    25. Preparation of (2S) - (benzyloxycarbonyl) amino-3- [4- [4 - {(1-t -butoxycarbonyl- lH-benzimidazol- 2- yl) amino} piperidin- 1-yl] benzoylamino] propionic acid t-butyl ester.
    26. Preparation of (2S) -amino- 3- [4- [4 - {(1-t -butoxycarbonyl- lH-benzimidazol- 2- yl) amino} piperidin- 1- yl] benzoylamino ] Propionic acid t-butyl ester.
    27. Preparation of (2S) - (butane- 1 -sulfonylamino) -3- [4- [4 - {(1-tert- butoxycarbonyl- Di-1-yl] benzoylamino] propionic acid t-butyl ester.
    28. (2S) -Butane-1-sulfonylamino-3- [4- (4- (1H-benzimidazol-2- ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    29. (2S) -amino-3- [4- (4- (1H-benzimidazol-2-ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    30. A compound according to any one of claims 1 to 3, which is a compound of formula (I), wherein R < 3 > - [4- [4 - {(1-tert- butoxycarbonyl- {(2,4,6-trimethylbenzenesulfonyl) amino} propionic acid t-butyl ester.
    31. A process for the preparation of 3 - [4- (4 - (1 H -benzimidazol-2-ylamino) piperidin-1 -yl} benzoylamino] - (2S) - {(2,4,6- Sulfonyl) amino} propionic acid.
    1-yl] benzoylamino] - (2S) - (4-fluorophenyl) propanoic acid. {(4-fluorobenzenesulfonyl) amino} propionic acid t-butyl ester.
    33. A compound according to claim 1 which is: 3- [4- (4 - (1 H -benzimidazol-2-ylamino) piperidin- 1 -yl} benzoylamino] - (2S) - {(4-fluorobenzenesulfonyl) } Propionic acid.
    1-yl] benzoylamino] - (2S) - (4-methyl-pyridin-2-yl) {(4-Nitrobenzenesulfonyl) amino} propionic acid t-butyl ester.
    (2S) - {(4-Nitrobenzenesulfonyl) amino} - 1 - benzoylamino] Propionic acid.
    36. (2S) - (4-Aminobenzenesulfonyl) amino-3- [4- [4- (1H-benzimidazol-2- ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    37. (2S) -Benzenesulfonylamino-3- [4- [4 - {(1H-imidazo [4,5- b] pyridin- 2- yl) amino} piperidin- 1 -yl] benzoyl Amino] propionic acid t-butyl ester.
    38. (2S) -Benzenesulfonylamino-3- [4- [4 - {(1H-imidazo [4,5-b] pyridin- 2- yl) amino} piperidin- Amino] propionic acid.
    39. (2S) -benzenesulfonylamino-3- [4- [4 - [{4,5-dihydro- 1- (4-methoxybenzyl) -1H- imidazol- Piperidin-1-yl] benzoylamino] propionic acid t-butyl ester.
    40. (2S) -Benzenesulfonylamino-3- [4- (4- (4,5-dihydro-1H-imidazol-2-ylamino) piperidin- 1- yl} benzoylamino] propionic acid .
    41. (2S) -Benzenesulfonylamino-3- [4- (4- (4,5,6,7-tetrahydro-1H- [1,3] diazepin- 2 -ylamino) piperidine -Yl} benzoylamino] propionic acid t-butyl ester.
    42. (2S) -Benzenesulfonylamino-3- [4- (4- (4,5,6,7-tetrahydro-1H- [1,3] diazepin- 2 -ylamino) piperidine 1-yl} benzoylamino] propionic acid.
    43. (2S) -Benzenesulfonylamino-3- [4- [4 - [{N-methyl-N- Propionic acid t-butyl ester.
    44. (2S) -Benzenesulfonylamino-3- [4- [4 - [{N-methyl-N- Propionic acid.
    45. Preparation of (2S) -benzenesulfonylamino-3- [4- [4 - [{N-methyl- N- (1,4,5,6- tetrahydropyrimidin- 2- yl)} amino] 1-yl] benzoylamino] -propionic acid. ≪ / RTI >
    46. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzylamino] propionic acid t-butyl ester.
    47. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin-1- yl} benzylamino] propionic acid.
    48. (2S) -Benzenesulfonylamino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- 1- yl} benzylamino] Propionic acid.
    49. (2S) -Benzenesulfonylamino-3 - [[N-benzyl-N- [4- [4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) piperidine - 1 -yl} benzyl]] amino] propionic acid.
    50. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (pyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester .
    51. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    52. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- Yl} benzoylamino] propionic acid.
    53. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (4,5- dihydro- lH- imidazol- 2- ylamino) piperidin- 1- yl } Benzoylamino] propionic acid t-butyl ester.
    54. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (4,5- dihydro- lH- imidazol- 2- ylamino) piperidin- 1- yl } Benzoylamino] propionic acid.
    55. (2S) -Benzenesulfonylamino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t -Butyl ester.
    56. (2S) -Benzenesulfonylamino-3- [2,3-difluoro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    57. (2S) -Benzenesulfonylamino-3- [2,3-difluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidine 1-yl} benzoylamino] propionic acid.
    58. (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid t-butyl ester.
    59. (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    60. (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- yl } Benzoylamino] propionic acid.
    61. 2- (N-Benzenesulfonyl-N-methyl) amino-3- [4- (4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester .
    62. 2- (N-Benzenesulfonyl-N-methyl) amino-3- [4- (4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    63. A compound according to claim 1 which is 2- (N-benzenesulfonyl-N-methyl) amino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin- 2- Yl} benzoylamino] propionic acid.
    64. A pharmaceutical composition comprising (2S) - (benzyloxycarbonyl) amino-3- [3-fluoro-4- [4- - N - (4-methoxybenzyl)} amino] piperidin-1-yl] benzoylamino] propionic acid t-butyl ester.
    65. A pharmaceutical composition comprising (2S) -amino- 3- [3-fluoro-4- [4- [{N- (1,4,5,6- tetrahydropyrimidin- 2- Methoxybenzyl)} amino] piperidin-1-yl] benzoylamino] propionic acid t-butyl ester.
    66. A pharmaceutical composition comprising 3- [3-fluoro-4- [4 - [{N- (1,4,5,6- tetrahydropyrimidin- 2- yl) -N- (4-methoxybenzyl)} amino] Piperidin-1-yl] benzoylamino] - (2S) - {(4-nitrobenzenesulfonyl) amino} propionic acid t-butyl ester.
    1-yl} benzoylamino] - (2S) -thiophene-2-carboxylic acid ethyl ester was prepared from 3- - {(4-nitrobenzenesulfonyl) amino} propionic acid.
    68. Preparation of (2S) - (4-aminobenzenesulfonyl) amino-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) 1 -yl} benzoylamino] propionic acid. ≪ / RTI >
    69. A mixture of (2S) - (benzyloxycarbonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t -Butyl ester.
    70. (2S) -Amino-3- [3-fluoro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid t-butyl ester.
    71. Preparation of 3- [3-fluoro-4- {4- (pyrimidin-2-ylamino) piperidin-1 -yl} benzoylamino] - (2S) - {(4- methoxybenzenesulfonyl ) Amino} propionic acid t-butyl ester.
    72. A compound according to claim 1 which is 3- (3-fluoro-4- {4- (pyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] - (2S) - {(4- methoxybenzenesulfonyl ) Amino} propionic acid.
    73. A compound according to claim 1 which is 3 - [3-fluoro-4- {4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] - {(4-methoxybenzenesulfonyl) amino} propionic acid.
    74. A compound according to claim 1 which is: 3 - [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] - (2S) - {(4-hydroxybenzenesulfonyl ) Amino} propionic acid.
    1-yl} benzoylamino] - (2S) -thiophene-2-carbonyl] amino} - {(4-hydroxybenzenesulfonyl) amino} propionic acid.
    76. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- Propionic acid t-butyl ester.
    77. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- Propionic acid.
    78. (2S) - (4-Carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) 1 -yl} benzoylamino] propionic acid. ≪ / RTI >
    79. (2S) -acetamido-3- [3-fluoro-4- [4- [N - (1,4,5,6-tetrahydropyrimidin- 2- 4-methoxybenzyl)} amino] piperidin-1-yl] benzoylamino] propionic acid t-butyl ester.
    80. (2S) -acetamido-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- } Benzoylamino] propionic acid.
    81. (2S) - (Benzyloxycarbonyl) amino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino ] Propionic acid t-butyl ester.
    82. (2S) -amino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester .
    83. A compound according to claim 1 which is: 3 - [2, 3-Difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] - (2S) Benzenesulfonyl) amino} propionic acid t-butyl ester.
    84. A compound according to claim 1 which is 3 - [2, 3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] - (2S) Benzenesulfonyl) amino} propionic acid.
    85. A compound according to claim 1 which is 3 - [(2,3-difluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- yljbenzoylamino] - 2S) - {(4-hydroxybenzenesulfonyl) amino} propionic acid.
    86. (2S) - (4-Carboxybenzenesulfonyl) amino-3- [2,3-difluoro-4- {4- Benzoylamino] propionic acid t-butyl ester.
    87. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [2,3- difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- Benzoylamino] propionic acid.
    88. Synthesis of (2S) - (4-carboxybenzenesulfonyl) amino-3- [2,3-difluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- Amino) piperidin-1-yl} benzoylamino] propionic acid.
    89. (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylmethyl) piperazin-1-yl} benzoylamino] propionic acid t-butyl ester.
    90. (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylmethyl) piperazin-1-yl} benzoylamino] propionic acid.
    91. (2S) -Benzenesulfonylamino-3- [3-methoxy-4- {4- (pyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester .
    92. (2S) -Benzenesulfonylamino-3- [3-methoxy-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    93. (2S) -Benzenesulfonylamino-3- [3-methoxy-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- Yl} benzoylamino] propionic acid.
    94. (2S) -Benzenesulfonylamino-3- [3-hydroxy-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    95. (2S) -Benzenesulfonylamino-3- [3-hydroxy-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidine- 1- Yl} benzoylamino] propionic acid.
    96. A process for the preparation of (2S) - (benzyloxycarbonyl) amino-3- [3-methoxy- 4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t -Butyl ester.
    97. (2S) -Amino-3- [3-methoxy-4- {4- (pyrimidin-2- ylamino) piperidin- 1 -yl} benzoylamino] propionic acid t-butyl ester.
    98. Preparation of (2S) - (4-methoxybenzenesulfonyl) amino-3- [3-methoxy- 4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino ] Propionic acid t-butyl ester.
    99. (2S) - (4-Hydroxybenzenesulfonyl) amino-3- [3-hydroxy-4- {4- ] Propionic acid.
    100. (2S) - (4-Hydroxybenzenesulfonyl) amino-3- [3-hydroxy-4- {4- (1,4,5,6-tetrahydropyrimidin- Piperidin-1-yl} benzoylamino] propionic acid.
    101. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-methoxy- 4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] Propionic acid t-butyl ester.
    102. (2S) - (4-Carboxybenzenesulfonyl) amino-3- [3-methoxy-4- {4- Propionic acid.
    103. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-methoxy- 4- {4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) 1 -yl} benzoylamino] propionic acid. ≪ / RTI >
    104. t-Butyl ester of (2S) -amino-3- [4- (4- (pyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid and
    105. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid methyl ester.
    The compound according to the present invention can be a pharmacologically acceptable salt thereof. Examples of such salts include non-toxic salts. Preferred salts include hydrochloride, hydrobromic acid salt, hydroiodic acid salt such as hydroiodic acid salt, nitric acid salt, perchloric acid salt, inorganic acid salt such as sulfate salt and phosphate salt, methanesulfonic acid salt, Methanesulfonic acid salts, ethanesulfonic acid salts and the like, organic sulfonic acid salts such as benzenesulfonic acid salts and P-toluenesulfonic acid salts, fumaric acid salts, acetic acid salts, citric acid salts, tartaric acid salts, Amino acid salts such as salts and aspartic acid salts, salts of alkali metals or alkaline earth metals such as sodium, potassium or calcium salts, organic alkali salts such as pyridine salts and triethylamine salts, and the like. In addition, the compound according to the present invention may be a solvate thereof (e.g., hydrate, ethanolate).
    Preparation of compounds
    Compounds of general formula (I) in which X represents CH and Z represents N may be prepared according to the following scheme.
    ≪ Step 1 &
    (4-hydroxypiperidine or 3-pyrrolidinol (piperidine derivative) which may have a substituent on the carbon atom and a 4-fluorobenzene derivative such as dimethylsulfoxide, sulfolane, butanol or the like The compound of the general formula (II) can be prepared by carrying out the reaction in a reaction solvent (preferably, dimethylsulfoxide) at a temperature of 50 to 180 ° C (preferably 80 to 140 ° C). In this reaction, an organic solvent such as diisopropylethylamine or an inorganic salt such as ammonium chloride may be added as an acid trapping agent.
    In addition to ethyl 4-fluorobenzoate, other ester compounds such as methyl ester, propyl ester, butyl ester or benzyl ester may be used as starting compounds.
    In addition to ethyl 4-fluorobenzoate, other 4-halogen substituents such as ethyl 4-iodobenzoate and ethyl 4-bromobenzoate may be used. In view of the yield, it is preferable to use ethyl 4-fluorobenzoate.
    Further, in addition to ethyl 4-fluorobenzoate, 4-fluorobenzenitrile which may be substituted may be used as a starting material. In this case, the compound of the general formula (VI) can be produced by appropriately carrying out a step of converting into a free carboxyl group by an operation such as acid hydrolysis in the next step.
    As the piperidine derivative, an aminopiperidine derivative in which a primary amine may be protected, for example, 4-aminopiperidine may be used. Use of an aminopiperidine derivative is advantageous in that it is possible to omit the step of introducing an amino group (Step 2).
    The compound of the formula (II) may also be produced by reacting ethyl 4-bromobenzoate and a piperidine derivative in the presence of palladium, a phosphine ligand or a base. Examples of the phosphine ligand used at this time include bis (diphenylphosphino) propane, bis (diphenylphosphino) ferrocene, tri -t-butylphosphine, tri-0-tolylphosphine and triphenylphosphine, and preferably 2,2'-bis (diphenylphosphino) -1,1'-binaph Til. Examples of the base include sodium t-butoxide, cesium carbonate, potassium potassium and triethylamine, preferably sodium t-butoxide. Examples of the piperidines include hydroxypiperidine, pyrrolidinol, azetidinol , Azepanol, and azocanol.
    ≪ Step 2 &
    The reaction of the compound of formula (II) and phthalimide together with an azo compound in a reaction solvent such as tetrahydrofuran, benzene, toluene, dioxane, dimethylformamide (preferably, tetrahydrofuran) (Preferably, -10 ° C to 40 ° C) in the presence of a base (preferably tributylphosphine) at a temperature of -40 ° C to 100 ° C (preferably, -10 ° C to 40 ° C) Compounds can be prepared. Examples of the azo compound include 1,1- (azodicarbonyl) dipiperidine, diethyl azodicarbonate, and 1,1'-azobis (N, N-dimethylformamide) '- (azodicarbonyl) dipiperidine.
    The compound of the general formula (III) can also be prepared by converting the hydroxyl group of the compound of the general formula (II) into a leaving group such as a sulfonyloxy group such as a methanesulfonyloxy group or a halogen atom such as a bromine atom, The compound of the general formula (III) can be prepared by reacting sodium with sodium azide, or by reacting hydro azidic acid with an azo compound to convert to an azide group and then reducing the azide group. Specifically, see intermediates 35, 36, 41, 42, 43, 47, 48,
    ≪ Step 3 >
    The compound of the general formula (IV) can be prepared by introducing the group A into the free primary amine of the compound of the general formula (III). The NC bond between the compound of the general formula (III) and the group A can be obtained by reacting the compound of the general formula (III) with an optionally substituted or optionally substituted 2-bromopyrimidine, a substituted or substituted 2-chlorobenzimidazole , Or 2-methylthio-2-imidazoline in the presence of a reaction solvent such as methylformamide, dimethylsulfoxide, sulfolane, pyridine, or methanol (preferably, dimethylformamide) At a temperature in the range of -170 ° C to 170 ° C, preferably 60 ° C to 140 ° C.
    The reagent which can be used in the present process is not limited to those listed here. As a result, a carbon atom bonded to two nitrogen atoms may form a single bond with the nitrogen atom of the primary amine bonded to the carbon atom of the piperidine derivative . It is also possible to react with zero-valent palladium, phosphine ligand and base to form N-C bonds by optimizing the kind of the substrate and the reaction conditions. The N-C bond can also be formed by the method described in Tetrahedron 51 (2), 353, 1995. Specifically, see Intermediates 26, 27, 29 and 39.
    From the viewpoint of improving the yield, it is preferable to add an organic base such as diisopropylethylamine, N-methylmorpholine, dimethylaminopyridine, triethylamine or the like as an acid scavenger. By adding diisopropylethylamine .
    If necessary, the compound of the formula (III) can be prepared by introducing a group A or introducing a group A into the primary amino group of the compound of the formula (III) after the usual or reductive N-alkylation, It is also possible to produce a compound of the general formula (IV) wherein R 4 is substituted with a substituent. Specifically, see Intermediate 30.
    The compound of the general formula (IV) can also be produced by introducing the hydroxyl group of the piperidine derivative portion of the compound of the general formula (II) into the ketone by an appropriate oxidation reaction, and then reacting the compound having the amino group (the compound corresponding to the group A) For example, 2-aminopyrimidine to carry out a reductive amination reaction.
    The compound of the general formula (IV) can also be produced by reacting a basic amino group corresponding to the group A in advance with a primary amino group of the aminopiperidines, for example, a compound in which pyrimidine or benzimidazole is combined with ethyl 4-fluorobenzoate And the like. Specifically, see intermediates 16, 17, 18, 23, 24 and 25.
    ≪ Step 4 &
    The compound of the general formula (V) can be prepared by hydrolyzing a carboxylic acid ester of the general formula (IV) and then forming an amide bond. Concretely, R 9 HNCHR 10 CHR 11 COOR 12 is added to the carboxyl group of the glass obtained by alkali hydrolysis by a conventional method
    (V) can be prepared by reacting an amine of the general formula (V) wherein R 9, R 10 , R 11 and R 12 have the same meanings as defined in formula (I) have.
    With regard to the compound having a pyrimidine ring which may be substituted in the compound of the general formula (V), it is possible to reduce it to the corresponding tetrahydropyrimidine if necessary.
    In the dehydration condensation reaction, a condensation agent such as dicyclohexylcarbodiimide, diisopropylcarbodiimide, or 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride may be used alone, And a peptide synthesis reagent such as N-hydroxysuccinimide, 1-hydroxybenztriazole, or benztriazol-1-yloxytri (dimethylamino) phosphonium hexafluorophosphate may be used in combination. By combining these reagents, the desired dehydration condensation reaction can proceed efficiently. In order to optimize the yield, it is preferable to use 1 to 3 equivalents of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride and 1 to 2 equivalents of 1-hydroxybenzotriazole, It is right.
    Examples of the reaction solvent in the dehydration condensation reaction include dimethylformamide, dioxane, and tetrahydrofuran. Dimethylformamide is preferred. The reaction can be carried out in the range of 0 to 80 캜, preferably 20 to 60 캜. In the dehydration condensation reaction, in order to improve the yield, tertiary amines such as diisopropylethylamine, N-methylmorpholine, dimethylaminopyridine, triethylamine and the like can be added as organic bases. It is preferable to add 2 to 10 equivalents of N-methylmorpholine.
    The compound of the general formula (V) wherein > C = O bonded to the phenylene moiety is > CH 2 is obtained by reducing the carbonic acid ester of the compound of the general formula (IV) to aldehyde,
    R 9 HNCHR 10 CHR 11 COOR 12
    (Wherein R 9 , R 10 , R 11 and R 12 are the same as defined in formula (I)),
    In the presence of a base. Specifically, see Example 46.
    Among compounds of the general formula (V) obtained by this reductive amination reaction, a compound in which R 9 is a group other than a hydrogen atom can be produced by a reaction step other than the method shown here. That is, in the aldehyde group of the glass
    H 2 NCHR 10 CHR 11 COOR 12
    (Wherein R 10 , R 11 and R 12 are the same as defined in formula (I)),
    Can be reacted in a reducing manner to produce a compound of the formula (V) wherein R 9 is a hydrogen atom. After this, it is also possible to introduce an alkyl group, an alkene group, or an aralkyl group into R 9 by providing a reductive amination reaction. The introduction of an alkyl group, an alkene atom or an aralkyl group located at R 9 is not always performed only for the compound of the general formula (V) in the reaction scheme. That is, introduction of an alkyl group, alkenyl group, or aralkyl group located at R 9 may be performed on the compound of formula (VI) in the reaction scheme. Specifically, see Example 49.
    In the reaction, R 12 of -COOR 12 corresponding to the carboxylic acid ester portion of the amine may be a hydrogen atom.
    ≪ Step 5 &
    In the reaction scheme, the carboxylic acid ester moiety of the compound of the general formula (V) can be converted into a free cardiac group, if necessary, to prepare the compound of the general formula (IV). The carbonic acid ester moiety of the compound of formula (V) can be converted to a desired free carboxyl group by, for example, alkaline hydrolysis, acid hydrolysis, or acid decomposition by a known method. In addition, this deesterification reaction may be achieved by a novel method, and the method thereof is not limited or limited.
    The compound of formula (V) is an integrin α V β 3 antagonist and / or a GP IIb / IIIa antagonist, which can be administered orally by itself. Therefore, this conversion step from a carboxylic acid ester to a carboxyl group of a glass is not necessarily required.
    The compound having a pyrimidine ring which may be substituted in the compound of the general formula (VI) can be reduced to the corresponding tetrahydropyrimidine if necessary. Reduction can be done according to the tolerance method. For example, the catalytic reduction may be carried out using palladium carbon, ruterup carbon, rhodium carbon, palladium oxide, platinum oxide, ruthenium oxide, platinum oxide rhodium complex, aluminum rhodium complex, Raney nickel, palladium black or the like as a catalyst , Metal sodium or metal lithium in liquid ammonium may be reacted. Preferably, hydrogen may be reacted at atmospheric pressure or under pressure in the presence of palladium carbon in an acidic solvent, for example, hydrochloric acid in acetic acid.
    ≪ Steps 6.7 and 8 >
    The primary amine of the piperidine derivative portion of the compound of the general formula (III) is protected in advance, then the benzoic acid ester is converted into a free carboxyl group,
    R 9 HNCHR 10 CHR 11 COOR 12
    (Wherein R 9 , R 10 , R 11 and R 12 are the same as defined in formula (I)),
    To react with an amine of formula (VII) to form an amide bond, whereby a compound of formula (VII) can be prepared. Among the compounds of the general formula (VII), R 31 represents a protecting group of an amino group. Examples of the protecting group of the amino group include a tert-butyloxycarbonyl group, a benzyloxycarbonyl group and a p-methoxybenzyloxycarbonyl group, and a tert-butyloxycarbonyl group is preferable.
    Subsequently, the protecting group of the piperidine derivative moiety is removed, and if necessary, the carboxylic acid ester moiety can be converted to the free carboxyl group to give the compound of the general formula (VIII). For example, pyrimidine, benzimidazole or an amino group by a step 3 with a deprotected primary amine, and then, if necessary, converting the carboxylic acid ester moiety to a free carboxyl group , The compound of formula (VI) can be prepared. Specifically, see Intermediates 20, 21 and 22, and Examples 21 and 22.
    In the reaction, for example, amide bond formation from the general formula (IV) to the general formula (V) is firstly carried out, and among the compounds of the general formula (VI), a pyrimidine ring Reduction was performed. However, among the compounds of the general formula (IV), for example, the amide bond forming reaction may be carried out after reducing the basic atom group bonded to the primary amino group of the piperidine derivative, for example, the pyrimidine ring which may be substituted . In the reaction scheme, in the compounds of the general formulas (V) and (VI), the atoms already incorporated in the molecule, such as R 7 , R 8 , R 9 , R 10 and R 11 , . The conversion of the compound R 11 in the general formula (VI) can be carried out, for example, in Examples 15, 16, 17, 26 , 27 , 30, 32, 34, 36, 61, 65, 66, 68, 70, , 76, 79, 82, 83, 84, 86, 97, 98, 99, 101,
    Compounds of general formula (I) wherein X and Z are N can be prepared from the corresponding phenylpiperazine derivatives of general formula (III) according to steps 3-5. The corresponding phenylpiperazine derivative of the general formula (III) can be prepared, for example, by reacting piperazine with ethyl 4-fluorobenzoate in dimethylsulfoxide at a temperature of 120 ° C according to Step 1.
    Compounds of general formula (I) in which X represents N and Z represents CH can be prepared according to the method described in WO94 / 12181 in 4-bromobenzyl alcohol in which the hydroxyl group is protected. Specifically, a 4-bromobenzyl alcohol obtained by lithiation (protected with a hydroxyl group) is reacted with N-Boc-4-piperidone to obtain a phenylpiperidine derivative, the resulting hydroxyl group is removed, The phenylpiperidine derivative corresponding to the formula (II) can be prepared by deprotecting the protected hydroxyl group, esterifying the deprotected hydroxyl group, and removing the Boc group. In this phenylpiperidine derivative, according to Steps 2 to 5, a compound represented by the general formula (I) in which X represents N and Z represents CH can be prepared.
    Compound (Ⅰ) D is> CR 5 R 6, can be a D> prepared according to the process 4 and 5 from the corresponding compound in CR 5 R 6 in the general formula (Ⅳ). Compounds corresponding to the general formula (IV) wherein D is > CR 5 R 6 can be obtained, for example, by reacting 2- (chloromethyl) benzimidazole and 4- (piperazin- 1-yl) benzoic acid ethyl ester in dimethylsulfoxide In the presence of potassium carbonate at room temperature. See Examples 89 and 90.
    Compounds of general formula (I) wherein D is O can be prepared according to steps 4 and 5 from compounds corresponding to general formula (IV) wherein D is O. A compound corresponding to the general formula (IV) wherein D is O can be prepared by reacting a basic group having an alkylsulfonyl group, that is, a compound corresponding to the group A, with respect to the hydroxyl group of the compound of the general formula (II). This reaction can be carried out according to the conditions described in, for example, Japanese Patent Application Laid-Open No. 1993-97818 or EP468766A1.
    Compounds of general formula (I) wherein D is S may be prepared according to steps 4 and 5 in a compound corresponding to general formula (IV) wherein D is S. The compound corresponding to the general formula (IV) wherein D is S is obtained by halogenating the hydroxyl group of the compound of the general formula (II) and reacting a basic atomic group having -SH group with respect to the halogen atom, that is, a compound corresponding to the group A Can be manufactured. The reaction of a halogen atom with an -SH group can be carried out, for example, in Res.Lab., Kohjin Co., Ltd, Jpapan Chem. Pharm. Bull. (1977), 25 (10), 2624-37.
    Uses of compounds / medicinal compositions
    The compounds according to the present invention have strong integrin V 3 antagonism as described in Pharmacological Study 1. Therefore, the compound of the present invention can be used for the treatment of diseases mediated by integrin V 3 . Integrin α v β 3 has been implicated in the pathogenesis of cardiovascular disease (eg, acute myocardial infarction, endothelial hypertrophy, restenosis after PTCA / stent export, unstable angina, ringworm, PTCA / stenting angina, (E.g., atherosclerotic) cancer (e. G., Solid tumors), < / RTI > and diseases related to angiogenesis (e. G., Diabetic retinopathy, diabetic vascular complications, vascular grafting) And its metastasis may be mediated by a variety of mechanisms including, but not limited to, immune disorders (e.g., arthritis, especially rheumatoid arthritis), bone diseases (such as osteoporosis, hypercalcemia, dermatomyositis, hyperparathyroidism, painful joints, (DN & P, 10 (8), 456 (1997)). Also, in this specification, "treatment" includes prevention.
    The compound according to the present invention also has a cell adhesion inhibiting action as described in 3 in the pharmacological test. Therefore, the compounds according to the present invention can be used for the treatment of diseases in which cell adhesion inhibition is therapeutically effective. Specifically, it is possible to treat diseases such as cardiovascular diseases, angiogenesis-related diseases, cerebrovascular diseases, cancer, and immune diseases by inhibiting adhesion of smooth muscle cells to cell adhesive proteins (in particular, vitronectin) (DN & P, 10 (8), 456 (1997)). In addition, cancer and its metastasis can be treated by inhibiting adhesion between vascular endothelial cells and cell adhesive proteins (particularly, vitronectin). In addition, bone diseases can be treated by inhibiting adhesion between osteoclasts and cell adhesive proteins (particularly, osteopontin).
    In the present specification, the term "cell adhesion" refers to adhesion of vascular cells (specifically, smooth muscle cells and endothelial cells) and cell adhesive proteins (specifically, vitronectin, osteopontin and von Willevrand factors ), Adherence between blood vessel cells and blood cells (specifically, white blood cells), and adhesion between blood cells, in particular, adhesion between human vascular smooth muscle cells and human vitronectin.
    The compounds according to the present invention also have GPIIb / IIIa antagonistic action and human platelet aggregation inhibitory action, as described in Pharmacological Test Example 2. Accordingly, the compounds of the present invention can be used for the treatment of diseases in which GPIIb / IIIa antagonism and inhibition of human platelet aggregation are therapeutically effective. Specifically, the compounds according to the present invention can be used for the treatment of platelet thrombosis and thromboembolism, for the improvement of peripheral circulating blood flow, during and after treatment of thrombus decay, and after coronary artery bypass surgery after coronary angioplasty or other arterial angioplasty. , And for suppressing blood coagulation during extracorporeal circulation. The compounds according to the present invention can also be used for the treatment of thrombotic thrombocytopenic purpura, hemolytic uremic syndrome. (Hyundai medicine, 29, (11), 2753, (1997)).
    The compound of the general formula (I) has oral absorption properties in rats even when the compound in which R 12 is an alkyl group is a water or a hydrogen atom (for example, the compound of Example 59) (data omitted). Therefore, any compound wherein R 12 is an alkyl group or a hydrogen atom can be used in the treatment of the above diseases.
    The compounds according to the present invention and their pharmacologically acceptable salts and solvates can be administered orally or parenterally (for example, by inhalation, rectal, topical, subcutaneous, intravenous, intravenous, intramuscular, Transdermal administration), and can be formulated as various pharmaceutical forms suitable for oral or parenteral administration, and can be used in animals other than humans and humans.
    The compound according to the present invention may be administered orally or parenterally, for example, in the form of tablets, capsules, granules, powders, pills, fine granules, troches, syrups and emulsions, oral preparations such as inhalants, A liquid preparation, an intravenous injection and an intramuscular injection, a drip intravenous injection, a rectal administration agent, a maintenance suppository, a water-soluble suppository, and an ointment.
    These various preparations can be prepared by using the usual agents such as excipients, extenders, binders, wetting agents, disintegrators, surface active agents, lubricants, dispersants, buffers, preservatives, solubilizers, preservatives, flavors, analgesics, ≪ / RTI > Examples of the non-toxic additives that can be used include lactose, fructose, glucose, starch, gelatin, magnesium carbonate, synthetic magnesium silicate, talc, magnesium stearate, methylcellulose, carboxymethylcellulose or its salts, Glycerin, ethanol, citric acid, sodium chloride, sodium sulfite, sodium phosphate, ascorbic acid, cyclodextrin, and the like.
    In the pharmaceutical composition, the content of the compound according to the present invention varies depending on its formulation, but is usually 1 to 70%, preferably 5 to 50% by weight in the total composition. The dosage for treatment and prevention of coronary diseases and the like is appropriately determined in consideration of the usage, age of the patient, sexually transmitted diseases, degree of symptoms, etc., but is usually about 0.1 to 2000 mg per day, preferably about 5 to 400 mg per day , Which may be administered once a day or divided into several times a day or several days. The present invention is illustrated by the following examples, but the present invention is not limited to these examples.
    Intermediate 1: 4- (4-Hydroxypiperidin-1-yl) benzoic acid ester
    To 5.0 g of 4-hydroxypiperidine was added 10 ml of dimethyl sulfoxide to dissolve it. To the solution was added 7.2 ml of 4-fluorobenzoic acid ethyl ester and the mixture was stirred at 120 캜 for 3 days. The reaction solution that had been cooled to room temperature was poured into 200 ml of water with vigorous stirring. The obtained insoluble matter was collected by filtration through a glass filter, and washed once with 50 ml of water and then with 50 ml of hexane. The obtained solid was dried to obtain 9.6 g of the title compound.
    Physicochemical Properties of Intermediate 1
    Intermediate 2: 4- (4-phthalimidopiperidin-1-yl) benzoic acid ethyl ester
    To 12.0 g of the intermediate, 80 ml of benzene was added and dissolved, and 2.4 g of phthalic anhydride and 4.0 ml of tributylphosphine were added and cooled to 0 占 폚. After the addition of 4.0 mg of 1.1 '- (azodicarbonyl) -dipiperidine at the same temperature, the mixture was stirred at room temperature for 23 hours. 300 mg of water was added to stop the reaction, extracted three times with 300 ml of methylene chloride, The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: chloroform-acetone = 50: 1) to obtain 1.6 g of the title compound.
    Physicochemical Properties of Intermediate 2
    Intermediate 3: 4- (4-Aminopiperidin-1-yl) benzoic acid ethyl ester
    To 850 mg of Intermediate 2, 56 ml of methanol was added and suspended, and 4.5 ml of hydrazine monohydrate was added, followed by stirring at room temperature for 16 hours. The reaction solution was filtered with a glass filter, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to give the title compound (551 mg).
    Physicochemical Properties of Intermediate 3
    Intermediate 4: 4- {4- (Pyrimidin-2-ylamino) piperidin-1-yl} benzoic acid ethyl ester
    250 mg of Intermediate 3 was dissolved in 10 ml of dimethylformamide, and 240 mg of 2-bromopyrimidine was added. Further, 0.1 ml of diisopropylethylamine was added and the mixture was heated to 125 캜 and stirred for 10 hours. After cooling to room temperature, 150 ml of saturated brine was added and extracted three times with 150 ml of methylene chloride. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: hexane-ethyl acetate = 1: 1) to obtain 212 mg of the title compound.
    Physicochemical Properties of Intermediate 4
    Intermediate 5: 4- {4- (Pyrimidin-2-ylamino) piperidin-1-yl} benzoic acid
    9.0 mg of tetrahydrofuran and 3.0 ml of methanol were added to and dissolved in 100 mg of Intermediate 4, and 3.0 ml of 1 N aqueous sodium hydroxide solution was added thereto. The mixture was stirred at 40 DEG C for 8 hours and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain the title compound (75 mg).
    Physicochemical Properties of Intermediate 5
    Example 1: (2S) -Benzenesulfonylamino-3- [4 {4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino]
    6.0 mg of Intermediate 5 was dissolved in 1.0 ml of methylene chloride and 1.0 ml of dimethylformamide, and 6 ml of diisopropylethylamine and 13 mg of benztriazol-1-yloxytri (dimethylamino) phosphonium hexafluorophosphate And the mixture was stirred at room temperature for 3 hours. This reaction solution was added to 1.0 ml of a methylene chloride solution of 8.1 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride cooled to -10 ° C. Further, 6 쨉 l of diisopropylethylamine was added and the mixture was stirred at the same temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol = 10: 1) to obtain 7.0 mg of the title compound.
    Physicochemical properties of the compound of Example 1
    Example 2: (2S) -Benzenesulfonylamino-3- [4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid
    To 7.0 mg of the compound of Example 1 was dissolved 0.3 ml of methylene chloride, and 0.3 ml of trifluoroacetic acid was added at 0 캜, followed by stirring at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel thin layer chromatography for separation (eluent: gluform-methanol-acetic acid = 10: 2: 1) and then purified by Sephadex LH-20 (eluent: methanol) 6.3 mg of the compound was obtained.
    Physicochemical properties of the compound of Example 2
    Example 3: (2S) -Benzenesulfonylamino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- Propionic acid
    To 3.6 mg of the compound of Example 2 was dissolved 5.0 ml of acetic acid and 0.5 ml of concentrated hydrochloric acid, 1.8 mg of 10% palladium carbon was added, and the mixture was shaken extensively at room temperature for 2.5 hours under hydrogen 3 atm. The insoluble matter was filtered, washed twice with water and methanol, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The residue azeotroped twice with toluene was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) and then eluted with Sephadex LH- : Methanol) to obtain 3.2 mg of the title compound.
    Physicochemical properties of the compound of Example 3
    Intermediate 6: 4 - {(3R) -hydroxypyrrolidin-1-yl} benzoic acid ethyl ester
    (R) - (+) - 3-pyrrolidino was dissolved in 20 ml of dimethylsulfoxide. To the solution was added 8.8 ml of 4-fluorobenzoic acid ethyl ester and the mixture was stirred at 110 ° C for 2 days. After cooling to room temperature, 300 ml of a saturated ammonium chloride aqueous solution was added and extracted three times with 300 ml of methylene chloride. The combined organic layers were washed twice with 200 ml of water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: chloroform-methanol = 20: 1) to obtain 7.0 g of the title compound.
    Physicochemical Properties of Intermediate 6
    Intermediate 7: 4 - {(3S) -phthalimidopyrrolidin-1-yl} benzoic acid ethyl ester
    To 200 mg of the intermediate 6, 8.5 ml of benzene was added and dissolved, 250 mg of phthalimide and 0.4 ml of tributylphosphine were added, and the mixture was cooled to 0 占 폚. After adding 430 mg of 1.1 '- (azodicarbonyl) -dipiperidine at the same temperature, the mixture was stirred at room temperature for 14 hours. The reaction was stopped by adding 150 ml of water and extracted three times with 100 ml of ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: chloroform-acetone = 50: 1) to obtain 133 mg of the title compound.
    Physicochemical Properties of Intermediate 7
    Intermediate 8: 4 - {(3S) -aminopyrrolidin-1-yl} benzoic acid ethyl ester
    80 ml of methanol was added to 1.5 g of Intermediate 7, and the mixture was suspended. 8.2 ml of hydrazine monohydrate was added, and the mixture was stirred at room temperature for 15 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 1.0 g of the title compound.
    Intermediate 9: 4 - {(3S) - (Pyrimidin-2-ylamino) pyrrolidin- 1 -yl} benzoic acid ethyl ester
    To 1.0 g of the crude compound of Intermediate 8 was dissolved 40 ml of dimethylformamide, and 2-bromopyrimidine (980 mg) was added. Further, 3.7 ml of diisopropylethylamine was added, and the mixture was heated to 120 占 폚 and stirred for 11 hours. After cooling to room temperature, 300 ml of water was added and extracted three times with 300 ml of methylene chloride. The combined organic layers were washed with 300 ml of water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue azeotroped twice with toluene was purified by silica gel column chromatography (eluent: hexane-ethyl acetate = 1: 1) to obtain 921 mg of the title compound.
    Physicochemical properties of intermediate 9
    Intermediate 10: 4 - {(3S) - (Pyrimidin-2-ylamino) pyrrolidin- 1 -yl} benzoic acid
    24 mg of tetrahydrofuran and 8.0 ml of methanol were added to and dissolved in 250 mg of Intermediate 9, and 8.0 ml of a 1N aqueous sodium hydroxide solution was added. The mixture was stirred at 40 占 폚 for 14 hours and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain the title compound (184 mg).
    Physicochemical Properties of Intermediate 10
    Example 4: (2S) -Benzenesulfonylamino-3- [4 {(3S) - (pyrimidin-2ylamino) pyrrolidin- 1 -yl} benzoylamino] propionic acid t-butyl ester
    3.5 mg of methyl formamide was added to 100 mg of Intermediate 10 and suspended. To this was added 125 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride. Further, 57 mg of 1-hydroxybenzotriazole, 77 μl of N-methylmorpholine and 81 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and the mixture was stirred at room temperature for 14 hours. The reaction solution was concentrated under reduced pressure, and the residue was azeotropically distilled five times with toluene. The residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 50: 1) to obtain 199 mg of the title compound.
    Physicochemical properties of the compound of Example 4
    Example 5: (2S) -Benzenesulfonylamino-3- [4 - {(3S) - (pyrimidin- 2- ylamino) pyrrolidin- 1 -yljbenzoylamino]
    102 mg of the compound of Example 4 was dissolved in 1.0 ml of methylene chloride, 0.1 ml of trifluoroacetic acid was added at 0 캜, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 15: 1) to obtain 76 mg of the title compound.
    Physicochemical properties of the compound of Example 5
    Example 6: (2S) -Benzenesulfonylamino-3- [4 - {(3S) - (1,4,5,6-tetrahydropyrimidin- 2- ylamino) pyrrolidin- Benzoylamino] propionic acid
    To 54 mg of the compound of Example 5, 5.0 ml of acetic acid and 0.5 ml of concentrated hydrochloric acid were added and dissolved, 25 mg of 10% palladium carbon was added, and the mixture was shaken extensively at room temperature for 3 hours under hydrogen 3 atm. The insoluble matter was filtered off and washed twice with water and methanol. The filtrate and the washing solution were combined and concentrated under reduced pressure. The residue azeotroped twice with toluene was purified by silica gel column chromatography (elution system: methylene chloride-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) and then eluted with Sephadex LH-20 (eluent: methanol- 0.05N hydrochloric acid = 1: 1) to obtain 29 mg of the trihydrochloride of the title compound.
    Physicochemical properties of the compound of Example 6
    Intermediate 11: 4 - {(3S) -hydroxypyrrolidin-1-yl} benzoic acid ethyl ester
    60 ml of tetrahydrofuran was added to 3.0 g of Intermediate 6 to dissolve it, and 4.0 g of triphenylphosphine and 920 mg of acetic acid were added and cooled to 0 占 폚. 2.4 ml of diethyl azodicarboxylate was added at the same temperature, followed by stirring at room temperature for 15 hours. The reaction was stopped by adding 200 ml of water, and extracted three times with 200 ml of ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: hexane-ethyl acetate = 3: 1) to obtain 2.75 mg of 4 - {(3S) -acetoxypyrrolidin- 1-yl} benzoic acid ester.
    To 2.7 g of the resulting compound, 50 ml of ethanol was added and dissolved, and 800 mg of sodium ethoxide was added at room temperature. After 3.5 hours, the reaction solution was poured into a mixed solution of 800 ml of an aqueous saturated ammonium chloride solution and 800 mg of methylene chloride while stirring. The organic layer was separated, and the aqueous layer was washed twice with 500 ml of methylene chloride. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: chloroform-acetone = 20: 1) to obtain 2.2 g of the title compound.
    Physicochemical Properties of Intermediate 11
    Intermediate 12: 4 - {(3R) -phthalimidopyrrolidin-1-yl} benzoic acid ethyl ester
    To 1.8 g of Intermediate 11 was added 36 ml of tetrahydrofuran to dissolve, 1.4 ml of phthalimide 2.3 ml of tributylphosphine was added and the mixture was cooled to 0 占 폚. At the same temperature, 2.4 g of 1.1 '- (azodicarbonyl) -dipiperidine was added and the mixture was stirred at room temperature for 11 hours. After completion of the reaction, the mixture was concentrated under reduced pressure, and 100 ml of methylene chloride was added. The precipitated solid was removed by using a glass filter, and the filtrate was concentrated under reduced pressure. 100 ml of methanol was added to the residue to suspend, and the precipitated solid was filtered with a glass filter to obtain 2.2 g of the title compound.
    Physicochemical properties of intermediate 12
    Intermediate 13: 4 - {(3R) -aminopyrrolidin-1-yl} benzoic acid ethyl ester
    To 1.5 g of Intermediate 12, 80 ml of methanol was added and suspended, and 8.2 ml of hydrazine monohydrate was added, followed by stirring at room temperature for 13 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 800 mg of the title compound.
    Physicochemical Properties of Intermediate 13
    Intermediate 14: 4 - {(3R) - (Pyrimidin-2-ylamino) pyrrolidin- 1 -yl} benzoic acid ethyl ester
    30 mg of dimethylformamide was added to 735 mg of Intermediate 13 to dissolve, and 750 mg of 2-bromopyrimidine was added thereto. Further, 2.8 ml of diisopropylethylamine was added and the mixture was heated to 120 캜 and stirred for 11 hours. After cooling to room temperature, 300 ml of water was added and extracted three times with 300 ml of methylene chloride. The combined organic layer was washed with 300 ml of water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue azeotroped twice with toluene was purified by silica gel column chromatography (eluent: hexane-ethyl acetate = 1: 1) to give the title compound (590 mg).
    Physicochemical properties of intermediate 14
    Intermediate 15: 4 - {(3R) - (Pyrimidin-2-ylamino) pyrrolidin- 1 -yl} benzoic acid
    To 200 mg of Intermediate 14, 20 ml of tetrahydrofuran and 6.4 ml of methanol were added and dissolved, and 6.4 ml of a 1N aqueous sodium hydroxide solution was added. After stirring at 40 DEG C for 5 hours, the obtained residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 156 mg of the title compound.
    Physicochemical Properties of Intermediate 15
    Example: 7 (2S) -Benzenesulfonylamino-3- [4 - {(3R) - (pyrimidin- 2- ylamino) pyrrolidin- 1 -yl} benzoylamino] propionic acid t-butyl ester
    3.5 mg of dimethylformamide was added to 100 mg of Intermediate 15, and the mixture was suspended. To this was added 137 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride. Further, 71 mg of 1-hydroxybenzotriazole, 77 占 퐇 of N-methylmorpholine and 101 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 14 hours. The reaction solution was concentrated under reduced pressure, and the residue purged with toluene five times was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 40: 1) to obtain the title compound (224 mg).
    Physicochemical properties of the compound of Example 7
    Example 8: (2S) -Benzenesulfonylamino-3- [4 - {(3R) -pyrimidin-2- ylamino) pyrrolidin- l- yl} benzoylamino] propionic acid
    1.0 mg of methylene chloride was added to 110 mg of the compound of Example 7 to dissolve it, and 1.0 ml of trifluoroacetic acid was added at 0 deg. C, followed by stirring at room temperature for 5 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (eluent: methylene chloride-methanol = 15: 1) to obtain 99 mg of the title compound.
    Physicochemical properties of the compound of Example 8
    Intermediate 16: 4- (1H-Benzimidazol-2-ylamino) -1- (ethoxycarbonyl) piperidine
    Amino-1-piperidinecarboxylate (11 ml) was added to 5.0 g of 2-chlorobenzimidazole, and the mixture was stirred at 170 占 폚 for 5 hours. After cooling to room temperature, 200 ml of heated chloroform was added and dissolved, and 500 ml of a saturated sodium carbonate aqueous solution was added. The organic layer was separated, and the aqueous layer was extracted twice with 200 ml of chloroform. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. To the obtained residue, 100 ml of ethyl acetate was added, and the insoluble matter was filtered with a glass filter and washed with 100 ml of ethyl acetate to obtain 6.8 g of the title compound.
    Physicochemical Properties of Intermediate 16
    Intermediate 17: 4- (1H-Benzimidazol-2-ylamino) piperidine
    To 150 mg of Intermediate 16, 2.5 ml of 47% hydrobromic acid was added and dissolved, and the mixture was heated under reflux for 7.5 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 91 mg of the title compound.
    Physicochemical properties of intermediate 17
    Intermediate 18: 4- {4- (1H-Benzimidazol-2-ylamino) piperidin-1-yl} benzoic acid ethyl ester
    5.2 ml of dimethyl sulfoxide was added to 1.1 g of Intermediate 17 and dissolved, and 0.77 ml of 4-fluorobenzoic acid ethyl ester was added. The mixture was stirred at 140 DEG C for 6.5 hours, cooled to room temperature, and 300 mL of saturated brine was added. The mixture was extracted three times with 300 ml of methylene chloride, and the combined organic layers were washed twice with 200 ml of brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 25: 1) to obtain the title compound (940 mg).
    Physicochemical properties of intermediate 18
    Intermediate 19: 4- {4- (1 H-Benzimidazol-2-ylamino) piperidin- 1 -yl} benzoic acid
    9.0 ml of tetrahydrofuran and 3.0 ml of methanol were added to 103 mg of Intermediate 18 to dissolve, and 3.0 ml of a 1N aqueous sodium hydroxide solution was added. After stirring at 40 ° C for 3.5 hours, the mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 92 mg of the title compound.
    Physicochemical Properties of Intermediate 19
    Example 9: (2S) -Benzenesulfonylamino-3- [4- {4- (1H-benzimidazol-2- ylamino) piperidin- 1 -yl} benzoylamino] propionic acid t-butyl ester
    1.5 mg of dimethylformamide was added to 50 mg of Intermediate 19 to dissolve and 59 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto. Further, 30 mg of 1-hydroxybenzotriazole, 50 ml of N-methylmorpholine and 43 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and the mixture was stirred at room temperature for 14 hours. The reaction solvent was concentrated under reduced pressure, and the residue azeotropically distilled five times with toluene was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol-concentrated ammonia water = 100: 10: 1) to give 62 mg of the title compound .
    Physicochemical properties of the compound of Example 9
    Example 10: (2S) -Benzenesulfonylamino-3- [4- {4- (lH-benzimidazol-2- ylamino) piperidin- l- yl} benzoylamino] propionic acid
    To 60 mg of the compound of Example 9, 0.5 mg of methylene chloride was added and dissolved, and 0.5 ml of trifluoroacetic acid was added at room temperature, followed by stirring at the same temperature. After 3.5 hours, the reaction solution was concentrated under reduced pressure and purified by silica gel thin layer chromatography for separation (eluent: methylene chloride-ethanol-water-concentrated ammonia water = 8: 8: 1: 1), followed by Sephadex LH- System: methanol-concentrated ammonia water = 9: 1) to obtain 36 mg of the title compound.
    Physicochemical properties of the compound of Example 10
    Example 11: (3S) - [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] pent-
    15 mg of Intermediate 5 was dissolved in 1.0 ml of dimethylformamide, and 11 mg of (3S) -ethynyl-3-aminopropionic acid ethyl ester hydrochloride was added thereto. Further, 10 mg of 1-hydroxybenzotriazole, 17 mu l of N-methylmorpholine and 15 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 14 hours. The reaction solution was concentrated under reduced pressure, and the residue was azeotropically distilled five times with toluene was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain 15 mg of the title compound.
    Physicochemical properties of the compound of Example 11
    Example 12: (3S) - [4- {4- (Pyrimidin-2-ylamino) piperidin- 1 -ylJbenzoylamino] pent-
    1.2 mg of tetrahydrofuran and 0.4 ml of methanol were added to 15 mg of the compound of Example 11 and dissolved, and 0.4 ml of a 1N sodium hydroxide aqueous solution was added. The mixture was stirred at 40 ° C for 30 minutes and then concentrated under reduced pressure. The residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) for separation and then eluted with Sephadex LH-20 (eluent: methanol- : 1) to obtain 13 mg of the title compound.
    Physicochemical properties of the compound of Example 12
    Example 13: Preparation of (2S) - (benzyloxycarbonyl) amino-3- [4- {4- (pyrimidin- 2- ylamino) piperidin- 1 -yljbenzoylamino] propionic acid t-butyl ester
    1.0 g of dimethylformamide and 1.0 ml of tetrahydrofuran were added to 64 mg of Intermediate 5, and 92 mg of (2S) -N-benzyloxycarbonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto . Further, 43 mg of 1-hydroxybenzotriazole, 71 μl of N-methylmorpholine and 62 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 14 hours. The reaction solution was concentrated under reduced pressure, and the residue was azeotroped with toluene five times. The residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 30: 1) to obtain 123 mg of the title compound.
    Physicochemical properties of the compound of Example 13
    Example 14: Preparation of (2S) - (benzyloxycarbonyl) amino-3- [4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid
    120 mg of the compound of Example 13 was dissolved in 0.5 ml of methylene chloride, and 0.5 ml of trifluoroacetic acid was added at 0 deg. C, followed by stirring at room temperature. After 2 hours, the reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (eluent: chloroform-methanol-acetic acid = 50: 10: 1) and then eluted with Sephadex LH-20 (eluent: methanol- : 1) to obtain 80 mg of the title compound.
    Physicochemical properties of the compound of Example 14
    Example 15: (2S) -Amino-3- [4 {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- 1 -yl} benzoylamino] propionic acid
    To 10 mg of the compound of Example 14, 5 ml of acetic acid and 0.5 ml of concentrated hydrochloric acid were added and dissolved, 5.0 mg of 10% palladium carbon was added, and the mixture was shaken vigorously at room temperature for 2 hours under hydrogen 3 atm. , Water and methanol twice, and the filtrate and the washing solution were combined and concentrated under reduced pressure. Twice with toluene to give 10 mg of the dihydrochloride of the title compound.
    Physicochemical properties of the compound of Example 15
    Example 16: Synthesis of (2S) - (benzyloxycarbonyl) amino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- } Benzoylamino] propionic acid
    To 15 mg of the compound of Example 15, 0.5 ml of acetone and 0.5 ml of water were added and dissolved, and 25 mg of potassium carbonate was added. Further, 8.0 ml of benzyloxycarbonyl chloride was added at room temperature, stirred for 2 hours, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: n-butanol-acetic acid-water = 8: 1: 1) and then purified by Sephadex G-10 (eluent: 0.05N hydrochloric acid) 6.7 mg.
    Physicochemical properties of the compound of Example 16
    Example 17: (2S) -butane-1-sulfonylamino-3- [4- {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- } Benzoylamino] propionic acid
    To 12 mg of the compound of Example 15, 0.5 ml of acetone and 0.5 ml of water were added and dissolved, and 14 mg of potassium carbonate was added. Also, 3.0 ml of n-butane sulfonyl chloride was added at room temperature, and 6 mg of potassium carbonate and 6.0 n- of n-butane sulfonyl chloride were added every 2 hours, followed by stirring for 6 hours, followed by concentration under reduced pressure. The residue was purified by silica gel column chromatography (eluent: n-butanol-acetic acid-water = 8: 1: 1) and then purified by Sephadex G-10 (eluent: 0.05N hydrochloric acid) n-butanesulfonic acid salt (11 mg).
    Physicochemical properties of the compound of Example 17
    Example 18: (2S) -Benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- {4- (pyrimidin- 2- ylamino) piperidin- Yl] amino] propionic acid t-butyl ester
    (2S) -benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester was added 116 mg of 50% methanol / 12 ml of ethylene chloride and dissolved, and 31 mg of cyclopropanecarboxaldehyde was added. A small amount of acetic acid was added to adjust the pH of the reaction solution to 3 to 4, 48 mg of sodium cyanoborohydride was added, and the mixture was reacted at room temperature for 2 hours. To the residue obtained by concentrating the reaction solution under reduced pressure, 10 ml of a saturated sodium carbonate aqueous solution was added, and the mixture was extracted twice with 10 ml of chloroform each time. The resulting residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 1000: 30: 1) to obtain (2S) -N-benzenesulfonyl-3 -N-cyclopropylmethyl-2,3-diaminopropionic acid tert-butyl ester (74 mg).
    Physicochemical properties of (2S) -N-benzenesulfonyl-3-N-cyclopropylmethyl-2,3-diaminopropionic acid t-butyl ester
    To 17 mg of Intermediate 5, 0.5 ml of dimethylformamide and 0.5 ml of methylene chloride were added and dissolved, and thereto was added dropwise a solution of (2S) -N-benzenesulfonyl-3-N-cyclopropylmethyl-2,3-diaminopropionic acid t- 20 mg of butyl ester was added. Further, 9.0 mg of 1-hydroxybenzotriazole, 12 ml of N-methylmorpholine and 13 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and the mixture was stirred at room temperature for 4 days. The reaction solution was concentrated under reduced pressure, and the residue azeotroped with toluene five times was purified by silica gel thin layer chromatography (eluent: chloroform-methanol = 10: 1) for separation to obtain 16 mg of the title compound.
    Physicochemical properties of the compound of Example 18
    Example 19: (2S) -Benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- {4- (pyrimidin- 2- ylamino) piperidin- Yl] amino] propionic acid
    To 31 mg of the compound of Example 18 was added 0.50 ml of methylene chloride and dissolved, and then 0.50 ml of trifluoroacetic acid was added at 0 占 폚. After raising the temperature to room temperature and stirring for 5 hours, the reaction solution was concentrated under reduced pressure and purified by silica gel thin layer chromatography for separation (eluent: chloroform-methanol = 5: 1) to obtain 19 mg of the title compound.
    Physicochemical properties of the compound of Example 19
    Example 20: (2S) -Benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- {4 - [(1,4,5,6-tetrahydropyrimidin- ) Piperidin-1-yl} benzyl] amino] propionic acid
    To 23 mg of the compound of Example 19, 5.0 ml of acetic acid and 0.50 ml of concentrated hydrochloric acid were added and dissolved, 11 mg of 10% palladium carbon was added, and the mixture was shaken extensively at room temperature for 1.5 hours under hydrogen 3 atm. The insoluble materials were filtered off, washed twice with water and methanol, respectively, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The residue azeotroped twice with toluene was purified by silica gel column chromatography (elution system: methylene chloride-ethanol-water-concentrated ammonia water = 15: 10: 1: 1) and then Sephadex LH-20 (eluent: methanol) To give the title compound (5.3 mg).
    Physicochemical properties of the compound of Example 20
    Intermediate 20: 4- [4- (t-Butoxycarbonyl) amino} piperidin-1-yl] benzoic acid
    2.04 ml of 1.4-dioxane and 1.0 ml of water were added to 154 mg of Intermediate 3 and dissolved, and 1.0 ml of a 1N sodium hydroxide aqueous solution and 170 mg of ditertiary-butyl carbonate were added at room temperature. After stirring for 30 minutes, the reaction solution was concentrated under reduced pressure to obtain 4- (4-t-butoxycarbonylamino-piperidin-1-yl) benzoic acid ethyl ester. Then, 9.0 ml of tetrahydrofuran and 3.0 ml of methanol were added to this compound and dissolved, and 6.0 ml of a 1N aqueous sodium hydroxide solution was added. After stirring at 50 DEG C for 4.5 hours, the pH was adjusted to 6 with 1N hydrochloric acid. After adding 100 ml of water, the mixture was extracted three times with 150 ml of ethyl acetate. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give 168 mg of the title compound.
    Physicochemical properties of the compound of intermediate 20
    Intermediate 21: (2S) -Benzenesulfonylamino-3- [4- [4 {(t-butoxycarbonyl) amino} piperidin- 1 -yl] benzoylamino] propionic acid t-
    Intermediate 20 (81 mg) was dissolved in 7.0 ml of dimethylformamide, and 77 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto. Further, 56 mg of 1-hydroxybenzotriazole, 0.15 ml of N-methylmorpholine and 98 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 22 hours. The reaction was stopped by adding 100 ml of a saturated aqueous solution of sodium hydrogencarbonate and extracted twice with 150 ml of methylene chloride. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: hexane-ethyl acetate = 1: 2) to obtain 111 mg of the title compound.
    Physicochemical properties of the compound of intermediate 21
    Intermediate 22: 3 {4- (4-Aminopiperidin-1-yl) benzoylamino} - (2S) - (benzenesulfonylamino) propionic acid t-butyl ester
    1.0 mg of saturated hydrochloric acid-methanol was added to 10 mg of Intermediate 21 to dissolve, and the mixture was stirred at room temperature. After 4 hours, the reaction solution was poured into a mixed solution of 5.0 mL of methanol and 5.0 mL of concentrated aqueous ammonia, and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 7.0 mg of the title compound.
    Physicochemical properties of intermediate 22
    Example 21: (2S) -Benzenesulfonylamino-3- {4- (4-guanidinopiperidin-l-yl) benzoylamino} propionic acid tert-butyl ester
    0.1 ml of dioxane and 0.1 ml of water were added to 18.8 mg of Intermediate 22, and further 0.03 ml of diisopropylethylamine and 22 mg of 1H-pyrazole-1-carboxyamidine hydrochloride were added, followed by stirring at room temperature for 31 hours did. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for separation (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain the title compound (17.1 mg).
    Physicochemical properties of the compound of Example 21
    Example 22: (2S) -Benzenesulfonylamino-3- {4- (4-guanidinopiperidin-l-yl) benzoylamino} propionic acid
    To 17.0 mg of the compound of Example 21, 0.5 ml of methylene chloride was added and dissolved. To this, 0.5 ml of trifluoroacetic acid was added, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (eluent: methylene chloride-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1) and then eluted with Sephadex LH-20 (eluent: Ammonia water = 10: 1) to obtain the title compound (10.2 mg).
    Physicochemical properties of the compound of Example 22
    Example 23: Preparation of 3- [4- {4- (lH-benzimidazol-2-ylamino) piperidin- 1 -ylJbenzoylamino] - (2S) - {(benzyloxycarbonyl) amino} propionic acid t-butyl ester
    Intermediate 19 (42 mg) was dissolved in 1.3 ml of dimethylformamide, and 53.7 mg of (2S) -N-benzyloxycarbonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto. Further, 25.4 mg of 1-hydroxybenztriazole, 41 占 퐇 of N-methylmorpholine and 36 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 19 hours. The reaction was terminated by the addition of 50 ml of a saturated aqueous sodium hydrogen carbonate solution and extracted three times with 50 ml of methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by thin layer chromatography on a separating funnel gel (eluent: methylene chloride-methanol = 7: 1) to give the title compound (58.8 mg).
    Physicochemical properties of the compound of Example 23
    Example 24: Preparation of 3- [4- {4- (lH-benzimidazol-2-ylamino) piperidin- l-yl} benzoylamino] - (2S) - {(benzyloxycarbonyl) amino}
    To 37.4 mg of the compound of Example 23 was added 0.5 ml of methylene chloride and dissolved, and 0.5 ml of trifluoroacetic acid was added, followed by stirring at room temperature for 1.5 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (eluent: methylene chloride-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1) and then eluted with Sephadex LH-20 (eluent: methanol- = 10: 1) to obtain 7.0 mg of the title compound.
    Physicochemical properties of the compound of Example 24
    Example 25: Synthesis of (2S) - (benzyloxycarbonyl) amino-3- [4- [4 - {(1-t-butoxycarbonyl-1H-benzimidazol- -1-yl] benzoylamino] propionic acid A-butyl ester
    To 50 mg of the compound of Example 23, 1.0 ml of methylene chloride was added and dissolved, and then 34 ml of triethylamine and 47 μl of ditertiary dicarbonate were added at room temperature, followed by stirring for 1 hour. To the reaction solution was added 30 ml of a saturated aqueous sodium hydrogencarbonate solution and extracted three times with 30 ml of methylene chloride. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain the title compound (60 mg).
    Physicochemical properties of the compound of Example 25
    Example 26: Preparation of (2S) -amino-3- [4- [4 - {(1-t-butoxycarbonyl-1H-benzimidazol-2- yl) amino} piperidin- Amino] propionic acid t-butyl ester
    To 50 mg of the compound of Example 25, 17.5 ml of tetrahydrofuran, 5.0 ml of water and 2.5 ml of acetic acid were added and dissolved. 50 mg of 10% palladium carbon was added and stirred vigorously at room temperature for 14 hours under hydrogen pressure of 1 atm. Insoluble materials were filtered off and washed twice with ethanol. The combined filtrate and wash solution was neutralized with a 1N aqueous sodium hydroxide solution, concentrated under reduced pressure at 30 ° C, and tetrahydrofuran and ethanol were removed. Salt was added to the obtained aqueous solution to be saturated, and extracted three times with 50 ml of methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain the title compound (26.1 mg).
    Physicochemical properties of the compound of Example 26
    Example 27: Synthesis of (2S) - (butane-1-sulfonylamino) -3- [4- [4- {1- tert -butoxycarbonyl-1H-benzimidazol- 1-yl] benzoylamino] propionic acid t-butyl ester
    To 10.5 mg of the compound of Example 26 was dissolved 0.5 ml of dimethylformamide, and 6.5 ml of diisopropylethylamine and 2.4 ml of n-butane sulfonyl chloride were added at room temperature. After stirring for 1.5 hours, 5 mg of piperazine was added and the mixture was further stirred for 5 minutes. To the reaction solution was added 30 ml of a saturated aqueous solution of sodium hydrogencarbonate and extracted three times with 30 ml of ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for elution (eluent: hexane-ethyl acetate = 1: 2) to give the title compound (10.5 mg).
    Physicochemical properties of the compound of Example 27
    Example 28: (2S) -butane-1-sulfonylamino-3- [4- {4- (lH-benzimidazol- 2- ylamino) piperidin- l- yl} benzoylamino] propionic acid
    To 15.2 mg of the compound of Example 27, 0.5 ml of methylene chloride was added and dissolved. Then, 5 占 퐇 of anisole and 0.5 ml of trifluoroacetic acid were added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure and purified by silica gel thin layer chromatography for separation (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1), followed by Sephadex LH-20 (eluent: methanol- 1) to obtain 7.5 mg of the title compound.
    Physicochemical properties of the compound of Example 28
    Example 29: (2S) -Amino-3- [4- {4- (lH-benzimidazol-2- ylamino) piperidin- l- yl} benzoylamino] propionic acid
    To 21 mg of the compound of Example 26 was dissolved 1.0 ml of methylene chloride, and 0.1 ml of trifluoroacetic acid was added, followed by stirring at room temperature for 24 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel thin layer chromatography for separation (elution system: methylene chloride-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1) followed by Sephadex LH-20 (eluent: methanol- Concentrated ammonia water = 10: 1) to obtain the title compound (8.7 mg).
    Physicochemical properties of the compound of Example 29
    Example 30: Preparation of 3- [4- [4 - {(1-t-butoxycarbonyl-1H-benzimidazol-2-yl) amino} piperidin- 1 -yl] benzoylamino] - {(2,4,6-trimethylbenzenesulfonyl) amino} propionic acid t-butyl ester
    To 20.2 mg of the compound of Example 26 was dissolved 0.5 mg of dimethylformamide, and 10.3 디 of diisopropylethylamine and 6.3 mg of 2,4,6-trimethylbenzenesulfonyl chloride were added at room temperature. After stirring for 1.5 hours, 5 mg of piperidine was added and the mixture was further stirred for 5 minutes. To the reaction solution was added 30 ml of a saturated aqueous solution of sodium hydrogencarbonate and extracted three times with 30 ml of ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for elution (eluent: hexane-ethyl acetate = 1: 2) to give the title compound (10.0 mg).
    Physicochemical properties of the compound of Example 30
    Example 31: 3- [4- {4- (1 H-Benzimidazol-2-ylamino) piperidin- 1 -yl} benzoylamino] - (2S) - {(2,4,6- Sulfonyl) amino} propionic acid
    To 10 mg of the compound of Example 30 was added 0.5 ml of methylene chloride and dissolved, and 3 占 퐇 of anisole and 0.5 ml of trifluoroacetic acid were added at 0 占 폚 and the mixture was stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel thin layer chromatography for separation (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1), followed by Sephadex LH-20 (eluent: methanol- 1) to obtain the title compound (5.0 mg).
    Physicochemical properties of the compound of Example 31
    Example 32: Preparation of 3- [4- [4 - {(1-t-butoxycarbonyl-1H-benzimidazol-2-yl) amino} piperidin- 1 -yl] benzoylamino] - {(4-fluorobenzenesulfonyl) amino} propionic acid t-butyl ester
    To 26.1 mg of the compound of Example 26 was dissolved 0.5 ml of dimethylformamide, and 16 ml of diisopropylethylamine and 8.8 ml of 4-fluorobenzene sulfonyl chloride were added at room temperature. After stirring for 2.5 hours, 5 mg of piperazine was added and the mixture was further stirred for 5 minutes. To the reaction solution was added 30 ml of a saturated aqueous solution of sodium hydrogencarbonate and extracted three times with 30 ml of ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (eluent: hexane-ethyl acetate = 1: 2) to obtain the title compound (23.0 mg).
    Physicochemical properties of the compound of Example 32
    Example 33: Preparation of 3- [4- {4- (lH-benzimidazol-2-ylamino) piperidin- 1 -ylJbenzoylamino] - (2S) {4- fluorobenzenesulfonyl) amino} Propionic acid
    To 23.0 mg of the compound of Example 32, 0.5 ml of methylene chloride was added and dissolved. 7 占 퐇 of anisole and 0.5 ml of trifluoroacetic acid were added at 0 占 폚, and the mixture was stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel thin layer chromatography for separation (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) and then eluted with Sephadex LH-20 (eluent: methanol- 1) to obtain the title compound (10.0 mg).
    Physicochemical properties of the compound of Example 33
    Example 34: Synthesis of 3- [4- [4 - {(1-t-butoxycarbonyl-1H-benzimidazol-2-yl) amino} piperidin- 1 -yl] benzoylamino] - {(4-nitrobenzenesulfonyl) amino} propionic acid t-butyl ester
    To 45.0 mg of the compound of Example 26 was dissolved 1.0 ml of dimethylformamide, and 30 μl of diisopropylethylamine and 17.2 mg of 4-nitrobenzenesulfonyl chloride were added at room temperature. After stirring for 2.5 hours, 5 mg of piperazine was added and the mixture was further stirred for 5 minutes. To the reaction solution was added 50 ml of a saturated aqueous sodium hydrogencarbonate solution and extracted three times with 50 ml of ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (eluent: nucleic acid-ethyl acetate = 1: 1) to give the title compound (54.2 mg).
    Physicochemical properties of the compound of Example 34
    Example 35: Preparation of 3- [4- {4- (1 H-benzimidazol-2-ylamino) piperidin- 1 -yl} benzoylamino] - (2S) - {(4-nitrobenzenesulfonyl) } Propionic acid
    To 58.0 mg of the compound of Example 34, 1.0 ml of methylene chloride was added and dissolved. 17 占 퐇 of anisole and 1.0 ml of trifluoroacetic acid were added at 0 占 폚, and the mixture was stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain the title compound (15.1 mg).
    Physicochemical properties of the compound of Example 35
    Example 36: Preparation of (2S) - (4-aminobenzenesulfonyl) amino-3- [4- {
    5.0 mg of ethanol was added to 15.0 mg of the compound of Example 35 to dissolve it, 15 mg of 10% palladium carbon was added, and the mixture was stirred vigorously under hydrogen at 1 atm for 3 hours. The insoluble materials were filtered, washed twice with methanol, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) and then purified by Sephadex LH-20 (eluent: methanol-concentrated ammonia water = 10: 1) 2.5 mg.
    Example 36 Physicochemical properties of this compound
    Intermediate 23: 1- (Ethoxycarbonyl) -4 - {(1 H-imidazo [4,5- b] pyridin- 2- yl) amino} piperidine
    To a solution of ethyl 4-amino-1-piperidin-4-ylamine in 1.50 g of 2-chloroimidazo [4,5, -b] pyridine (F. Jung et al., J. Med. Chem. 34 (3), 1110, 1991) 3.76 g of carboxylate was added, and the mixture was stirred at 170 占 폚 for 7 hours. After cooling to room temperature, the reaction solution was poured into a mixed solution of 300 ml of methylene chloride and 300 ml of saturated sodium carbonate aqueous solution while stirring. The organic layer was separated, and the aqueous layer was extracted twice with 200 ml of methylene chloride. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 15: 1) to obtain 1.12 g of the title compound.
    Physicochemical properties of intermediate 23
    Intermediate 24: 4 - {(1 H-imidazo [4,5-b] pyridin-2-yl) amino} piperidine
    To 500 mg of Intermediate 23, 47% of hydrobromic acid (9.0 ml) was added and dissolved, and the mixture was refluxed for 5 hours. The reaction solution was cooled to room temperature, and poured into ammonia water while stirring at 0 캜. This mixed solution was concentrated under reduced pressure, and the obtained residue was purified by Amberlyst 15 (eluent: methanol-concentrated aqueous ammonia-water = 4: 3: 1) to obtain 226 mg of the title compound.
    Physicochemical Properties of Intermediate 24 6
    Intermediate 25: 4- [4 - {(1 H-imidazo [4,5-b] pyrimidin-2- yl) amino} piperidin- 1 -yl] benzoic acid ethyl ester
    To 188 mg of Intermediate 24, 1.0 ml of dimethylformamide was added and dissolved, and 152 쨉 l of 4-fluorobenzoic acid ethyl ester was added. After stirring at 30 DEG C for 18 hours, the reaction mixture was cooled to room temperature, and 100 mL of a saturated sodium carbonate aqueous solution was added. The mixture was extracted three times with methylene chloride, and the combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 20: 1) to obtain 147 mg of the title compound.
    Physicochemical Properties of Intermediate 25
    Example 37: (2S) - (Benzenesulfonylamino-3- [4- (4 - {(1H-imidazo [4,5- b] pyridin- 2- yl) amino} piperidin- ) Benzoylamino] propionic acid t-butyl ester
    4.5 ml of tetrahydrofuran and 1.5 ml of methanol were added to 100 mg of Intermediate 25 and dissolved, and 1.5 ml of a 1N aqueous sodium hydroxide solution was added. The mixture was stirred at 40 ° C for 7 hours and then concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 92 mg of a crude compound. Subsequently, 3.0 ml of dimethylformamide was added to this compound, which was then suspended. To this, 111 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added. Further, 56 mg of 1-hydroxybenzotriazole, 90 占 퐇 of N-methylmorpholine and 79 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 20 hours.
    To the reaction solution were added 60 ml of a saturated aqueous sodium hydrogencarbonate solution and 30 ml of a saturated aqueous calcium carbonate solution and extracted three times with 60 ml of methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 10: 1) to obtain 83.2 mg of the title compound.
    Physicochemical properties of the compound of Example 37
    Example 38: (2S) -Benzenesulfonylamino-3- [4- [4 - {(1 H-imidazo [4,5- b] pyridin- 2- yl) amino} piperidin- Benzoylamino] propionic acid
    To 42.0 mg of the compound of Example 37, 0.5 ml of methylene chloride was added and dissolved, and 0.5 ml of trifluoroacetic acid was added, followed by stirring at room temperature for 7 hours. The reaction solution was concentrated under reduced pressure and the obtained residue was purified by silica gel thin layer chromatography for separation (elution system: methylene-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1), followed by Sephadex LH-20 System: methanol-concentrated ammonia water = 10: 1) to obtain 38.0 mg of the title compound.
    Physicochemical properties of the compound of Example 38
    Intermediate 26: 4- [4- [3- {2- (t-Butoxycarbonylamino) ethyl} thioureido] piperidin- 1 -yl] benzoic acid ethyl ester
    0.5 ml of tetrahydrofuran was added to 30.0 mg of Intermediate 3 and dissolved, and 0.5 ml of a tetrahydrofuran solution of 29 mg of Nt-butoxycarbonyl-2-isothiocyanatoethylamine was added, followed by stirring at room temperature for 19 hours . The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain the title compound (50.1 mg).
    Physicochemical properties of intermediate 26
    Intermediate 27: 4- {4- (4,5-Dihydro-1H-imidazol-2-ylamino) piperidin- 1 -yl} benzoic acid ethyl ester
    To 14.2 mg of Intermediate 26, 0.5 ml of ethanol and 0.5 ml of ethyl bromide were added and dissolved, followed by stirring at 60 占 폚 for 13 hours. The reaction solution cooled to room temperature was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain crude compound. Then, 0.5 ml of water and 1.0 ml of trifluoroacetic acid were added to this compound and dissolved, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and 1.0 ml of ethanol was added to the residue to dissolve. This solution was added dropwise to 1.0 ml of an ethanol solution of 18.0 mg of sodium ethoxide over 3 hours, followed by stirring at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain 6.1 mg of the title compound.
    Physicochemical properties of intermediate 27
    Intermediate 28: Ethyl 4- (4- {4- [4,5-dihydro-1- (4-methoxybenzyl) -lH- imidazol-2-yl} amino] piperidin- 1 -yl] benzoic acid ethyl ester
    To 43.9 mg of Intermediate 27 was dissolved 1.5 ml of dimethylformamide, and 58 mg of potassium carbonate and 23 쨉 l of 4-methoxybenzyl chloride were added. After stirring at room temperature for 16 hours, 60 ml of a saturated aqueous potassium carbonate solution was added and extracted three times with 60 ml of methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue azeotroped twice with toluene was purified by silica gel thin layer chromatography for elution (eluent: chloroform: methanol: concentrated ammonia water = 30: 10: 1) to obtain the title compound (15.0 mg).
    Physicochemical properties of intermediate 28
    Example 39: (2S) -Benzenesulfonylamino-3- [4- [4- [4- {4,5-dihydro- 1- (4- methoxybenzyl) Piperidin-1-yl] benzoylamino] propionic acid t-butyl ester
    To 18.0 mg of Intermediate 28 was dissolved 1.5 ml of tetrahydrofuran and 0.5 ml of methanol, and 0.5 ml of a 1N aqueous sodium hydroxide solution was added. The mixture was stirred at 40 ° C for 5 hours and then concentrated under reduced pressure. 2 ml of water was added to the obtained residue, and 1N hydrochloric acid was added thereto while stirring to adjust the pH to 4. The resulting precipitate was filtered with a glass filter, washed twice with water, and dried to obtain 14.2 mg of a combined product. Subsequently, 0.5 ml of dimethylformamide was added to this compound, and the suspension was suspended. To this, 14.0 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added. Further, 7.0 mg of 1-hydroxybenzotriazole, 20 μl of N-methylmorpholine and 10.0 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and the mixture was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue azeotropically distilled twice with toluene was purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain the title compound (20.8 mg).
    Physicochemical properties of the compound of Example 39
    Example 40: (2S) -Benzenesulfonylamino-3- [4- (4- (4,5-dihydro-1H-imidazol-2- ylamino) piperidin- 1 -yl} benzoylamino]
    To 20.0 mg of the compound of Example 39, 0.5 ml of methylene chloride was added and dissolved, and 0.5 ml of trifluoroacetic acid was added, followed by stirring at 40 占 폚 for 20 hours. The reaction solution was concentrated under reduced pressure and the resulting residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1) followed by addition of Sephadex LH-20 Eluent: methanol-concentrated ammonia water = 10: 1) to obtain the title compound (12.1 mg).
    Physicochemical properties of the compound of Example 40
    Intermediate 29: 4- {4- [4,5,6,7-Tetrahydro-1H- [1.3] diazepin-2-ylamino) piperidin- 1- yl} benzoic acid ethyl ester
    In the middle, 3 100 mg of tetrahydrofuran (2.9 ml) was added to dissolve and 0.5 ml of a tetrahydrofuran solution of 111 mg of Nt-butoxycarbonyl-4-isothiocyanatobutylamine was added. The mixture was stirred at room temperature for 18 hours Lt; / RTI > The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for separation (solvent system: methylene chloride-methanol = 7: 1) to obtain 230.3 mg of a crude compound. Then, 4.0 ml of ethanol and 4.0 ml of ethyl bromide were added to this compound and dissolved, followed by stirring at 60 占 폚 for 24 hours. The reaction solution cooled to room temperature was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain 161.1 mg of a crude compound. Then, 1.0 mL of water and 1.0 mL of trifluoroacetic acid were added to and dissolved in 138.2 mg of this compound, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and 5.0 ml of ethanol was added to the residue to dissolve. This solution was added dropwise to 5.0 ml of an ethanol solution of 149 mg of sodium ethoxide over 2 hours at room temperature, followed by stirring for 13 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7-1) to give the title compound (71.8 mg).
    29 physicochemical properties in the middle
    Example 41: (2S) -Benzenesulfonylamino-3- [4- {4- (4,5,6,7, -tetrahydro-1H- [1.3] diazepin-2-ylamino) piperidine -1-yl} benzoylamino] propionic acid t-butyl ester
    0.6 ml of tetrahydrofuran and 0.2 ml of methanol were added to and dissolved in 6.9 mg of Intermediate 29, and 0.2 ml of a 1N aqueous sodium hydroxide solution was added. The mixture was stirred at 40 ° C for 25 hours and then concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 4.5 mg of a crude compound. Subsequently, 0.5 ml of dimethylformamide was added to this compound and dissolved. To this, 6.7 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added. Further, 3.2 mg of 1-hydroxybenztriazole, 11 μl of N-methylmorpholine and 4.6 mg of l-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 12 hours . The reaction solution was concentrated under reduced pressure, and the residue was azeotropically distilled twice with toluene was purified by silica gel thin layer chromatography (eluent: methylene chloride-methanol = 7: 1) for separation to obtain 2.0 mg of the title compound.
    Physicochemical properties of the compound of Example 41
    Example 42: (2S) -Benzenesulfonylamino-3- [4- (4- (4,5,6,7-tetrahydro-1H- [1.3] diazepin-2-ylamino) piperidine- 1-yl} benzoylamino] propionic acid
    2.0 mg of the compound of Example 41 was dissolved in 0.5 ml of methylene chloride, and 0.5 ml of trifluoroacetic acid was added, followed by stirring at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 1.7 mg of the title compound.
    Physicochemical properties of the compound of Example 42
    Intermediate 30: 4- [4 - [{N-methyl-N- (pyrimidin-2- yl)} amino] piperidin- 1 -yl] benzoic acid ethyl ester
    3.6 ml of anhydrous dimethylformamide was added to 179 mg of Intermediate 4 to dissolve, and 156 mg of methyl iodide was added. 43.9 mg of 60% aqueous sodium hydrogen hydride was added and reacted at 45 ° C for 11 hours. The reaction solution was extracted with 200 ml of ethyl acetate and washed once with distilled water, once with saturated aqueous sodium hydrogencarbonate solution and once with saturated brine, and dried over anhydrous sodium sulfate. This was dried under reduced pressure and dried to obtain 186 mg of the title compound.
    Physicochemical Properties of Intermediate 30
    Intermediate 31: 4- [4 - [{N-methyl-N- (pyrimidin-2- yl)} amino] piperidin- 1 -yl]
    To 209 mg of Intermediate 30, 18 ml of tetrahydrofuran and 6.0 ml of methanol were added and dissolved, 6.0 ml of a 1N sodium hydroxide aqueous solution was added, and the mixture was reacted at 45 ° C for 10 hours. To the residue obtained by concentrating the reaction solution under reduced pressure, 19 ml of distilled water was added and dissolved, and neutralized with 5N hydrochloric acid to precipitate carbonic acid. The mixture was allowed to stand at 0 ° C for 16 hours, filtered, and washed with 4 ml of distilled water. This was dried on phosphorus pentoxide at 50 DEG C to give 68.0 mg of the title compound. On the other hand, the filtrate and the washings were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (12 g of chloroform-methanol-concentrated ammonia water = 30: 10: 1) to give the title compound (102 mg).
    Physicochemical Properties of Intermediate 31
    Example 43: (2S) -Benzenesulfonylamino-3- [4- [4 - [(N-methyl-N-pyrimidin- 2- yl)} amino] piperidin- Propionic acid t-butyl ester
    4.1 ml of anhydrous dimethylformamide and 4,1 ml of methylene chloride were added to and dissolved in 162 mg of Intermediate 31 and 344 mg of benztriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate, and diisopropylethyl Amine (0.14 ml) was added and reacted at room temperature for 2 hours to prepare an active ester. On the other hand, 4.17 ml of methylene chloride was added to and dissolved in 187 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester, and this was added to the above-mentioned aliphatic ester solution. Further, 68 디 of diisopropylethylamine was added, and the reaction was allowed to proceed at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was extracted with ethyl acetate (30 ml). This was washed once with saturated aqueous sodium hydrogencarbonate solution and once with saturated brine, and dried over anhydrous sodium sulfate. The residue was purified by silica gel column chromatography (22 g, 2.5% methanol / methylene chloride) to obtain 303 mg of the title compound.
    Physicochemical Properties of Compounds of Salicylate 43
    Example 44: (2S) -Benzenesulfonylamino-3- [4- [4 - [{N-methyl-N- (pyrimidin- 2- yl)} amino] piperidin- ] Propionic acid
    4.02 ml of methylene chloride was added to 292 mg of the compound of Example 43 to dissolve, and 0.20 ml of anisole was added, followed by cooling to 0 占 폚. 4.0 ml of trifluoroacetic acid was added at 0 deg. C, and the reaction was allowed to proceed at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was azeotropically distilled twice with toluene and dried. The solid was washed twice with 10 ml of diisopropyl ether by decantation and the obtained residue was purified by silica gel column chromatography (22 g, chloroform-methanol-concentrated ammonia water = 90: 20: 1) 262 mg of the title compound was obtained.
    Physicochemical properties of the compound of Example 44
    Example 45: (2S) -Benzenesulfonylamino-3- [4- [4 - [{N-methyl-N- (1,4,5,6-tetrahydropyrimidin- Piperidin-1-yl] benzoylamino] propionic acid
    To 36.5 mg of the compound of Example 44, 4.0 ml of acetic acid and 0.36 ml of concentrated hydrochloric acid were added and dissolved, 36 mg of 10% palladium carbon was added, and the mixture was shaken extensively at room temperature for 2 hours under hydrogen at 2.5 atm. The catalyst was filtered and washed twice with 2.0 mL of acetic acid, and the clearance and the washing solution were combined. The residue obtained by concentration under reduced pressure was azeotropically distilled twice with toluene and the residue was purified by silica gel thin layer chromatography for separation (eluent: methylene chloride-ethanol-water-concentrated ammonia water = 15: 10: 1: 1) Purification by Sephadex LH-20 column chromatography (30 mL, methanol) gave the title compound (29.0 mg).
    Physicochemical properties of the compound of Example 45
    Intermediate 32: 4- {4- (Pyrimidin-2-ylamino) piperidin-1-yl] benzyl alcohol
    To 200 mg of Intermediate 4, 5.6 ml of anhydrous methylene chloride was added and dissolved. The mixture was cooled to -78 캜, and 1.5 ml of a 1 M toluene solution of diisobutylaluminum hydride was added dropwise over 10 minutes. After reacting at -78 ° C for 3 hours, 0.50 ml of methanol was added and the temperature was raised to room temperature. 30 ml of methylene chloride was added to the reaction solution, and the mixture was extracted. 30 ml of a saturated aqueous solution of Rochelle salt was added and stirred vigorously at room temperature for 20 minutes. The methylene chloride layer was separated, washed twice with saturated brine, and dried over anhydrous sodium sulfate. This was concentrated under reduced pressure to give the title compound (170 mg).
    Physicochemical properties of intermediate 32
    Intermediate 33: 4- {4- (Pyrimidin-2-ylamino) piperidin-1-yl} benzaldehyde
    156 mg of Intermediate 32 was dissolved in 16 ml of methylene chloride, and 312 mg of active manganese dioxide was added and stirred vigorously at room temperature for 16 hours. Insolubles were filtered off and washed twice with 5.0 ml of 50% methanol / methylene chloride. The filtrate and the washings were combined and concentrated under reduced pressure, and 4.0 ml of methylene chloride was added to the residue to dissolve and exposed to ultrasonic waves for about 30 seconds. This was filtered, and the filtrate was concentrated under reduced pressure to give 144 mg of the title compound.
    Physicochemical properties of intermediate 33
    Example 46: (2S) -Benzenesulfonylamino-3- [4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yljbenzylaminolpropionic acid t-butyl ester
    11 mg of methanol and 7.4 ml of methylene chloride were added to and dissolved in 144 mg of Intermediate 33 and 230 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester, and 0.30 ml of acetic acid was added . To this was added 161 mg of sodium cyanoborohydride and the mixture was reacted at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the obtained filtrate was extracted with 28 ml of chloroform and washed once with a saturated aqueous solution of sodium hydrogencarbonate. The chloroform layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (40 g, chloroform-methanol-concentrated ammonia water = 100: 33: 1) to give the title compound (289 mg).
    Physicochemical properties of the compound of Example 46
    Example 47: (2S) -Benzenesulfonylamino-3- [4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yljbenzylamino] propionic acid
    To 289 mg of the compound of Example 46, 4.0 ml of methylene chloride was added and dissolved, and 0.2 ml of anisole was added. 4.0 ml of trifluoroacetic acid was added under cooling at 0 캜, and the reaction was allowed to proceed at room temperature for 10 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was azeotropically distilled twice with toluene and dried. This solid was washed twice with 10 ml of diisopropyl ether by decantation and dried to obtain 402 mg of the title compound. 23.3 mg of the product was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 90: 20: 1) to obtain the title compound (13.1 mg).
    Physicochemical properties of the compound of Example 47
    Example 48: (2S) -Benzenesulfonylamino-3- [4- {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- ] Propionic acid
    20 mg of acetic acid and 1.8 ml of concentrated hydrochloric acid were added to 200 mg of the crude compound before purification in Example 47, and 180 mg of 10% palladium carbon was added. The mixture was shaken vigorously at room temperature for 2 hours under hydrogen at 3.0 atm. The catalyst was filtered, washed twice with 8.0 ml of acetic acid, and the filtrate and the washing solution were combined. The residue obtained by concentrating under reduced pressure was azeotropically distilled twice with toluene and the residue was purified by silica gel column chromatography (10 g, methylene chloride-ethanol-water-concentrated ammonia water = 12: 10: 1: 1) to obtain 108 mg . 24.5 mg thereof was purified by Sephadex LH-20 column chromatography (30 mL, methanol) to obtain 21.4 mg of the title compound.
    Physicochemical properties of the compound of Example 48
    Example 49: (2S) -Benzenesulfonylamino-3 - [[N-benzyl-N- [4- {4- (1,4,5,6-tetrahydropyrimid- L-yl} benzyl]] amino] pyropionic acid
    2.1 ml of methanol and 2.1 ml of methylene chloride were added to and dissolved in 41.7 mg of the crude compound before the Sepadex column of Example 48, and 17.2 mg of benzaldehyde and 0.03 ml of acetic acid were added. 10.2 mg of sodium cyanoborohydride was added thereto, and the reaction was allowed to proceed at room temperature for 16 hours. The reaction solution was purified by silica gel thin layer chromatography (eluent: methylene chloride-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) without any post-treatment, followed by Sephadex LH-20 column chromatography 30 mL, 90% methanol / methylene chloride) to obtain 34.6 mg of the title compound.
    Physicochemical properties of the compound of Example 49
    Intermediate 34: 3-Fluoro-4- (4-hydroxypiperidin-1-yl) benzoic acid methyl ester
    To 24.5 g of 4-hydroxypiperidine was added 100 ml of dimethylsulfoxide and dissolved. To the solution was added 33.2 g of 3,4-difluorobenzoic acid methyl ester, and the mixture was stirred at 120 캜 for 8 hours. The reaction solution cooled to room temperature was poured into 1000 ml of water and extracted twice with 750 ml of methyl acetate. The combined organic layers were washed twice with 500 ml of brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain 42.3 g of the title compound.
    Physicochemical properties of intermediate 34
    Intermediate 35: 4- (4-azidopiperidin-1-yl) -3-fluorobenzoic acid methyl ester
    To 24.8 g of the intermediate 34, 700 ml of methylene chloride was added and dissolved, and 70.0 ml of triethylamine was added. 11.5 ml of methanesulfonyl chloride was slowly added dropwise at room temperature, and the mixture was stirred at the same temperature for 1 hour. 1000 ml of water was added to stop the reaction and extracted twice with 1000 ml of chloroform. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. 500 ml of water was added to the obtained residue and extracted twice with 1000 ml of a mixed organic solvent (ethyl acetate-nucleic acid-methylene chloride = 1: 1: 1). The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain 30.0 g of 3-fluoro-4- {4- (methanesulfonyloxy) piperidin-1-yl} benzoic acid methyl ester. To 10.0 g of the resulting 3-fluoro-4- {4- (methanesulfonyloxy) piperidin-1-yl} benzoic acid methyl ester was added and dissolved dimethylformamide, 3.9 g of sodium azide was added, C < / RTI > for 5 hours. The reaction solution cooled to room temperature was poured into 1000 ml of water and extracted twice with 500 ml of ethyl acetate. The combined organic layers were washed twice with 500 ml of brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. 1000 ml of water was added to the obtained residue and extracted with 500 ml of hexane. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (7.7 g).
    Physicochemical Properties of Intermediate 35
    Intermediate 36: 4- (4-Aminopiperidin-1-yl) -3-fluorobenzoic acid methyl ester
    190 ml of dioxane, 27 ml of acetic acid and 54 ml of water were added to 7.5 g of Intermediate 35 to dissolve the product. 750 mg of 10% palladium carbon was added thereto and stirred vigorously at room temperature for 4 hours under 1 atm of hydrogen pressure. The insoluble material was filtered, washed twice with methanol, and the filtrate and the washing solution were combined and concentrated under reduced pressure. 500 ml of water and 500 ml of 1N hydrochloric acid were added to the residue which was azeotropically azeotroped twice with toluene, and the mixture was washed twice with 500 ml of ethyl acetate. The obtained aqueous layer was cooled to 0 占 폚, and aqueous ammonia water was added to adjust the pH to 14. The salt was added at room temperature to saturate and extracted three times with 1 liter of methylene chloride. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 5.78 g of the title compound.
    Physicochemical properties of intermediate 36
    Intermediate 37: 3-Fluoro-4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoic acid methyl ester
    230 ml of dimethylsulfoxide was added to 5.78 g of Intermediate 36 and dissolved, and 3.64 g of 2-bromopyrimidine was added. Further, 23 ml of diisopropylethylamine was added, and the mixture was heated to 122 占 폚 and stirred for 12 hours. After cooling to room temperature, 1 L of saturated brine and 1 L of water were added, and extracted three times with 500 mL of ethyl acetate. The combined organic layers were washed twice with saturated brine (500 ml), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound (6.74 g).
    Physicochemical properties of intermediate 37
    Intermediate 38: 3-Fluoro-4- {4- (pyrimidin-2-ylamino) piperidin-
    300 ml of tetrahydrofuran and 100 ml of methanol were added to and dissolved in 6.6 g of Intermediate 37, and 100 ml of a 1N sodium hydroxide aqueous solution was added. After stirring at 40 DEG C for 6 hours, the reaction mixture was concentrated under reduced pressure, and 1 liter of water was added to the residue. The residue was dissolved and washed with 1 liter of ethyl acetate. 1N hydrochloric acid was added to the obtained water layer to adjust pH to 6. The precipitated solid was filtered with a glass filter and washed twice with water to obtain 4.96 g of the title compound.
    Physicochemical properties of intermediate 38
    Example 50: (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester
    30 ml of dimethylformamide was added to 1.0 g of Intermediate 38, and the mixture was suspended. To this, 1.17 g of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added. Further, 512 mg of 1-hydroxybenzotriazole, 1.04 ml of N-methylmorpholine and 727 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and the mixture was stirred at room temperature for 13 hours. To the reaction solution were added 300 ml of a saturated aqueous sodium hydrogencarbonate solution and 100 ml of a saturated potassium carbonate aqueous solution and extracted three times with 200 ml of methylene chloride. The combined organic layers were washed with a mixed solution of 250 ml of saturated brine and 250 ml of water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 25: 1) to obtain 1.77 g of the title compound.
    Physicochemical properties of the compound of Example 50
    Example 51: (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid
    600 mg of the compound of Example 50 was dissolved in 10 ml of methylene chloride, 10 ml of tripleurooacetic acid was added, and the mixture was stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure to give 542 mg of the title compound, 3-trifluoroacetic acid salt.
    Physicochemical properties of the compound of Example 51
    Example 52: (2S) -benzenesulfonylamino-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- Yl} benzoylamino] propionic acid
    To 542 mg of the triphouroacetic acid salt of the compound of Example 51 was dissolved 10 ml of dioxane and 1.0 ml of water and 120 mg of 10% palladium carbon was added and stirred vigorously at room temperature for 24 hours under 1 atm of hydrogen pressure did. The insoluble matter was filtered off, washed with a mixed solvent of dioxane (100 ml) and water (10 ml), and the filtrate and washings were combined and concentrated under reduced pressure. 10 ml of a mixed solvent of ethanol: water-concentrated ammonia water = 8: 1: 1 was added to the residue which was azeotropically azeotroped twice with toluene, and the mixture was allowed to stand at 5 占 폚 for 22 hours. The resulting precipitate was filtered, washed twice with 5 ml of water and dried to obtain 451 mg of the title compound.
    Physicochemical properties of the compound of Example 52
    Intermediate 39: 3-Fluoro-4- {4- (4,5-dihydro-1H-imidazol-2- ylamino) piperidin-
    To 100 mg of Intermediate 36 was dissolved 2.0 ml of tetrahydrofuran, and 109 mg of N-t-butoxycarbonyl-2-isothiocyanatoethylamine was added, followed by stirring at room temperature for 23 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain a crude compound. Then, 4.0 ml of ethanol and 4.0 ml of ethyl bromide were added to this compound and dissolved, followed by stirring at 60 캜 for 9 hours. The reaction solution which had been cooled to room temperature was concentrated under reduced pressure, and the resulting residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain a crude compound. Then, 1.0 ml of water and 1.0 ml of trifluoroacetic acid were added to this compound and dissolved, and the mixture was stirred at room temperature for 19 hours. The reaction solution was concentrated under reduced pressure, and 8.0 ml of ethanol was added to the residue to dissolve. This solution was added dropwise to 9.0 ml of an ethanol solution of 195 mg of sodium ethoxide at room temperature over 1 hour and further stirred for 22 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 84.8 mg of a crude compound. 3.0 ml of tetrahydrofuran and 1.0 ml of methanol were added to and dissolved in 53.6 mg of this compound, and 1.0 ml of a 1N sodium hydroxide aqueous solution was added. The mixture was stirred at 40 ° C for 3 hours and then concentrated under reduced pressure. 30 ml of water was added to the obtained residue, and further 1N hydrochloric acid was added to adjust the pH to 5, and the mixture was concentrated under reduced pressure. The obtained residue was purified by Sephadex LH-20 (eluent: methanol) to obtain 49.0 mg of the title compound.
    Physicochemical Properties of Intermediate 39
    Example 53: (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (4,5-dihydro-1 H-imidazol- 2- ylamino) piperidin- Yl} benzoylamino] propionic acid t-butyl ester
    100 mg of Intermediate 39 was dissolved in 1.0 ml of dimethylformamide, and 108 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto. Further, 66.1 mg of 1-hydroxybenztriazole, 108 占 퐇 of N-methylmorpholine and 93.7 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 8.2 mg of the title compound.
    Physicochemical properties of the compound of Example 53
    Example 54: (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (4,5-dihydro-1 H-imidazol- 2- ylamino]
    17.0 mg of the compound of Example 53 was dissolved in 0.5 ml of methylene chloride, 0.5 ml of trifluoroacetic acid was added, and the mixture was stirred at 40 占 폚 for 3 hours. The reaction solution was concentrated under reduced pressure and the resulting residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1), followed by Sephadex LH- : Methanol) to obtain 7.4 mg of the title compound.
    The physical and chemical properties of the compound of Example 54
    Intermediate 41: 2,3-Difluoro-4- {4- (methanesulfonyloxy) piperidin-1-yl} benzoic acid methyl ester
    94 ml of methylene chloride was added to 4.70 g of Intermediate 40 to dissolve, and 1.5 ml of methanesulfonyl chloride was added. Under cooling at 0 占 폚, 2.9 ml of triethylamine and 106 mg of 4-dimethylaminopyridine were added and reacted at room temperature for 2 hours. 1,3-diaminopropane (257 mg) was added, and 150 ml of methylene chloride was further added to the reaction mixture. This was washed once with a 5% aqueous solution of sodium hydrogen sulfate, a saturated aqueous solution of sodium hydrogencarbonate and a saturated saline solution each time. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound (5.95 g).
    Physicochemical properties of intermediate 41
    Intermediate 42: 4- (4-azidopiperidin-1-yl) -2,3-difluorobenzoic acid methyl ester
    118.9 ml of anhydrous dimethylformamide was added to 5.92 g of the intermediate 41 and 2.20 g of sodium azide, and the mixture was extracted and heated at 90 占 폚 for 8 hours. 2.0 L of ethyl acetate was added to the reaction solution, which was then extracted and washed with 2.0 L of distilled water. The aqueous layer was re-extracted with 500 ml of ethyl acetate and the ethyl acetate layers were combined. This was washed sequentially with a saturated aqueous sodium hydrogen solution and a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (300 g, 30% ethyl acetate / hexane) to obtain 4.898 g of the title compound.
    Physicochemical properties of intermediate 42
    Intermediate 43: 4- (4-Aminopiperidin-1-yl) -2,3-difluorobenzoic acid methyl ester
    140 ml of 1,4-dioxane, 40 ml of distilled water and 20 ml of acetic acid were added to and dissolved in 4.86 g of Intermediate 42, and 1.20 g of 10% palladium carbon was added. Under a hydrogen atmosphere, the mixture was stirred vigorously at room temperature for 16 hours. The catalyst was filtered and washed twice with an organic solvent of the same composition as the reaction solvent. The filtrate and the washing solution were combined, concentrated under reduced pressure, and azeotropically distilled twice with 50 ml of toluene. The resulting residue was purified by silica gel column chromatography (250 g, chloroform-methanol-concentrated aqueous ammonia = 100: 10: 1 - > 100: 15: 1) to obtain 2.10 g of the title compound.
    Physicochemical Properties of Intermediate 43
    Intermediate 44: 2,3-Difluoro-4- {4- (pyrimidin-2-ylamino) piperidin-1-yl} benzoic acid methyl ester
    To 600 mg of Intermediate 43 was added 24 ml of dimethylsulfoxide and dissolved. To the reaction mixture were added 2.0 ml of diisopropylethylamine and 529 mg of 2-brominated pyrimidine, and the mixture was reacted at 120 ° C for 12 hours. 500 ml of ethyl acetate was added to the reaction mixture, and the mixture was extracted and washed with 500 ml of distilled water. The aqueous layer was re-extracted with 125 ml of ethyl acetate and the ethyl acetate layer was combined. This was washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (65 g, 8.5% acetone / chloroform) to give the title compound (638 mg).
    Physicochemical properties of intermediate 44
    Intermediate 45: 2,3-Difluoro-4- {4- (pyrimidin-2-ylamino) piperidin-
    In 638 mg of Intermediate 44, 42 ml of tetrahydrofuran and 14 ml of methanol were added and dissolved, 14 ml of a 1N sodium hydroxide aqueous solution was added, and the mixture was reacted at 45 캜 for 2 hours. To the residue obtained by concentrating the reaction solution under reduced pressure, 28 ml of distilled water was added and dissolved. Then, 2.1 ml of 5N hydrochloric acid followed by 2.8 ml of 1N hydrochloric acid was added to neutralize the residue. After the solid-precipitated mixture was allowed to stand at 0 占 폚 for 48 hours, the solid was filtered and washed three times with distilled water. This was heated and dried at 60 DEG C for 1 hour under pentoxide pentoxide to obtain 402 mg of the title compound.
    Physicochemical properties of intermediate 45
    Example 55: (2S) -Benzenesulfonylamino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester
    6.8 ml of anhydrous dimethylformamide and 6.8 ml of methylene chloride were added to 130 mg of Intermediate 45 and dissolved, and 258 mg of benztriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate and 25 mg of diisopropylethylamine And the mixture was reacted at room temperature for 2 hours to prepare an active ester. On the other hand, 6.8 ml of methylene chloride was added to 140 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester, and 5 占 퐇 of diisopropylethylamine was added thereto. The above-mentioned active ester solution was added while cooling to -10 캜, and the reaction was carried out at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure, and the resulting residue was extracted with ethyl acetate (50 ml). The extract was washed with saturated aqueous sodium hydrogencarbonate solution once, saturated saline solution once, and dried over anhydrous sodium sulfate. The residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (2 ng, chloroform-methanol-concentrated aqueous ammonia = 400: 20: 1) to obtain 239 mg of the title compound.
    Physicochemical properties of the compound of Example 55
    Example 56: (2S) -Benzenesulfonylamino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid
    To 226 mg of the compound of Example 55, 3.0 ml of methylene chloride was added and dissolved, and 0.15 ml of anisole was added. 3.0 ml of trifluoroacetic acid was added under cooling at 0 占 폚, and the mixture was reacted at 0 占 폚 for 12 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was azeotropically distilled twice with 8.0 ml of toluene, followed by drying. This solid was washed twice with 8.0 ml of diisopropyl ether by decantation and dried. The resulting residue was purified by silica gel column chromatography (27 g, chloroform-methanol-concentrated ammonia water = 90: 20: 1) 177 mg of a compound was obtained.
    Physicochemical properties of the compound of Example 56
    Example 57: (2S) -benzenesulfonylamino-3- [2,3-difluoro-4- {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) pyrimidine -1-yl} benzoylamino] propionic acid
    7.0 mg of 1,4-dioxane, 4.0 ml of acetic acid and 4.0 ml of 0.5 N hydrochloric acid were added to 100 mg of the compound of Example 56, and 25 mg of 10% palladium carbon was added thereto. Under a hydrogen atmosphere, at room temperature for 16 hours. The catalyst was filtered, washed twice with a mixed solvent (1,4-dioxane-acetic acid-water = 7: 2: 2), and the filtrate and the washing solution were combined. The residue obtained by concentration under reduced pressure was azeotropically distilled twice with 4.0 mL of toluene. This was purified by silica gel column chromatography (12 g, methylene-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) followed by Sephadex LH-20 column chromatography (120 ml, methylene-ethanol- Ammonia water = 6: 8: 1: 1) to obtain 87.2 mg of the title compound.
    Physicochemical properties of the compound of Example 57
    Intermediate 46: 3-Chloro-4- (4-hydroxypiperidin-1-yl) benzoic acid methyl ester
    To 2.6 g of 4-hydroxypiperidine was added 10 ml of dimethyl sulfoxide and dissolved, and 6.2 g of methyl 3-chloro-4-fluorobenzamide was added and the mixture was stirred at 120 캜 for 2 hours. The reaction solution cooled to room temperature was poured into 2000 ml of water and extracted twice with 1000 ml of ethyl acetate. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (5.8 g).
    Physicochemical properties of intermediate 46
    Intermediate 47: 3-Chloro-4- {4- (methanesulfonyloxy) piperidin-1-yl} benzoic acid methyl ester
    200 ml of methylene chloride was added to and dissolved in 5.8 g of Intermediate 46, and 15 ml of triethylamine was added. 2.5 ml of methanesulfonyl chloride was slowly added dropwise at room temperature, and the mixture was stirred at the same temperature for 20 minutes. 1000 ml of water was added to stop the reaction and extracted twice with 500 ml of chloroform. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. 500 ml of water was added to the obtained residue, and the mixture was extracted with 1000 ml of a mixed organic solvent (ethyl acetate-hexane = 1: 2). The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (5.8 g).
    Physicochemical properties of intermediate 47
    Intermediate 48: 4- (4-azidopiperidin-1-yl) -3-chlorobenzoic acid methyl ester
    Dimethylformamide was added to and dissolved in 5.8 g of Intermediate 47, and 2.5 g of sodium azide was added, followed by stirring at 120 캜 for 4 hours. The reaction solution cooled to room temperature was poured into 1500 ml of water and extracted three times with 500 ml of ethyl acetate. The combined organic layers were washed twice with 500 ml of brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: hexane-ethyl acetate = 1: 1) to obtain 4.1 g of the title compound.
    Physicochemical properties of intermediate 48
    Intermediate 49: 4- (4-Aminopiperidin-1-yl) -3-chlorobenzoic acid methyl ester
    To 4.0 g of the intermediate 48 was dissolved 200 ml of ethyl acetate and 20 ml of concentrated hydrochloric acid, and 1.09 g of 10% palladium carbon was added. The mixture was stirred vigorously under hydrogen at 1 atm for 6 hours. The insoluble matter was filtered, washed with acetic acid, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol-concentrated ammonia water = 90: 10: 1) to obtain 595 mg of the title compound.
    Physicochemical Properties of Intermediate 49
    Intermediate 50: 3-Chloro-4- {4- (pyrimidin-2-ylamino) piperidin- 1-yl} benzoic acid methyl ester
    255 mg of Intermediate 49 was dissolved in 10 ml of dimethylsulfoxide, and 153 mg of 2-bromopyrimidine was added. Further, 1.0 ml of diisopropylethylamine was added, and the mixture was heated at 120 占 폚 and stirred for 11 hours. The reaction solution cooled to room temperature was poured into 500 ml of water and extracted twice with 500 ml of ethyl acetate. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol-concentrated aqueous ammonia = 190: 10: 1) to obtain the title compound (169 mg).
    Physicochemical Properties of Intermediate 50
    Intermediate 51: 3-Chloro-4- {4- (piperidin-2-ylamino) piperidin-
    6.09 ml of tetrahydrofuran and 2.0 ml of ethanol were added to and dissolved in 169 mg of Intermediate 50, and 2.0 ml of a 1N aqueous sodium hydroxide solution was added. The mixture was stirred at 60 ° C for 7 hours, cooled to room temperature, adjusted to pH 4 with 1N hydrochloric acid, and poured into 1000 ml of water. The resulting precipitate was filtered with a glass filter and dried to obtain 109 mg of the title compound.
    Physicochemical properties of intermediate 51
    Example 58: (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (pyrimidin-2- ylamino) piperidin- 1 -yl} benzoylamino] propionic acid t-butyl ester
    To 107 mg of Intermediate 51 was dissolved 30 ml of dimethylformamide, and 97 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto. Further, 69 mg of 1-hydroxybenzotriazole, 180 占 퐇 of N-methylmorpholine and 126 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 1 day. A saturated aqueous solution of sodium hydrogencarbonate was added to stop the reaction and extracted twice with 400 ml of ethyl acetate. The combined organic layer was washed with 500 ml of saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained residue was dissolved in 10 ml of methanol, and the solution was added dropwise to 1000 ml of water. The resulting precipitate was filtered with a glass filter and dried to obtain 168 mg of the title compound.
    Physicochemical properties of the compound of Example 58
    Example 59: (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid
    168 mg of the compound of Example 58 was dissolved in 10 ml of methylene chloride, 10 ml of trifluoroacetic acid was added, and the mixture was stirred at room temperature for 5 hours. The reaction solution was concentrated under reduced pressure to obtain 180 mg of the title compound, 3-trifluoroacetic acid salt.
    Physicochemical properties of the compound of Example 59
    Example 60 (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- } Benzoylamino] propionic acid
    To 51 mg of the compound of Example 59, 25 ml of acetic acid and 25 ml of concentrated hydrochloric acid were added and dissolved. 26 mg of 10% palladium carbon was added, and the mixture was shaken vigorously at room temperature for 5 hours under hydrogen 3 atm. The insoluble matter was filtered, washed with acetic acid, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: methylene chloride-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) and then purified with Sephadex LH-20 (eluent: methanol) 15 mg of the compound was obtained.
    Physicochemical properties of the compound of Example 66
    Example 61: 2- (N-Benzenesulfonyl-N-methyl) amino- {4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino} propionic acid t-butyl ester
    1.2 ml of anhydrous dimethylformamide was added to and dissolved in 60.0 ml of the compound of Example 1, and 73.3 mg of methyl iodide and 94.4 mg of diazabicyclooctane were sequentially added, followed by reaction at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was extracted with 20 ml of ethyl acetate. The extract was washed once with saturated brine once with distilled water, and then dried with anhydrous sodium sulfate. The residue obtained by concentration under reduced pressure was purified by silica gel thin layer chromatography for separation (eluent: chloroform-methanol-concentrated ammonia water = 40: 20: 1) to obtain the title compound (53.1 mg).
    Physicochemical properties of the compound of Example 61
    Example 62: 2- (N-Benzenesulfonyl-N-methyl) amino-3- [4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid
    0.7 ml of methylene chloride was added to 52.9 mg of the compound of Example 61 and dissolved, and 0.03 ml of anisole was added. 0.70 ml of trifluoroacetic acid was added under cooling at 0 占 폚, and the reaction was allowed to proceed at 0 占 폚 for 16 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was azeotropically distilled twice with toluene and dried. The solid was washed twice with diisopropyl ether by recontaining, dried and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol-concentrated ammonia water = 90: 20: 1) 44.1 mg of a compound was obtained.
    Physicochemical properties of the compound of Example 62
    Example 63: 2- (N-Benzenesulfonyl-N-methyl) amino-3- [4- (4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) piperidin- 1-yl} benzoylamino] propionic acid
    To 38.5 mg of the compound of Example 62, 4.0 ml of acetic acid and 0.36 ml of concentrated hydrochloric acid were added and dissolved, and 36 mg of 10% palladium carbon was added thereto. And was shaken vigorously for 3 hours at room temperature under hydrogen at 3.0 atm.
    The catalyst was filtered off and washed twice with acetic acid. The filtrate and the washings were combined, and the residue obtained by concentration under reduced pressure was azeotropically distilled twice with toluene. The residue was purified by silica gel thin layer chromatography (eluent: methylene chloride-ethanol-water-concentrated ammonia water = 15: 10: 1: 1) for separation and then subjected to Sephadex LH-20 column chromatography (30 ml, methylene chloride- - concentrated ammonia water = 2: 10: 1) to obtain the title compound (14.1 mg).
    Physicochemical properties of the compound of Example 63
    Intermediate 52: 3-Fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin-2-ylamino) piperidin- 1 -yljbenzoic acid methyl ester
    50 ml of dioxane and 10 ml of water were added to and dissolved in 1.73 g of Intermediate 37, 5.0 ml of acetic acid and 350 g of 10% palladium carbon were added, and the mixture was stirred vigorously under 1 atm of hydrogen at room temperature for 15 hours. The insoluble matter was filtered, washed with methanol, and the filtrate and the washing solution were combined and concentrated under reduced pressure. Twice with toluene to give the title compound (1.7 g).
    Physicochemical properties of intermediate 52
    Intermediate 53: 3-Fluoro-4- [4 - [{N- (1,4,5,6-tetrahydropyrimidin-2-yl) -N- (4-methoxybenzyl)} amino] piperidine -1-yl] benzoic acid methyl ester
    8.02 ml of dimethylformamide was added to 262 mg of Intermediate 52 to dissolve, and 540 mg of calcium carbonate and 320 4- of 4-methoxybenzyl chloride were added. After stirring at room temperature for 18 hours, 200 ml of a saturated aqueous ammonium chloride solution was added and extracted three times with 100 ml of methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue azeotroped twice with toluene was purified by silica gel column chromatography (eluent: methylene chloride: methanol = 15: 1) to obtain 153 mg of the title compound.
    Physicochemical properties of intermediate 53
    Example 64: (2S) - (Benzyloxycarbonyl) amino-3- [3-fluoro-4- [4- Yl) -N- (4-methoxybenzyl)} amino] piperidin-1-yl] benzoylamino] propionic acid t-butyl ester
    12 ml of tetrahydrofuran and 4.0 ml of methanol were added to and dissolved in 176 mg of Intermediate 53, and 4.0 ml of a 1N aqueous solution of sodium hydroxide was added. The mixture was stirred at 40 ° C for 16 hours and then concentrated under reduced pressure. 100 ml of water was added to the obtained residue, and 1N hydrochloric acid was further added to adjust the pH to 4. The salt solution was saturated with the salt solution, and extracted three times with 100 ml of methylene chloride. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain 170 mg of a crude compound. Subsequently, 2.0 mg of dimethylformamide was added to 100 mg of the compound to dissolve it, and 66.8 mg of (2S) -N-benzyloxycarbonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto. Further, 33.6 mg of 1-hydroxybenzotriazole, 50 占 퐇 of N-methylmorpholine and 47.9 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 16 hours. The reaction was stopped by adding 20 ml of a saturated aqueous potassium carbonate solution and 40 ml of a saturated aqueous solution of sodium chloride, and extracted three times with 50 ml of methylene chloride. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 7: 1) to obtain 45.0 mg of the title compound.
    Physicochemical properties of the compound of Example 64
    Example 65: (2S) -Amino-3- [3-fluoro-4- [4 - [{N- (1,4,5,6, -tetrahydropyrimidin- 4-methoxybenzyl)} amino] piperidin-1-yl] benzoylamino] propionic acid t-butyl ester
    1.0 mL of tetrahydrofuran was added to 40.0 mg of the compound of Example 64 to dissolve it, 8.0 mg of 10% palladium carbon was added, and the mixture was stirred vigorously under a hydrogen pressure of 1 hour at room temperature for 20 hours. Insolubles were filtered off and washed twice with methanol. The combined filtrate and washings were concentrated under reduced pressure, and the obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to give the title compound (25.3 mg).
    Physicochemical properties of the compound of Example 65
    Example 66: 3- [3-Fluoro-4- [4 - [{N- (1,4,5,6, -tetrahydropyrimidin- 2- yl) -N- (4- methoxybenzyl) } Amino) piperidin- 1 -yl] benzoylamino] - (2S) - {(4-nitrobenzenesulfonyl) amino} propionic acid t-butyl ester
    To 12.8 mg of the compound of Example 65, 0.5 ml of dimethylformamide was added and dissolved, and 8.0 디 of diisopropylethylamine was added. Further, 4.9 mg of 4-nitrobenzenesulfonyl chloride was added at room temperature. After stirring for 3 hours, 5 mg of piperazine was added, and the mixture was further stirred for 5 minutes. To the reaction solution was added 30 ml of a saturated aqueous sodium hydrogencarbonate solution and extracted three times with 30 ml of methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride: methanol: acetic acid = 70: 10: 1) to obtain the title compound (8.3 mg).
    Physicochemical properties of the compound of Example 66
    Example 67: 3- [3-Fluoro-4- {4- (1,4,5,6, -tetrahydropyrimidin-2- ylamino) piperidin- 1- yljbenzoylamino] - 2S) - {(4-nitrobenzenesulfonyl) amino} propionic acid
    0.5 ml of trifluoroacetic acid was added to 2.7 mg of the compound of Example 66, and the mixture was stirred at 40 占 폚 for 4.5 hours. The reaction solution was concentrated under reduced pressure and the residue was azeotropically distilled twice with toluene was purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1), followed by Sephadex LH-20 : Methanol) to obtain 2.2 mg of the title compound.
    Physicochemical properties of the compound of Example 67
    Example 68: (2S) - (4-Aminobenzenesulfonyl) amino-3- [3-fluoro-4- {4- (1,4,5,6, -tetrahydropyrimidin- ) Piperidin-1-yl} benzoylamino] propionic acid
    0.7 ml of dioxane and 0.2 ml of water were added to 6.9 mg of the compound of Example 67 and dissolved, 7.0 mg of 10% palladium carbon was added, and the mixture was vigorously stirred at room temperature for 5 hours under hydrogen pressure of 1 atm. The insoluble matter was filtered, and then washed twice with a mixed solvent of methanol and 7 ml of dioxane and 2 ml of water. The combined filtrate and washings were concentrated under reduced pressure, and 0.1N hydrochloric acid was added to the obtained residue, and CHP-20 (eluent: dioxane-water = 4: 1) was purified to obtain 2.8 mg of the title compound dihydrochloride.
    Physicochemical properties of the compound of Example 68
    Example 69: Synthesis of (2S) - (benzyloxycarbonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1 -yljbenzoylamino] t-butyl ester
    To 43.1 mg of Intermediate 38, 1.5 ml of dimethylformamide was added and dissolved, and 37.3 mg of (2S) -N-benzyloxycarbonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto. Further, 22.0 mg of 1-hydroxybenzotriazole, 45 占 퐇 of N-methylmorpholine and 31.3 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 15 hours. 20 ml of a saturated aqueous solution of calcium carbonate and 40 ml of a saturated saline solution were added to terminate the reaction and extracted three times with 50 ml of methyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 25: 1) to obtain 74.9 mg of the title compound.
    Physicochemical properties of the compound of Example 69
    Example 70: Synthesis of (2S) -amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester
    To 500 mg of the compound of Example 69 was dissolved 10 ml of tetrahydrofuran, 100 mg of 10% palladium carbon was added, and the mixture was stirred vigorously at room temperature for 12 hours under hydrogen pressure of 1 atm. Insolubles were filtered off and washed twice with methanol. The combined filtrate and washings were concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 7: 1) to give the title compound (334 mg).
    Physicochemical properties of the compound of Example 70
    Example 71: 3- [3-Fluoro-4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] - (2S) - { Trifluoromethyl-phenyl) amino} propionic acid t-butyl ester
    To a solution of 31.0 mg of the compound of Example 70 was dissolved 1.0 ml of dimethylformamide, and 25 μl of diisopropylethylamine and 14.2 mg of 4-methoxybenzenesulfonyl chloride were added at room temperature. After stirring for 0.5 hours, 5 mg of piperazine was added, and the mixture was further stirred for 5 minutes. To the reaction solution was added 30 ml of a saturated aqueous sodium hydrogencarbonate solution and extracted three times with 30 ml of methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain the title compound (39.0 mg).
    Physicochemical properties of the compound of Example 71
    Example 72: 3- [3-Fluoro-4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] - (2S) - { Phenyl) amino} propionic acid
    1.09 ml of methylene chloride was added to and dissolved in 8.9 mg of the compound of Example 71, cooled to -78 캜, and 30 1.0 of a 1.0 M methylene chloride solution of boron tribromide was added. After raising the temperature to 0 占 폚 over 3 hours, it was cooled again to -78 占 폚 and 30 占 퐇 of a 1.0 M methylene chloride solution of boron tribromide was added. The mixture was heated to room temperature over 3 hours, and stirred at this temperature for 13 hours. Methanol was added to the reaction solution and the mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for elution (eluent: chiroform-methanol-concentrated ammonia water = 30: 10: 1) to give the title compound ≪ / RTI >
    Physicochemical properties of the compound of Example 72
    Example 73: 3- [3-Fluoro-4- (4- (1,4,5,6, -tetrahydropyrimidin-2-ylamino) piperidin- 1- yljbenzoylamino] - 2S) - {(4-methoxybenzenesulfonyl) amino} propionic acid
    1.0 mL of dioxane and 0.1 mL of water were added to 30.0 mg of 3 trifluoroacetic acid salt of the compound of Example 72, 6.0 mg of 10% palladium carbon was added, and the mixture was stirred vigorously for 12 hours at room temperature under 1 atm of hydrogen pressure did. The insoluble matter was filtered, washed with a mixed solvent of 20 ml of dioxane and 20 ml of water, and the filtrate and the washing solution were combined and concentrated under reduced pressure. 0.35 ml of dimethyl sulfoxide was added to the residue to dissolve, and then 3.5 ml of water was added. The resulting precipitate was collected by filtration, washed twice with 0.5 ml of water and dried to obtain 24.7 mg of the title compound.
    Physicochemical properties of the compound of Example 73
    Example 74: 3- [3-Fluoro-4- {4- (pyrimidin-2-ylamino) piperidin- 1 -ylJbenzoylamino] - (2S) - { Phenyl) amino} propionic acid
    5.0 ml of dichloroethane was added to 66.8 mg of the compound of Example 71 and dissolved, and 1.1 ml of a 1.0 M solution of boron tribromide in methylene chloride was added. The suspended reaction solution was stirred at 40 占 폚 for 2.5 hours. A mixed solution of 1.0 ml of dioxane and 0.2 ml of water was added to the reaction solution, and 1.0 ml of triethylamine was further added thereto, followed by concentration under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) and then purified by Sephadex LH-20 (eluent: methanol) to obtain 20.0 mg .
    Physicochemical properties of the compound of Example 74
    Example 75: 3- [3-Fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] - ) - {(4-hydroxybenzenesulfonyl) amino} propionic acid
    0.7 ml of dioxane, 0.1 ml of acetic acid and 0.2 ml of water were added to and dissolved in 36.3 mg of the compound of Example 74, 7.0 mg of 10% palladium carbon was added, and the mixture was vigorously stirred at room temperature for 8 hours under hydrogen pressure of 1 atm. The insoluble matter was filtered, washed with 20 ml of dioxane, a mixed solvent of 2 ml of water and 1 ml of acetic acid, and methanol, and the filtrate and washings were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1) and then purified by Sephadex LH-20 (eluent: methanol) 10.7 mg.
    Physicochemical properties of the compound of Example 75
    Example 76: Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- ] Propionic acid t-butyl ester
    0.7 ml of pyrimidine was added to 30.0 mg of the mixture of Example 70 and dissolved, and 1.6 mg of 4-dimethylaminopyridine was added. Further, 15.9 mg of 4- (chlorosulfonyl) benzoic acid was added over 3.5 hours at room temperature. After stirring for 1 hour, the reaction solution was concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for elution (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain the title compound (22.4 mg).
    Physicochemical properties of the compound of Example 76
    Example 77: (2S) - (4-Carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- ] Propionic acid
    0.5 ml of methylene chloride and 0.5 ml of trifluro acetic acid were added to 26.0 mg of the compound of Example 76 at room temperature and the mixture was stirred for 15 hours. The reaction solution was concentrated under reduced pressure and azeotroped twice with toluene to give 3 trifluoro compound of the title compound 26 mg of rosacetate was obtained.
    Physicochemical properties of the compound of Example 77
    Example 78: (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- Piperidin-1-yl} benzoylamino] propionic acid
    1.0 ml of dioxane and 0.1 ml of water were added to 25.0 mg of 3 trifluoroacetic acid salt of the compound of Example 77, 5.0 mg of 10% palladium carbon was added and stirred vigorously for 9 hours at room temperature under 1 atm of hydrogen pressure did. The insoluble matter was filtered, washed with a mixed solution of 8 ml of ethanol, 1 ml of concentrated ammonia water and 1 ml of water, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (eluent: methylene chloride: ethanol: concentrated ammonia water: water = 8: 8: 1: 1), followed by Sephadex LH-20 (elution: ethanol- Water = 8: 1: 1) to obtain the title compound (15.1 mg).
    Physicochemical properties of the compound of Example 78
    Example 79: (2S) -acetamido-3- [3-fluoro-4- [4 - [{N- (1,4,5,6, -tetrahydropyrimidin- - (4-methoxybenzyl)} amino] piperidin- 1 -yl] benzoylamino] propionic acid t-butyl ester
    1.0 ml of dimethylformamide was added to 26.0 mg of the acetic acid salt of the compound of Example 65 to dissolve, and 15.9 占 퐇 of diisopropylethylamine was added. Further, 9.9 mg of 4-nitrobenzenesulfonyl chloride was added at room temperature. After stirring for 3.5 hours, 5 mg of piperazine was added and the mixture was further stirred for 5 minutes. To the reaction solution was added 30 ml of a saturated aqueous sodium hydrogencarbonate solution and extracted three times with 30 ml of methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for elution (eluent: chloroform: methanol: concentrated ammonia water = 30: 10: 1) to obtain 4.7 g of 4-nitrobenzene sulfonate of the title compound.
    Physicochemical properties of the compound of Example 79
    Example 80: (2S) -acetamido-3- [3-fluoro-4- {4- (1,4,5,6, -tetrahydropyrimidin- 2- ylamino) piperidin- Yl} benzoylamino] propionic acid
    1.0 ml of methylene chloride and 1.0 ml of trifluoroacetic acid were added to 10.7 mg of the compound of Example 79, and the mixture was stirred at 40 占 폚 for 16 hours. The reaction solution was concentrated under reduced pressure and the residue azeotroped twice with toluene was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1) And purified by Sephadex LH-20 (eluent: methanol) to obtain 3.3 mg of the title compound.
    Physicochemical properties of the compound of Example 80
    Example 81: (2S) - (Benzyloxycarbonyl) amino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- Amino] propionic acid t-butyl ester
    20 ml of anhydrous dimethylformamide and 20 ml of methylene chloride were added to 398 mg of Intermediate 45, and 790 mg of benztriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate and 0.31 ml of diisopropylethylamine were added thereto, And the mixture was reacted at room temperature for 2 hours to prepare an active ester. On the other hand, 20 ml of methylene chloride was added to 421 mg of (2S) -N-benzyloxycarbonyl-2,3-diaminopropionic acid t-butyl ester and dissolved, and 0.16 ml of diisopropyl ethylamine was added. The above-mentioned active ester solution was added thereto while cooling to -10 DEG C, and the reaction was allowed to proceed at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was extracted with ethyl acetate (50 ml). The extract was washed successively with distilled water, saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried over anhydrous sodium sulfate. The residue obtained by concentrating under reduced pressure was purified by silica gel column chromatography (90 g, 2% → 3% methanol / methylene chloride) to give the title compound (713 mg).
    Physicochemical properties of the compound of Example 81
    Example 82: (2S) -Amino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1 -yljbenzoylamino] propionic acid t-butyl ester
    22 mg of freshly distilled tetrahydrofuran was added to 216 mg of the compound of Example 81 and dissolved, and 110 mg of 10% palladium carbon was added. Was stirred vigorously under a hydrogen atmosphere at room temperature for 4 hours. The catalyst was filtered and washed twice with 10 ml of tetrahydrofuran. The filtrate and the washings were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (50 g, diethyl ether-methylene-methanol = 2: 7: 1 → 0: 9: 1) to obtain 79.1 mg . At this time, 61.4 mg of the compound of Example 81 was recovered.
    Physicochemical properties of the compound of Example 82
    Example 83: 3- [2,3-Difluoro-4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] - (2S) Methoxybenzenesulfonyl) amino} propionic acid tert-butyl ester
    To 127 mg of the compound of Example 82 was added 25 ml of anhydrous dimethylformamide and dissolved. 70 占 퐇 of diisopropylethylamine and 54.9 mg of 4-methoxybenzenesulfonyl chloride were added successively, and the mixture was reacted at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was extracted with 25 ml of ethyl acetate. The extract was washed successively with 5% aqueous sodium hydrogen carbonate solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over anhydrous sodium sulfate. The residue obtained by concentrating under reduced pressure was purified by silica gel column chromatography (13 g, chloroform-methanol-concentrated ammonia water = 90: 30: 1) to obtain 172 mg of the title compound.
    Physicochemical properties of the compound of Example 83
    Example 84: 3- [2,3-Difluoro-4- {4- (pyrimidin-2-ylamino) piperidin- 1 -ylJbenzoylamino] - (2S) Hydroxybenzenesulfonyl) amino} propionic acid
    2.6 ml of anhydrous 1,2-dichloroethane was added to 52.8 mg of the compound of Example 83, and 0.82 ml of a 1M methylene chloride solution of boron tribromide was added, followed by reaction at 40 ° C for 2 hours. To the reaction mixture was added a 80% aqueous solution of 1,4-dioxane and the pH was adjusted to 4 by adding iodine sodium hydrogencarbonate as a solid, followed by concentration under reduced pressure. This was purified by silica gel column chromatography (5 g, chloroform-methanol-concentrated ammonia water = 90: 30: 2) and subjected to Sephadex LH-20 column chromatography (30 ml, methanol- 1) to obtain the title compound (17.5 mg).
    Physicochemical properties of the compound of Example 84
    Example 85: 3- [2,3-Difluoro-4- {4- (1,4,5,6, -tetrahydropyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino ] - (2S) - {(4-hydroxybenzenesulfonyl) amino} propionic acid
    7.0 ml of 1,4-dioxane, 4.0 ml of acetic acid and 4.0 ml of 0.5 N hydrochloric acid were added to and dissolved in 80.0 mg of the compound of Example 84, and 40 mg of 10% palladium carbon was added. Was stirred vigorously under a hydrogen atmosphere at room temperature for 6 hours. The catalyst was filtered, washed twice with a mixed solvent (1,4-dioxane-acetic acid-water = 7: 2: 2), and the filtrate and the washing solution were combined. The residue obtained by concentration under reduced pressure was azeotropically evacuated twice with 4.0 ml of toluene. This was purified by silica gel column chromatography (14 g, methylene-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) and then purified by Sephadex LH-20 column chromatography (50 ml, methanol- : 1: 1) to obtain 51.3 mg of the title compound.
    Physicochemical properties of the compound of Example 85
    Example 86: (2S) - (4-Carboxybenzenesulfonyl) amino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- } Benzoylamino] propionic acid t-butyl ester
    To 78.9 mg of the compound of Example 82 was dissolved 1.2 ml of pyridine and 2.8 mg of 4-dimethylaminopyridine was added. Further, 36.5 mg of 4- (chlorosulfonyl) benzoic acid was added over 5 hours at room temperature. After stirring for 1 hour, 10.0 mg of piperazine was added and the mixture was stirred for 5 minutes and then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography for separation (eluent: chloroform-methanol-concentrated ammonia water = 30: 10: 1) to obtain the title compound (38.1 mg).
    Physicochemical properties of the compound of Example 86
    Example 87: Synthesis of (2S) - (4-carboxybenzenesulfonyl) amino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- } Benzoylamino] propionic acid
    0.5 ml of methylene chloride and 0.5 ml of trifluoroacetic acid were added to 38.0 mg of the compound of Example 86 at room temperature, and the mixture was stirred for 4 hours. The reaction solution was concentrated under reduced pressure and azeotroped twice with toluene to obtain 40.0 mg of the title compound, 3-trifluoroacetic acid salt.
    Physicochemical properties of the compound of Example 87
    Example 88: (2S) - (4-Carboxybenzenesulfonyl) amino-3- [2,3-difluoro-4- {4- (1,4,5,6, -tetrahydropyrimidin- -Ylamino) piperidin-1-yl} benzoylamino] propionic acid
    1.0 mL of dioxane and 0.1 mL of water were added to 40.0 mg of the trifluoroacetic acid salt of the compound of Example 87 and 80 mg of 10% palladium carbon was added thereto. The mixture was stirred at room temperature for 6,5 hours Lt; / RTI > The insoluble matters were filtered off, washed with a mixed solution of 10 ml of methanol and 1 ml of concentrated ammonia water, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (eluent: methylene chloride: ethanol: concentrated ammonia water: water = 8: 8: 1: 1) and then purified with Sephadex LH-20 (eluent: methanol) 14.5 mg of the title compound was obtained.
    Physicochemical properties of the compound of Example 88
    Intermediate 54: 4- {4- (1H-Benzimidazol-2-ylmethyl) piperazin-1-yl} benzoic acid ethyl ester
    To 250 mg of 4- (piperazin-1-yl) benzoic acid ethyl ester was added 10 ml of acetone and 5.0 ml of dimethyl sulfoxide and dissolved, and 180 mg of 2- (chloromethyl) benzimidazole was added. Further, 300 mg of a potassium carbonate bath was added, and the mixture was stirred at room temperature for 1 day. The reaction solution was poured into 200 ml of water and extracted four times with 100 ml of methylene chloride. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol-concentrated ammonia water = 100: 10: 1) to obtain the title compound (274 mg).
    Physicochemical properties of intermediate 54
    Intermediate 55: 4- {4- (1H-Benzimidazol-2-ylmethyl) piperazin-1-yl} benzoic acid
    To 101 mg of Intermediate 54, 10 ml of tetrahydrofuran and 2.5 ml of methanol were added and dissolved, and 10 ml of a 1N aqueous sodium hydroxide solution was added thereto. After stirring at 50 ° C for 1 day, the mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) to obtain the title compound (36 mg).
    Physicochemical Properties of Intermediate 55
    Example 89: (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylmethyl) piperazin-1-yl} benzoylamino] propionic acid t-
    To 30 mg of Intermediate 55, 2.0 ml of dimethylmorphamide was added and dissolved, and 30 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride was added thereto. Further, 18 mg of 1-hydroxybenztrimazole, 60 ml of N-methylmorpholine and 34 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride were added and stirred at room temperature for 6.5 hours. The reaction was stopped by adding a saturated aqueous sodium hydrogen carbonate solution and extracted twice with 100 ml of methylene chloride. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol-concentrated ammonia water 90: 10: 1) to obtain the title compound (31 mg).
    Physicochemical properties of the compound of Example 89
    Example 90: (2S) -Benzenesulfonylamino-3- [4- {4- (lH-benzimidazol-2- ylmethyl) piperazin- 1- yl} benzoylamino] propionic acid
    1.0 mL of methylene chloride was added to 10.0 mg of the compound of Example 89 and dissolved, and 1.0 mL of trifluoroacetic acid was added. Further, 10 ml of anisole was added, and the mixture was stirred at room temperature for 5.5 hours. The reaction solution was concentrated under reduced pressure and the obtained residue was purified by silica gel thin layer chromatography for separation (elution system: methylene-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1), followed by Sephadex LH-20 System: methanol) to obtain 0.64 mg of the title compound.
    Physicochemical properties of the compound of Example 90
    Intermediate 56: 4-Fluoro-3-methoxybenzoic acid methyl ester
    Fluoro-3-hydroxybenzoic acid was added and dissolved in 6.0 ml of dimethylformamide, to which 195 mg of potassium carbonate and 88 ml of methyl iodide were added at room temperature, and the mixture was stirred for 17 hours. The reaction solution was diluted with saturated ammonium chloride Poured into a mixed solution of 100 ml of aqueous solution and 60 ml of ethyl acetate, and extracted three times with ethyl acetate. The combined organic layers were washed twice with 100 ml of water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for elution (eluent: hexane-ethyl acetate = 3: 1) to obtain 96.7 mg of the title compound.
    Physicochemical properties of intermediate 56
    Intermediate 57: 4- (4-Hydroxypiperidin-1-yl) -methoxybenzoic acid methyl ester
    To 903 mg of Intermediate 56 was dissolved 10 ml of dimethyl sulfoxide, to which 744 mg of 4-hydroxypiperidine was added, followed by stirring at 90 ° C for 24 hours. A mixed solution of 150 ml of a saturated saline solution and 150 ml of water was added to the reaction solution which had been cooled to room temperature and extracted three times with 100 ml of ethyl acetate. The combined organic layers were washed twice with a mixed solution of 50 ml of a saturated saline solution and 50 ml of water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 20: 1) to obtain the title compound (605 mg).
    Physicochemical Properties of Intermediate 57
    Intermediate 58: 4- (4-azidopiperidin-1-yl) -3-methoxybenzoic acid methyl ester
    20 ml of methylene chloride was added to 550 mg of Intermediate 57 to dissolve, and 0.8 ml of trimethylamine was added. 225 메 of methanesulfonyl chloride was added dropwise at room temperature, and the mixture was stirred at the same temperature for 15 minutes. The reaction was stopped by adding 200 ml of a saturated aqueous solution of sodium hydrogencarbonate and extracted three times with 100 ml of ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 690 mg of 4- {4- (methanesulfonyloxy) piperidin-1-yl} -3-methoxybenzoic acid methyl ester. Subsequently, 20 ml of dimethylformamide was added to 690 mg of the compound and dissolved, and 161 mg of sodium azide was added, followed by stirring at 90 ° C for 4.5 hours. The reaction solution cooled to room temperature was poured into 300 ml of water and extracted three times with 200 ml of ethyl acetate. The combined organic layers were washed twice with 300 ml of water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound (590 mg).
    Physicochemical properties of intermediate 58
    Intermediate 59: 3-Methoxy-4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoic acid methyl ester
    Intermediate 58 (590 mg) was dissolved in 21 ml of dioxane, to which 60 mg of 10% palladium carbon was added, followed by stirring at room temperature for 6 hours
    Lt; / RTI > The insoluble matter was filtered off, washed with dioxane, and the filtrate and the washing solution were combined and concentrated under reduced pressure to obtain a crude compound. Then, 21 ml of dimethylsulfoxide was added to this compound to dissolve the solution, and 2.1 ml of diisopropylethylamine was added thereto. Further, 346 mg of 2-bromopyrimidine was added, the mixture was heated at 120 ° C and stirred for 15 hours. After cooling to room temperature, a mixed solution of 100 ml of a saturated saline solution and 100 ml of water was added, and extracted three times with 100 ml of ethyl acetate. The combined organic layers were washed twice with 100 ml of water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: hexane-ethyl acetate = 1: 1) to give the title compound (452 mg).
    Physicochemical Properties of Intermediate 59
    Intermediate 60: 3-Methoxy-4- {4- (pyrimidin-2-ylamido) piperidin-
    15 ml of tetrahydrofuran and 5.0 ml of methanol were added to 400 mg of Intermediate 59 and dissolved, and 5.0 ml of a 1N aqueous sodium hydroxide solution was added. The mixture was stirred at 40 ° C for 5 hours and then concentrated under reduced pressure. 25 ml of water was added to the obtained residue, and further 1 N hydrochloric acid was added to adjust the pH to 7. The resulting precipitate was filtered, washed with water and then dried to obtain 261 mg of the title compound.
    Physicochemical Properties of Intermediate 60
    Example 91: (2S) -Benzenesulfonylamino-3- [3-methoxy-4 {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t butyl ester
    To 50.0 mg of Intermediate 60 was added 1.5 ml of dimethylformamide, followed by addition of 53.9 mg of (2S) -N-benzenesulfonyl-2,3-diaminopropionic acid t-butyl ester hydrochloride. Further, 41 mg of 1-hydroxybenzotriazole, 50 占 퐇 of N-methylmorpholine and 58.2 mg of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide hydrochloride were added thereto, followed by stirring at room temperature for 12 hours . A mixed solution of 10 ml of a saturated aqueous potassium carbonate solution and 20 ml of a saturated saline solution was added to stop the reaction and extracted three times with 30 ml of ethyl acetate. The combined organic layers were washed twice with a mixed solution of 10 ml of saturated brine and 10 ml of water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (eluent: methylene chloride-methanol = 7: 1) to obtain the title compound (99.2 mg).
    Physicochemical properties of the compound of Example 91
    Example 92: (2S) -Benzenesulfonylamino-3- [3-methoxy-4 {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid
    1.5 ml of methylene chloride was added to and dissolved in 99 mg of the compound of Example 91, and 1.5 ml of trifluoroacetic acid was added thereto, followed by stirring at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure to obtain 100 mg of the title compound, 3-trifluoroacetic acid salt.
    Physicochemical properties of the compound of Example 92
    Example 93; (2S) -benzenesulfonylamino-3- [3-methoxy-4- {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- Benzoylamino] propionic acid
    1.0 ml of dioxane and 0.1 ml of water were added to 31.4 mg of 3-trifluoroacetic acid of the compound of Example 92 to dissolve it. 6.0 mg of 10% palladium carbon was added thereto, and the mixture was stirred at room temperature for 5 hours Lt; / RTI > The insoluble matter was filtered off, washed with a mixed solution of 10 ml of dioxane and 1 ml of water, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (elution system: methylene chloride-ethanol-water-concentrated ammonia water = 8: 8: 1: 1) and then purified by Sephadex LH-20 (eluent: methanol) 16.6 mg of the title compound was collected.
    Physicochemical properties of the compound of Example 93
    Example 94: (2S) -Benzenesulfonylamino-3- [3-hydroxy-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid
    3.6 ml of dichloroethane was added to and dissolved in 23.7 mg of the compound of Example 91, and 0.7 ml of a 1.0 M methylene chloride solution of boron tribromide was added thereto. The suspended reaction solution was stirred at 40 ° C for 7 hours. A mixed solution of 1.0 ml of dioxane and 0.1 ml of water was added to the reaction solution, and 1.0 ml of concentrated ammonia water was further added, followed by concentration under reduced pressure. 20 ml of water was added to the obtained residue, and the mixture was washed twice with 20 ml of methylene chloride and then concentrated under reduced pressure. The obtained residue was purified by CHP-20 (eluent: methanol-water = 3: 7) to obtain the title compound (8.4 mg).
    Physicochemical properties of the compound of Example 94
    Example 95: (2S) -Benzenesulfonylamino-3- [3-hydroxy-4- {4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- Yl} benzoylamino] propionic acid
    0.7 mg of dioxane, 0.1 ml of acetic acid and 0.2 ml of water were added to 8.0 mg of the compound of Example 94 to dissolve it. To this, 2.0 mg of 10% palladium carbon was added and stirred vigorously for 5 hours at room temperature under hydrogen pressure . The insoluble matter was filtered off, washed with a mixed solution of 20 ml of dioxane and 2 ml of water and methanol, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (elution system: methylene-ethanol-concentrated ammonia water-water = 8: 8: 1: 1) and then eluted with Sephadex LH-20 (eluent: methanol- 1) to give the title compound (3.5 mg).
    Physicochemical properties of the compound of Example 95
    Example 96: Synthesis of (2S) - (benzyloxycarbonyl) amino-3- [3-methoxy-4- {4- (pyrimidin- 2- ylamino) piperidin- 1 -ylJbenzoylamino] t butyl ester
    To 80.0 mg of Intermediate 60, 2.5 ml of dimethylformamide was added and dissolved, and 78.9 mg of (2S) -N-benzyloxycarbonyl-2,3-diaminopropionic acid t-butyl ester was added thereto. Further, 66.0 mg of 1-hydroxybenzotriazole, 81 占 퐇 of N-methylmorpholine and 93.5 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiamide hydrochloride were added and stirred at room temperature for 12 hours. The reaction was terminated by adding 20 ml of a saturated aqueous potassium carbonate solution and 40 ml of a saturated aqueous solution of sodium chloride, and extracted three times with 50 ml of ethyl acetate. The combined organic layers were washed twice with a mixed solution of 15 ml of saturated brine and 15 ml of water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 25: 1) to obtain 145 mg of the title compound.
    Physicochemical properties of the compound of Example 90
    Example 97: (2S) -Amino-3- [3-methoxy-4- {4- (pyrimidin- 2- ylamino) piperidin- 1 -yljbenzoylamino] propionic acid t-butyl ester
    120 mg of the compound of Example 96 was dissolved in 2.0 ml of tetrahydrofuran, to which 24 mg of 10% palladium carbon was added, followed by vigorous stirring at room temperature for 22 hours under hydrogen pressure of 1 atm. Insolubles were filtered off and washed twice with methanol. The combined filtrate and washings were concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride-methanol = 7: 1) to obtain the title compound (74.1 mg).
    Physicochemical properties of the compound of Example 97
    Example 98: (2S) - (4-Methoxybenzenesulfonyl) amino-3- [3-methoxy-4- {4- (pyrimidin- 2- ylamino) piperidin- Amino] propionic acid t-butyl ester
    47.0 mg of the compound of Example 97 was dissolved in 1.0 ml of dimethylformamide, and 35 占 퐇 of diisopropylethylamine and 20.6 mg of 4-methoxybenzenesulfonyl chloride were added at room temperature. After stirring for 2 hours, 5 mg of piperazine was added and the mixture was further stirred for 5 minutes. To the reaction solution was added 30 ml of a saturated aqueous sodium hydrogencarbonate solution and extracted three times with 30 ml of ethyl acetate. The combined organic layers were washed twice with a mixed solution of 20 ml of saturated brine and 20 ml of water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-methanol = 7: 1) to obtain the title compound (62.6 mg).
    Physicochemical properties of the compound of Example 98
    Example 99: Preparation of (2S) - (4-hydroxybenzenesulfonyl) amino-3- [3-hydroxy-4- {4- (pyrimidin- 2- ylamino) piperidin- Amino] propionic acid
    5.0 ml of dichloroethane was added to 60.0 mg of the compound of Example 98 to dissolve it, and 0.94 ml of a 1.0 ml methylene chloride solution of boron tribromide was added. The suspended reaction solution was stirred at 40 ° C for 25 hours. To the reaction mixture was added a mixed solution of 1.0 ml of dioxane and 0.1 ml of water, and 1.0 ml of concentrated ammonia water was added thereto, followed by concentration under reduced pressure. The resulting residue was purified by CHP-20 (eluent: methanol-water = 3: 7) to give the title compound (28.2 mg).
    Physicochemical properties of the compound of Example 99
    Example 100: (2S) - (4-Hydroxybenzenesulfonyl) amino-3- [3-hydroxy-4- {4- (1,4,5,6-tetrahydropyrimidin- ) Piperidin-1-yl} benzoylamino] propionic acid
    0.7 mL of dioxane, 0.1 mL of acetic acid and 0.2 mL of water were added to 27.5 mg of the compound of Example 99 and dissolved therein. 6.0 mg of 10% palladium carbon was added thereto and stirred vigorously at room temperature for 4 hours under 1 atm of hydrogen pressure . The insoluble matter was filtered, washed with methanol, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: ethanol-concentrated ammonia water-water-4: 1: 1) and then purified by CHP-20 (eluent: methanol- water = 1: 1) 19.8 mg.
    Physicochemical properties of the compound of Example 100
    Example 101: (2S) - (4-Carboxybenzenesulfonyl) amino-3- [3-methoxy-4- {4- (pyrimidin- 2- ylamino) piperidin- ] Propionic acid t-butyl ester
    1.7 mg of pyridine was added to 82.0 mg of the compound of Example 97 to dissolve, and to this was added 4.3 mg of 4-dimethylaminopyridine. Further, 38.3 mg of 4- (chlorosulfonyl) benzoic acid was added over 7 hours at room temperature. After stirring for 12 hours, 10.0 mg of piperazine was added, stirred further for 5 minutes, and then concentrated under reduced pressure. The resulting residue was purified by silica gel thin layer chromatography for separation (eluent: methylene chloride-methanol = 7: 1) to obtain 57.6 mg of the title compound.
    Physicochemical properties of the compound of Example 101
    Example 102: Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-methoxy-4- {4- (pyrimidin- 2- ylamino) piperidin- ] Propionic acid
    0.5 ml of methylene chloride and 0.5 ml of trifluoroacetic acid were added to 32.0 mg of the compound of Example 101 at room temperature, and the mixture was stirred for 16 hours. The reaction solution was concentrated under reduced pressure and azeotropically distilled twice with toluene was purified by silica gel thin layer chromatography for elution (eluent: methylene chloride-ethanol-concentrated aqueous ammonia-water = 8: 8: 1: 1) to obtain the title compound 27.0 mg.
    Physicochemical properties of the compound of Example 102
    Example 103: (2S) - (4-Carboxybenzenesulfonyl) amino-3- [3-methoxy- 4- {4- (1,4,5,6-tetrahydropyrimidin- Piperidin-1-yl} benzoylamino] propionic acid
    1.4 ml of dioxane, 0.2 ml of acetic acid and 0.4 ml of water were added to 27.0 mg of the compound of Example 102 to dissolve the mixture, 6.0 mg of 10% palladium carbon was added thereto, and the mixture was stirred vigorously under hydrogen at 1 atm for 6 hours . The insoluble matter was filtered, washed with a mixed solution of methanol (10 mL) and concentrated ammonia water (1 mL), and the filtrate and washings were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography for separation (eluent: methylene chloride: ethanol: concentrated ammonia water: water = 8: 8: 1: 1), followed by CHP-20 (eluent: methanol- 10) to obtain 8.5 mg of the title compound.
    Physicochemical properties of the compound of Example 103
    Example 104: (2S) -Amino-3- [4- {4- (pyrimidin-2-ylamino) piperidin- 1-yl]} benzoylamino] propionic acid t-butyl ester
    50 ml of freshly distilled tetrahydrofuran was added to 670 mg of the compound of Example 13 to dissolve it, and 335 mg of 10% palladium carbon was added thereto. Under a hydrogen atmosphere, at room temperature for 18 hours. The catalyst was filtered off and washed twice with tetrahydrofuran (20 ml). The filtrate and the washings were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (70 g, diethyl ether-methylene-methanol = 2: 7: 1 to 0: 9: 1) to obtain 285 mg of the title compound .
    Physicochemical properties of the compound of Example 104
    Example 105: (2S) -Benzenesulfonylamino-3- [4- {4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid methyl ester
    8.0 mg of anhydrous methanol was added to and dissolved in 80 mg of the compound of Example 2. 0.5 ml of a 1M diethyl ether solution of hydrogen chloride was added thereto and the reaction was allowed to proceed at room temperature for 16 hours. After neutralization with 87 mg of triethylamine and concentration under reduced pressure, the obtained residue was purified by silica gel column chromatography (8 g, 5% ⇒ 20% methanol / methylene chloride) to obtain the title compound (11.8 mg).
    Physicochemical properties of the compound of Example 105
    Pharmacological Test Example 1: V 3 binding assay
    With reference to the method of Kunus et al. (WC Kouns, D. Kirchhofer, P. Hadvary, A. Eddenhofer, T. Weller, G. Pfenninger, HR Baumgartner, LK Jennings and B. Steiner, Blood, 80, 2539-2547, 1992) The intragrano v [beta] ant antagonism of the compounds of the present invention was measured in a binding test system of vitoronectin-bitonectin receptor.
    That is to say, the human placenta can be isolated from the human placenta by the use of the vitronectin receptor (protein) purified by the method of Pitella et al. (R.Pytela, MD Pierschbacher, S.Argraves, S. Suzuki and E. Ruoslahti, Method in Enzymology, 144, 475-489, 1987) concentration 118㎍ / ㎖) a TBS (20mM Tris-HCl, 150mM NaCl, 1mM CaCl 2, 1mM MgCl 2, pH 7.4) to a 50-fold dilution, and the plate (Maxisorp, Nunc Inc. preparation, 96 to 50 well Immuno plate) Ml / well. The plate was allowed to stand at 4 ° C for 1 day, washed twice with TBS 200 μl / well, and blocked with TBS (150 μl / well) containing 1% bovine serum albumin (SIGMA) overnight at 4 ° C. After washing twice with TBS 200 μl / well, 50 μl of bitonectin (CALBIOCHEM) adjusted to 0.2 μg / ml by adding TBS (TBS-Tween) containing 0.01% Tween-20, 50 ml of each test substance was mixed in the well and reacted at room temperature for 4 hours. After completion of the reaction, the cells were washed 5 times with TBS-Tween, and 50 μl / well of anti-bitonectin rabbit antiserum (CHEMICON) diluted 1500 times with TBS-Tween as a primary antibody was added and reacted at room temperature for 1.5 hours . After washing 5 times with TBS-Tween 200 μl / well, 50 μl / well of peroxidase (POD) labeled anti-rabbit IgG antibody solution (CAPPEL) diluted 500 times with TBS-Tween as a secondary antibody was added, For 1.5 hours. ABTS (2.2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid), SIGMA Company) was added to POD-buffer (ZYMED Co.) diluted 10 times with TBS-Tween 200 μl / 1 mg / ml, and this was added at 50 ㎕ / well, followed by reaction for 5 to 10 minutes. The reaction was stopped by adding 50 μl / well of 0.1 M citric acid buffer (pH 4.3) containing 0.05% NaN 3, and the absorbance at 415 nm was measured using a microplate reader (Corona Electric, MTP32) 675 nm). Absorbance was determined by absorbing 50 μl of TBS-Tween in place of the covering material and reacting with 50 μl of TBS-Tween containing 2 × 10 -3 M of RGDS for nonspecific binding (100% inhibition) did. The inhibition rate was calculated by the following equation.
    Inhibition rate (%) = 100- (absorbance in the presence of the test substance - non-specific binding) / (total binding-nonspecific binding) x 100
    The IC50 values were obtained from the linear regression line of the logarithm of each concentration of the test substance and the logarithm of (100-inhibition) / inhibition.
    As a result of the test, the compounds of Examples 22, 28, 31, 33, 35, 36, 38, 42, 52, 54, 57, 60, 68, 73, 75, 78, 93, V 3 antagonistic activity, and their IC 50 values were all 1.0 nM or less.
    Pharmacological Test Example 2: GP IIb / IIIa antagonistic action and inhibition of human platelet aggregation
    It was tested whether the compounds of the present invention had GP IIb / IIIa antagonism. The measurement of GP IIb / IIIa antagonism was carried out according to the method of pharmacological test 2 described in WO94 / 21599. As a result, the compounds of Examples 24, 28, 31, 33, 35, 36, 38, 40, 42, 45, 52, 54, 57, 60, 68, 73, 75, 78, 93, GP IIb / IIIa antagonistic activity, and their IC 50 values were all below 1.0 nM.
    It was tested whether the compounds of the present invention had a human platelet aggregation inhibiting action. Measurement of human platelet aggregation action was carried out according to the method of Pharmacological Test 1 described in WO94 / 21599. As a result, the compounds of Examples 22, 40, 42, 45, 54 and 60 extremely inhibited the action of human platelet aggregation, and the IC 50 value thereof was 90 nM or less.
    Pharmacological Test Example 3: Vitonectin-inhibitory effect on human vascular smooth muscle cell adhesion
    Adhesion of human vascular smooth muscle cells to solid phase human bitronectin was performed according to the method of Liow et al. (Almeida M. Hart CE, Schwartz SM, Giachelli CM, Circulation Research, 74 (2), 214-224 .
    First, 50 占 퐇 of a solution of Dulbecco's PBS (-), Nissui Pharmaceutical Co., Ltd. in human plasma-derived vitronectin (CALBIOCHEM) prepared at a concentration of 4 占 퐂 / ml was added to a microplate (Maxisorp, Nunc) , And reacted overnight at 4 ° C to solidify.
    After washing twice with 150 μl of dulbecco's phosphate buffer, dulbecutate buffer containing 10 mg / ml of bovine serum albumin (SIGMA) was added. After blocking at 37 ° C. for 1 hour, 150 μl of two And washed twice with a buffer solution of becocoin to prepare a test plate.
    Next, human vascular smooth muscle cells cultured at 37 占 폚 under 5% carbon dioxide using a medium for vascular smooth muscle cells (Clonetics) were separated by a Dulbecco's phosphate buffer solution containing trypsin-EDTA (GIBCO BRL) Washed with a buffer of becococcinic acid, and then suspended in a Dulbecco's modified Eagle's medium (Nissui Pharmaceutical Co., Ltd.) containing 0.1% bovine serum albumin at a concentration of 5 x 10 < 5 > / ml.
    50 μl of Dulbecco's modified Eagle medium containing 10 mg / ml bovine serum albumin supplemented with drug was added to a test microplate coated with human bitronectin, and the mixture was incubated at 37 ° C for 10 minutes under 5% 50 mu l of a medium suspended in human vascular smooth muscle cells was added, stirred well, and reacted at 37 DEG C for 90 minutes under 5% carbon dioxide. Next, the reaction solution containing the non-adherent cells was taken out and washed three times with dulbecco's buffer. Cells to be adhered were prepared by adding 100 μl of a solution of 4% paraformaldehyde (Wako Junyaku) in Dulbeco's phosphate buffer solution, fixing the solution at room temperature for 10 minutes, adding 0.5% toluidine blue (Croma) and 4% paraformaldehyde Was added, and the mixture was stained at room temperature for 5 minutes, and sufficiently washed with distilled water. Next, the wells were air-dried, and 1% sodium dodecylsulfate solution was added to dissolve the cells. The absorbance of the resulting microplate was measured at 595 nm. Total binding was determined as the absorbance in wells containing no test substance, and nonspecific binding (100% inhibition) was absorbed in the wells blocked with bovine serum albumin without bitronectin. The inhibition rate was calculated by the following equation, and the IC 50 value was obtained from the first regression line of the logarithm of the respective concentrations of the test substance and the logarithm of (100-inhibition rate) / inhibition rate.
    Inhibition rate = 100 - (absorbance in the presence of the test substance - non-specific binding) / (total binding - nonspecific binding) x 100
    As a result, the compounds of Examples 35, 52, 57, 60, 75 and 93 had a strong cell adhesion inhibitory action and none of the IC 50 values related to vitronectin-human vascular smooth muscle cell adhesion inhibitory action were 70 nM or less.
    Pharmaceutical Test Example 4: α 5 β 1 binding asia
    Refer to WC Kouns, D. Kirchhofer, P. Hadvary, A. Edenhofer, T. Weller, G. Pfenninger, HR Baumgartner, LK Jennings and B. Steiner, Blood, 80, 2539-2547, , The integrin 5 1 antagonistic action (lethality) of the compound of the present invention was measured in a binding test system of fibronectin-fibronectin receptor.
    That is, the fibronectin receptor purified from the human placenta by the method of Pittella et al. (R. Pytela, MD Pierchbacher, S. Argraves, S. Suzuki and E. Ruoslahti, Method in Enzymology, 144, 475-489, 1987) (Protein concentration 52.1 μg / ml) was diluted 25 times with TBS (20 nM Tris-HCl, 150 nM NaCl, 1 nM CaCl 2 , 1 nM MgCl 2 , pH 7.4) and added to a plate (Maxisorp, Nunc, 96 well Immuno Plate) Mu] l / well. The plate was allowed to stand at 4 ° C for 1 day, washed twice with TBS 200 μl / well, and blocked with TBS (150 μl / well) containing 3% Schememilk (DIFCO) overnight at 4 ° C. The cells were washed twice with 200 μl / well of TBC containing 0.05% Tween-20 and twice with 200 μl / well of TBS, followed by the method of E. Invall, E. Rouslahti and EJ Miller, J. Exp. 50 μl of fibronectin purified with 0.2 μg / ml of TBS (TBS-Tween) containing 0.01% Tween-20 and 50 μl of each test substance prepared at each concentration Were mixed in a month and reacted at room temperature for 3 hours. After completion of the reaction, the resultant was washed five times with TBS-Tween, and 50 μl / well of a solution of peroxidase labeled fibronectin antibody (CAPPEL) diluted 500 times with TBS-Tween was added and reacted at room temperature for 1.5 hours . After 5 times of washing with TBS-Tween 200 μl / well, ABTS (SIGMA) was adjusted to 1 mg / ml with 10-fold diluted POD-buffer (ZYMED Co.) The reaction was carried out for 10 minutes. The reaction was stopped by adding 50 μl / well of 0.1 M citric acid buffer (pH 4.3) containing 0.05% NaN 3 and the absorbance at 415 nm was measured using a microplate reader (Corona Electc, MTP32) : 675 nm). Total binding was defined as the absorbance obtained by reacting 50 μl of TBS-Tween in place of the test substance, and the absorbance obtained by reacting 50 μl of TBS-Tween containing 2 × 10 -3 M RGDS with nonspecific binding (100% inhibition) . The inhibition rate was calculated by the following equation.
    Inhibition rate (%) = 100- (absorbance in the presence of the test substance - non-specific binding) / (total binding-nonspecific binding) x 100
    The IC 50 values were obtained from the linear regression line of logarithms of the respective concentrations of the test substance and the logarithm of (100-inhibition) / inhibition.
    Example No.α 5 β 1 binding inhibitory activity (μM) 31.6 101.6 222.5 246.9 281.3 520.33 6811.5
    The above results indicate that the compound of the present invention is a drug with remarkably low side effects.
    Acute toxicity test
    Three mice were administered intravenously with 50 mg / kg of the compound of Example 52. As a result, all the mice survived, and the change in body weight was the same as that in the solvent administration group.
    Structure of compounds
    The structures of the compounds of Examples 1 to 105 are as follows.


    权利要求:
    Claims (21)
    [1" claim-type="Currently amended] A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof

    (Wherein,
    A is a saturated or unsaturated 5- to 7-membered heterocyclic group containing two nitrogen atoms (which heterocyclic group may be condensed with another saturated or unsaturated 5- to 7-membered monocyclic or heterocyclic ring to form a bicyclic group, heterocyclic ring group and 2 is C 1-6 alkyl group, amino group, C 1-6 alkoxy, C 1-6 alcohol when a carbonyl group, or an aralkyl group (the C 1-6 alkyl group, amino group, C 1-6 alkoxy Group, a C 1-6 alkoxycarbonyl group and an aralkyl group may be substituted by a C 1-6 alkyl group or a C 1-6 alkoxy group), or the following groups

    (Wherein R 1 , R 2 and R 3 may be the same or different and each represents a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, an aralkyl group or a nitrile group Or R 1 and R 2 together may form a group - (CH 2 ) i- (i represents 4 or 5) or a group - (CH 2 ) 2 -O- (CH 2 ) 2 - , A C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, and an aralkyl group may be substituted by a halogen atom, a C 2-6 alkoxy group, an amino group, or a hydroxyl group)
    D is > NR 4 (R 4 is a hydrogen atom or a C 2-6 alkyl group (this alkyl group may be substituted by a phenyl group which may be substituted by a C 2-6 alkoxy group)
    ,> CR 5 R 6 (wherein R 5 and R 6 each represent a hydrogen atom or a C 2-6 alkyl group, which alkyl group may be substituted by a phenyl group which may be substituted by a C 2-6 alkoxy group) ), -O-, or -S-,
    X and Z may be the same or different and represent either CH or N,
    R 7 is, C 1-6 alkyl, C 1-6 alkoxy group, a halogen atom, an amino group, denotes a nitro group, a hydroxyl group, or an oxygen atom, a C 1-6 alkyl group and a C 1-6 alkoxy group a halogen atom, C 1 -6 alkoxy group, an amino group, or a hydroxyl group,
    R 8 is, C 1-6 alkyl, C 1-6 alkoxy group, a halogen atom, an amino group, a nitro group, or represents a hydroxyl group, C 1-6 alkyl group and a C 1-6 alkoxy group a halogen atom, a C 1-6 alkoxy An amino group, or a hydroxyl group,
    Q represents > C = O, > CHR 13 or > CHOR 13 (R 13 represents a hydrogen atom or a C 1-6 alkyl group)
    R 9 is a hydrogen atom, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, or represents an aralkyl group, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl And the aralkyl group may be substituted by a halogen atom, a C 1-6 alkoxy group, an amino group, or a hydroxyl group,
    R 10 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, an aralkyl group, or an amino group, these C 1-6 alkyl, C 2-6 alkenyl group, C 2 -6 alkynyl group and aralkyl group may be substituted with a halogen atom, a C 1-6 alkoxy group, an amino group, or a hydroxyl group, and the amino group may be substituted with a C 1-6 alkyl group, a C 1-6 alkoxycarbonyl group, a benzenesulfonyl group The phenyl moiety may be substituted by a C 1-6 alkyl group), or a benzyloxycarbonyl group (the phenyl moiety may be substituted by a C 1-6 alkyl group)
    R 11 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, a represents an aralkyl group, or an amino, C 1-6 alkyl, C 2-6 alkenyl, C 2- The alkynyl group and the aralkyl group may be substituted by a halogen atom, a C 1-6 alkoxy group, an amino group, or a hydroxyl group, and the amino group may be substituted with a carboxyl group, a sulfonyl group, a C 1-6 alkyl group, a C 1-6 alkylcarbonyl group , C 1-6 alkoxycarbonyl groups, C 1-6 alkali sulfonyl group, - (C = O) -O- (CH 2) uR 14 (u is an integer of 0 ~ 4, R 14 is a saturated or unsaturated 5 To R < 7 > each independently represent a hydrogen atom or a heterocyclic group, and the carbocyclic group and the heterocyclic group may be the same or different and each represents a C 1-6 alkyl group, a C 1-6 alcohol group, a phenyl group (the phenyl group may be condensed with the carbocyclic group or heterocyclic group (= O) 2 - (CH 2 ) v -R 14 (optionally substituted with a halogen atom), a carboxyl group, a hydroxyl group, a nitro group, an amino group, a C 1-6 alkylamino group or a halogen atom) v is an integer from 0 to 4 Out other, R 14 is good and optionally substituted by indicating the same content as described above),
    R 12 represents a hydrogen atom or a C 1-6 alkyl group,
    m represents an integer of 0 to 5,
    n represents an integer of 0 to 4,
    p represents an integer of 1 to 3,
    g represents an integer of 1 to 3,
    R represents 0 or 1).
    [2" claim-type="Currently amended] The compound according to claim 1, wherein X represents CH and Z represents N.
    [3" claim-type="Currently amended] 2. The compound according to claim 1, wherein X and Z together represent N.
    [4" claim-type="Currently amended] The compound according to claim 1, wherein X represents N and Z represents CH.
    [5" claim-type="Currently amended] The compound according to any one of claims 1 to 4, wherein A represents the group

    (In the above group,
    Het represents a saturated or unsaturated 5- to 7-membered heterocyclic group containing two nitrogen atoms, and this heterocyclic group may be condensed with another saturated or unsaturated 5- to 7-membered monocyclic or heterocyclic ring to form a bicyclic group , a heterocyclic ring group and 2 is C 1-6 alkyl group, amino group, C 1-6 alkoxy, C 1-6 alkoxycarbonyl group, or an aralkyl group (the C 1-6 alkyl group, amino group, C 1-6 An alkoxy group, a C 1-6 alkoxycarbonyl group and an aralkyl group may be substituted by a C 1-6 alkyl group or a C 1-6 alkoxy group).
    [6" claim-type="Currently amended] The compound according to any one of claims 1 to 4, wherein A represents the group

    (The above air,
    R21, R22, And R23May be the same or different and are a hydrogen atom, C1-6Alkyl group, C1-6An alkoxy group, C1-6Alkoxycarbonyl group, C2-6An alkenyl group, or an aralkyl group, and C1-6Alkyl group, C1-6An alkoxy group, C1-6Alkoxycarbonyl group, C2-6Alkenyl group, or aralkyl group is a halogen atom, C1-6An alkoxy group, an amino group, or a hydroxyl group, or ROneAnd R23(CH2)4-, - (CH2)3-, -CHR24CH2CH2- (R24C1-6An alkyl group or an amino group, and the amino group is C1-6Alkyl group, C1-6An alkoxycarbonyl group, an aralkyl group, or an aralkyloxycarbonyl group), a group -CH2CHR24CH2- (R24Have the same meanings as described above), group -CH2CH2- group -CHR24CH2- (R24Have the same meanings as described above), a group -CR25= CR26- (R25And R26The same Or a hydrogen atom, or a C1-6Alkyl group, or R25And R26Together are -CH = CH-CH = CH-, CR24= CH-CH = CH- (R24Have the same meanings as described above), -CH = CR4-CH = CH- (R24May have the same meanings as defined above, -N = CH-CH = CH-, or -CH = N-CH = CH-)
    R 21 and R 23 together form ═CH-CH═CH-, ═CH-CH═N-, or ═CH-N═CH-, and R 22 is a bond between R 21 and the nitrogen atom to which it is bonded May be represented by a single bond.
    [7" claim-type="Currently amended] The compound according to any one of claims 1 to 6, wherein D represents > NH or > CH 2 .
    [8" claim-type="Currently amended] The compound according to any one of claims 1 to 7, wherein Q represents > C = O or > CH 2 .
    [9" claim-type="Currently amended] The compound according to any one of claims 1 to 8, wherein m and n each represent an integer of 0 to 2.
    [10" claim-type="Currently amended] 2. The compound according to claim 1, wherein A represents the following group.

    (In the above groups, R 21 , R 22 , and R 23 are the same as defined in claim 6)
    D represents > NH,
    X represents CH,
    Z represents > N,
    Q represents > C = O or > CH 2 ,
    R 9 represents a hydrogen atom, a C 1-6 alkyl group or an aralkyl group, the C 1-6 alkyl group and the aralkyl group may be substituted by a halogen atom, a C 1-6 alkoxy group, an amino group or a hydroxyl group,
    R 10 represents a hydrogen atom or a C 1-6 alkynyl group,
    R 11 represents a hydrogen atom or an amino group, and the amino group represents a C 1-6 alkyl group, an acetyl group, a C 1-6 alkoxycarbonyl group, a C 1-6 alkylsulfonyl group, a benzyloxycarbonyl group (the phenyl moiety is a C 1-6 alkyl group , A C 1-6 alkoxy group, a carboxyl group, a hydroxyl group, a nitro group, an amino group or a halogen atom), or a benzenesulfonyl group (the phenyl moiety is preferably a C 1-6 alkyl group, a C 1-6 alkoxy group, A hydroxyl group, a nitro group, an amino group, or a halogen atom)
    m and n each represent an integer of 0 to 2,
    p represents 2,
    q represents 1 or 2,
    r represents 1.
    [11" claim-type="Currently amended] 2. The compound according to claim 1, wherein A represents the following group.

    (Wherein, in the above groups, R 21 , R 22 , and R 23 are the same as defined in claim 6)
    D represents > CH 2 ,
    X and Z taken together represent N,
    Q represents > C = O or > CH 2 ,
    R 9 represents a hydrogen atom, a C 1-6 alkyl group or an aralkyl group, the C 1-6 alkyl group and the aralkyl group may be substituted by a halogen atom, a C 1-6 alkoxy group, an amino group, or a hydroxyl group,
    R 10 represents a hydrogen atom or a C 1-6 alkynyl group,
    R 11 represents a hydrogen atom or an amino group, and the amino group represents a C 1-6 alkyl group, an acetyl group, a C 1-6 alkoxycarbonyl group, a C 1-6 alkylsulfonyl group, a benzyloxycarbonyl group (the phenyl moiety is a C 1-6 alkyl group , A C 1-6 alkoxy group, a carboxyl group, a hydroxyl group, a nitro group, an amino group or a halogen atom), or a benzenesulfonyl group (the phenyl moiety is preferably a C 1-6 alkyl group, a C 1-6 alkoxy group, A hydroxyl group, a nitro group, an amino group, or a halogen atom)
    m and n each represent an integer of 0 to 2,
    p represents 2,
    q represents 1 or 2,
    r represents 1.
    [12" claim-type="Currently amended] Or a pharmaceutically acceptable salt or solvate thereof.
    1. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid t-butyl ester.
    2. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid.
    3. Preparation of (2S) -benzenesulfonylamino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] Propionic acid.
    4. (2S) -Benzenesulfonylamino-3- [4 - {(3S) - (pyrimidin-2- ylamino) pyrrolidin-1-yl} benzoylamino] propionic acid t-butyl ester.
    5. (2S) -Benzenesulfonylamino-3- [4 - {(3S) - (pyrimidin-2- ylamino) pyrrolidin-1-yl} benzoylamino] propionic acid.
    6. (2S) -Benzenesulfonylamino-3- [4 - {(3S) - (1,4,5,6-tetrahydropyrimidin- 2- ylamino) pyrrolidin- Benzoylamino] propionic acid.
    7. (2S) -Benzenesulfonylamino-3- [4 - {(3R) - (pyrimidin-2- ylamino) pyrrolidin-1-yl} benzoylamino] propionic acid t-butyl ester.
    8. (2S) -Benzenesulfonylamino-3- [4 - {(3R) - (pyrimidin-2- ylamino) pyrrolidin-1-yl} benzoylamino] propionic acid.
    9. (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid t-butyl ester.
    10. (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    11. (3S) - [4- (4- (Pyrimidin-2-ylamino) piperidin-1-yl} benzoylamino] pent- 4 -phosphoric acid ethyl ester.
    12. (3S) - [4- (4- (Pyrimidin-2-ylamino) piperidin-1-yl} benzoylamino] pent- 4-phosphate.
    13. t-Butyl ester of (2S) - (benzyloxycarbonyl) amino-3- [4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    14. (2S) - (Benzyloxycarbonyl) amino-3- [4- [4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    15. (2S) -amino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    16. Preparation of (2S) - (benzyloxycarbonyl) amino-3- [4- [4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- Benzoylamino] propionic acid.
    17. (2S) -butane-1-sulfonylamino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- Benzoylamino] propionic acid.
    18. Preparation of (2S) -benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- [4- (pyrimidin- 2- ylamino) piperidin- 1- yl} ] Amino] propionic acid t-butyl ester.
    19. Preparation of (2S) -benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} ] Amino] propionic acid.
    20. Preparation of (2S) -benzenesulfonylamino-3- [N- (cyclopropylmethyl) -N- [4- {4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) Piperidin-1-yl} benzyl] amino] propionic acid.
    21. (2S) -Benzenesulfonylamino-3- {4- (4-guanidinopiperidin-1-yl) benzoylamino} propionic acid t-butyl ester.
    22. (2S) -Benzenesulfonylamino-3- {4- (4-guanidinopiperidin-1-yl) benzoylamino} propionic acid.
    Benzylamino} - (2S) - {(benzyloxycarbonyl) amino} propionic acid t < RTI ID = 0.0 > -Butyl ester.
    24. 3- [4 - (4 - (lH-Benzimidazol-2-ylamino) piperidin-1 -yl} benzoylamino] - (2S) - {(benzyloxycarbonyl) amino} propionic acid.
    25. Preparation of (2S) - (benzyloxycarbonyl) amino-3- [4- [4 - {(1-t -butoxycarbonyl- lH-benzimidazol- 2- yl) amino} piperidin- 1-yl] benzoylamino] propionic acid t-butyl ester.
    26. Preparation of (2S) -amino- 3- [4- [4 - {(1-t -butoxycarbonyl- lH-benzimidazol- 2- yl) amino} piperidin- 1- yl] benzoylamino ] Propionic acid t-butyl ester.
    27. Preparation of (2S) - (butane- 1 -sulfonylamino) -3- [4- [4 - {(1-tert- butoxycarbonyl- Di-1-yl] benzoylamino] propionic acid t-butyl ester.
    28. (2S) -Butane-1-sulfonylamino-3- [4- (4- (1H-benzimidazol-2- ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    29. (2S) -amino-3- [4- (4- (1H-benzimidazol-2-ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    30. A compound according to any one of claims 1 to 3, which is a compound of formula (I), wherein R < 3 > - [4- [4 - {(1-tert- butoxycarbonyl- {(2,4,6-trimethylbenzenesulfonyl) amino} propionic acid t-butyl ester.
    31. A process for the preparation of 3 - [4- (4 - (1 H -benzimidazol-2-ylamino) piperidin-1 -yl} benzoylamino] - (2S) - {(2,4,6- Sulfonyl) amino} propionic acid.
    1-yl] benzoylamino] - (2S) - (4-fluorophenyl) propanoic acid. {(4-fluorobenzenesulfonyl) amino} propionic acid t-butyl ester.
    33. A compound according to claim 1 which is: 3- [4- (4 - (1 H -benzimidazol-2-ylamino) piperidin- 1 -yl} benzoylamino] - (2S) - {(4-fluorobenzenesulfonyl) } Propionic acid.
    1-yl] benzoylamino] - (2S) - (4-methyl-pyridin-2-yl) {(4-Nitrobenzenesulfonyl) amino} propionic acid t-butyl ester.
    (2S) - {(4-Nitrobenzenesulfonyl) amino} - 1 - benzoylamino] Propionic acid.
    36. (2S) - (4-Aminobenzenesulfonyl) amino-3- [4- [4- (1H-benzimidazol-2- ylamino) piperidin-1-yl} benzoylamino] propionic acid.
    37. (2S) -Benzenesulfonylamino-3- [4- [4 - {(1H-imidazo [4,5- b] pyridin- 2- yl) amino} piperidin- 1 -yl] benzoyl Amino] propionic acid t-butyl ester.
    38. (2S) -Benzenesulfonylamino-3- [4- [4 - {(1H-imidazo [4,5-b] pyridin- 2- yl) amino} piperidin- Amino] propionic acid.
    39. (2S) -benzenesulfonylamino-3- [4- [4 - [{4,5-dihydro- 1- (4-methoxybenzyl) -1H- imidazol- Piperidin-1-yl] benzoylamino] propionic acid t-butyl ester.
    40. (2S) -Benzenesulfonylamino-3- [4- (4- (4,5-dihydro-1H-imidazol-2-ylamino) piperidin- 1- yl} benzoylamino] propionic acid .
    41. (2S) -Benzenesulfonylamino-3- [4- (4- (4,5,6,7-tetrahydro-1H- [1,3] diazepin- 2 -ylamino) piperidine -Yl} benzoylamino] propionic acid t-butyl ester.
    42. (2S) -Benzenesulfonylamino-3- [4- (4- (4,5,6,7-tetrahydro-1H- [1,3] diazepin- 2 -ylamino) piperidine 1-yl} benzoylamino] propionic acid.
    43. (2S) -Benzenesulfonylamino-3- [4- [4 - [{N-methyl-N- Propionic acid t-butyl ester.
    44. (2S) -Benzenesulfonylamino-3- [4- [4 - [{N-methyl-N- Propionic acid.
    45. Preparation of (2S) -benzenesulfonylamino-3- [4- [4 - [{N-methyl- N- (1,4,5,6- tetrahydropyrimidin- 2- yl)} amino] 1-yl] benzoylamino] -propionic acid. ≪ / RTI >
    46. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzylamino] propionic acid t-butyl ester.
    47. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin-1- yl} benzylamino] propionic acid.
    48. (2S) -Benzenesulfonylamino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin-2- ylamino) piperidin- 1- yl} benzylamino] Propionic acid.
    49. (2S) -Benzenesulfonylamino-3 - [[N-benzyl-N- [4- [4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) piperidine - 1 -yl} benzyl]] amino] propionic acid.
    50. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (pyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester .
    51. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    52. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- Yl} benzoylamino] propionic acid.
    53. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (4,5- dihydro- lH- imidazol- 2- ylamino) piperidin- 1- yl } Benzoylamino] propionic acid t-butyl ester.
    54. (2S) -Benzenesulfonylamino-3- [3-fluoro-4- {4- (4,5- dihydro- lH- imidazol- 2- ylamino) piperidin- 1- yl } Benzoylamino] propionic acid.
    55. (2S) -Benzenesulfonylamino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t -Butyl ester.
    56. (2S) -Benzenesulfonylamino-3- [2,3-difluoro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    57. (2S) -Benzenesulfonylamino-3- [2,3-difluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidine 1-yl} benzoylamino] propionic acid.
    58. (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid t-butyl ester.
    59. (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    60. (2S) -Benzenesulfonylamino-3- [3-chloro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- yl } Benzoylamino] propionic acid.
    61. 2- (N-Benzenesulfonyl-N-methyl) amino-3- [4- (4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester .
    62. 2- (N-Benzenesulfonyl-N-methyl) amino-3- [4- (4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    63. A compound according to claim 1 which is 2- (N-benzenesulfonyl-N-methyl) amino-3- [4- (4- (1,4,5,6-tetrahydropyrimidin- 2- Yl} benzoylamino] propionic acid.
    64. A pharmaceutical composition comprising (2S) - (benzyloxycarbonyl) amino-3- [3-fluoro-4- [4- - N - (4-methoxybenzyl)} amino] piperidin-1-yl] benzoylamino] propionic acid t-butyl ester.
    65. A pharmaceutical composition comprising (2S) -amino- 3- [3-fluoro-4- [4- [{N- (1,4,5,6- tetrahydropyrimidin- 2- Methoxybenzyl)} amino] piperidin-1-yl] benzoylamino] propionic acid t-butyl ester.
    66. A pharmaceutical composition comprising 3- [3-fluoro-4- [4 - [{N- (1,4,5,6- tetrahydropyrimidin- 2- yl) -N- (4-methoxybenzyl)} amino] Piperidin-1-yl] benzoylamino] - (2S) - {(4-nitrobenzenesulfonyl) amino} propionic acid t-butyl ester.
    1-yl} benzoylamino] - (2S) -thiophene-2-carboxylic acid ethyl ester was prepared from 3- - {(4-nitrobenzenesulfonyl) amino} propionic acid.
    68. Preparation of (2S) - (4-aminobenzenesulfonyl) amino-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) 1 -yl} benzoylamino] propionic acid. ≪ / RTI >
    69. A mixture of (2S) - (benzyloxycarbonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t -Butyl ester.
    70. (2S) -Amino-3- [3-fluoro-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid t-butyl ester.
    71. Preparation of 3- [3-fluoro-4- {4- (pyrimidin-2-ylamino) piperidin-1 -yl} benzoylamino] - (2S) - {(4- methoxybenzenesulfonyl ) Amino} propionic acid t-butyl ester.
    72. A compound according to claim 1 which is 3- (3-fluoro-4- {4- (pyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] - (2S) - {(4- methoxybenzenesulfonyl ) Amino} propionic acid.
    73. A compound according to claim 1 which is 3 - [3-fluoro-4- {4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] - {(4-methoxybenzenesulfonyl) amino} propionic acid.
    74. A compound according to claim 1 which is: 3 - [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] - (2S) - {(4-hydroxybenzenesulfonyl ) Amino} propionic acid.
    1-yl} benzoylamino] - (2S) -thiophene-2-carbonyl] amino} - {(4-hydroxybenzenesulfonyl) amino} propionic acid.
    76. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- Propionic acid t-butyl ester.
    77. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- Propionic acid.
    78. (2S) - (4-Carboxybenzenesulfonyl) amino-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) 1 -yl} benzoylamino] propionic acid. ≪ / RTI >
    79. (2S) -acetamido-3- [3-fluoro-4- [4- [N - (1,4,5,6-tetrahydropyrimidin- 2- 4-methoxybenzyl)} amino] piperidin-1-yl] benzoylamino] propionic acid t-butyl ester.
    80. (2S) -acetamido-3- [3-fluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- } Benzoylamino] propionic acid.
    81. (2S) - (Benzyloxycarbonyl) amino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino ] Propionic acid t-butyl ester.
    82. (2S) -amino-3- [2,3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester .
    83. A compound according to claim 1 which is: 3 - [2, 3-Difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] - (2S) Benzenesulfonyl) amino} propionic acid t-butyl ester.
    84. A compound according to claim 1 which is 3 - [2, 3-difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] - (2S) Benzenesulfonyl) amino} propionic acid.
    85. A compound according to claim 1 which is 3 - [(2,3-difluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- yljbenzoylamino] - 2S) - {(4-hydroxybenzenesulfonyl) amino} propionic acid.
    86. (2S) - (4-Carboxybenzenesulfonyl) amino-3- [2,3-difluoro-4- {4- Benzoylamino] propionic acid t-butyl ester.
    87. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [2,3- difluoro-4- {4- (pyrimidin- 2- ylamino) piperidin- Benzoylamino] propionic acid.
    88. Synthesis of (2S) - (4-carboxybenzenesulfonyl) amino-3- [2,3-difluoro-4- {4- (1,4,5,6-tetrahydropyrimidin- Amino) piperidin-1-yl} benzoylamino] propionic acid.
    89. (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylmethyl) piperazin-1-yl} benzoylamino] propionic acid t-butyl ester.
    90. (2S) -Benzenesulfonylamino-3- [4- (4- (1H-benzimidazol-2-ylmethyl) piperazin-1-yl} benzoylamino] propionic acid.
    91. (2S) -Benzenesulfonylamino-3- [3-methoxy-4- {4- (pyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t-butyl ester .
    92. (2S) -Benzenesulfonylamino-3- [3-methoxy-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    93. (2S) -Benzenesulfonylamino-3- [3-methoxy-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidin- 1- Yl} benzoylamino] propionic acid.
    94. (2S) -Benzenesulfonylamino-3- [3-hydroxy-4- {4- (pyrimidin-2- ylamino) piperidin-1- yl} benzoylamino] propionic acid.
    95. (2S) -Benzenesulfonylamino-3- [3-hydroxy-4- {4- (1,4,5,6-tetrahydropyrimidin- 2- ylamino) piperidine- 1- Yl} benzoylamino] propionic acid.
    96. A process for the preparation of (2S) - (benzyloxycarbonyl) amino-3- [3-methoxy- 4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid t -Butyl ester.
    97. (2S) -Amino-3- [3-methoxy-4- {4- (pyrimidin-2- ylamino) piperidin- 1 -yl} benzoylamino] propionic acid t-butyl ester.
    98. Preparation of (2S) - (4-methoxybenzenesulfonyl) amino-3- [3-methoxy- 4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino ] Propionic acid t-butyl ester.
    99. (2S) - (4-Hydroxybenzenesulfonyl) amino-3- [3-hydroxy-4- {4- ] Propionic acid.
    100. (2S) - (4-Hydroxybenzenesulfonyl) amino-3- [3-hydroxy-4- {4- (1,4,5,6-tetrahydropyrimidin- Piperidin-1-yl} benzoylamino] propionic acid.
    101. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-methoxy- 4- {4- (pyrimidin- 2- ylamino) piperidin- 1- yl} benzoylamino] Propionic acid t-butyl ester.
    102. (2S) - (4-Carboxybenzenesulfonyl) amino-3- [3-methoxy-4- {4- Propionic acid.
    103. Preparation of (2S) - (4-carboxybenzenesulfonyl) amino-3- [3-methoxy- 4- {4- (1,4,5,6- tetrahydropyrimidin- 2- ylamino) 1 -yl} benzoylamino] propionic acid. ≪ / RTI >
    104. t-Butyl ester of (2S) -amino-3- [4- (4- (pyrimidin-2- ylamino) piperidin- 1- yl} benzoylamino] propionic acid and
    105. (2S) -Benzenesulfonylamino-3- [4- (4- (pyrimidin-2-ylamino) piperidin- 1 -yl} benzoylamino] propionic acid methyl ester.
    [13" claim-type="Currently amended] A pharmaceutical composition comprising the compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt or solvate thereof as an active ingredient.
    [14" claim-type="Currently amended] 14. A pharmaceutical composition according to claim 13 for use in the treatment of a disease mediated by integrin [alpha] v [ beta] 3 .
    [15" claim-type="Currently amended] 14. The pharmaceutical composition according to claim 13, wherein the cell adhesion inhibition is used for the treatment of a therapeutically effective disease.
    [16" claim-type="Currently amended] The pharmaceutical composition according to claim 13, wherein the GP IIb / IIIa antagonistic action and / or the platelet aggregation inhibitory action is used for the treatment of a therapeutically effective disease.
    [17" claim-type="Currently amended] The pharmaceutical composition according to claim 13, which is used for the treatment of diseases selected from the group consisting of cardiovascular diseases, diseases related to angiogenesis, cerebrovascular diseases, cancer and metastasis thereof, immunological diseases and bone diseases.
    [18" claim-type="Currently amended] The pharmaceutical composition according to claim 13, which is used for the treatment of platelet thrombosis or thromboembolism, improvement of peripheral circulation blood flow, inhibition of blood coagulation during extracorporeal circulation, or treatment of thrombotic thrombocytopenic purpura or hemolytic uremic syndrome.
    [19" claim-type="Currently amended] The pharmaceutical composition according to claim 13, which is used as a platelet aggregation inhibitor.
    [20" claim-type="Currently amended] A medicament for the treatment of a disease mediated by integrin V 3 , a therapeutically effective disease inhibiting cell adhesion and a GP IIb / IIIa antagonistic action and / or a platelet aggregation inhibitory action selected from the group consisting of therapeutically effective diseases Use of a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt or solvate thereof.
    [21" claim-type="Currently amended] To claim 1 to 12, wherein any of the preceding compounds or a pharmaceutically acceptable salt or solvate thereof according to of an effective amount of integrin integrin α v that it comprises administering to a mammal including human together with a pharmaceutically acceptable carrier a disease mediated by 3- mediated disease, a cell adhesion inhibition, a therapeutically effective disease, and a GP IIb / IIIa antagonistic action and / or a platelet aggregation inhibitory action are selected from the group consisting of therapeutically effective diseases.
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2636050C2|2017-11-20|SUBSTITUTED PYRROLIDINES AS XIa FACTOR INHIBITORS FOR THROMBOEMBOLIC DISEASES TREATMENT
    AU2004220225B2|2010-06-17|Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
    US6291469B1|2001-09-18|Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    KR100748150B1|2007-08-09|Urea compounds having muscarinic receptor antagonist activity
    JP4326468B2|2009-09-09|Indole derivatives useful as histamine H3 antagonists
    TWI222971B|2004-11-01|Antagonists of MCP-1 function and methods of use thereof
    US6096773A|2000-08-01|Compounds that inhibit the binding of integrins to their receptors
    KR100714154B1|2007-05-07|Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
    US8030318B2|2011-10-04|Fused bicyclic inhibitors of HCV
    US6433165B1|2002-08-13|Chemokine receptor antagonists and methods of use therefor
    US6262069B1|2001-07-17|1-amino-7-isoquinoline derivatives as serine protease inhibitors
    US7119098B2|2006-10-10|Heteroarylakanoic acids as intergrin receptor antagonists
    JP4629036B2|2011-02-09|Arylalkylamine compound and process for producing the same
    US7183270B2|2007-02-27|Cyclic derivatives as modulators of chemokine receptor activity
    TW580501B|2004-03-21|Heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
    US6559160B1|2003-05-06|Compounds and methods for modulating cxcr3 function
    US6890915B2|2005-05-10|Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
    KR101231466B1|2013-02-07|Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
    EP1107959B1|2006-10-11|Quinazoline derivatives as medicaments
    JP4491072B2|2010-06-30|Vitronectin receptor antagonist
    AU2004274309B2|2010-04-08|Novel piperidine derivative
    DE69730490T2|2005-09-29|Amino-etherocyclic compounds as antithrombotic or anticoagulating agent
    AU2003252715B2|2009-06-04|Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
    JP5134248B2|2013-01-30|Dihydropyridinone derivatives
    CN101663293B|2013-07-31|Quinoline-carboxamide derivatives as p2y12 antagonists
    同族专利:
    公开号 | 公开日
    ES2381591T3|2012-05-29|
    CN1303377A|2001-07-11|
    AU759449B2|2003-04-17|
    CA2327673A1|1999-10-21|
    AU3167899A|1999-11-01|
    JP4064059B2|2008-03-19|
    AT542797T|2012-02-15|
    AU759449C|2003-10-30|
    EP1074543A1|2001-02-07|
    WO1999052872A1|1999-10-21|
    US6420558B1|2002-07-16|
    EP1074543A4|2006-04-26|
    NZ507222A|2003-05-30|
    CA2327673C|2009-08-25|
    EP1074543B1|2012-01-25|
    CN1140511C|2004-03-03|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1998-04-09|Priority to JP9706698
    1998-04-09|Priority to JP1998/97066
    1999-04-09|Application filed by 기따자또 이찌로, 메이지 세이카 가부시키가이샤
    1999-04-09|Priority to PCT/JP1999/001903
    2001-05-25|Publication of KR20010042587A
    优先权:
    申请号 | 申请日 | 专利标题
    JP9706698|1998-04-09|
    JP1998/97066|1998-04-09|
    PCT/JP1999/001903|WO1999052872A1|1998-04-09|1999-04-09|AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS|
    [返回顶部]